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1. Summary 
Xenotransplantation - the transplantation of cells, organs or tissues between 
members of different species – might have the potential to overcome the severe 
shortage of human organs available for transplantation. For several reasons the 
miniature pig is viewed as a suitable source of animal organs for transplantation into 
human patients. However, the problems associated with xenotransplantation are 
complex, and include immunological and physiological obstacles. Pre-formed 
xenoreactive natural antibodies (NAb) in human serum, and an immediate and 
vigorous rejection reaction, the so-called hyperacute rejection (HAR), can lead to a 
loss of the porcine organ within hours. Most of these Nab are directed against the 
galactose-α-1,3-galactose (αGAL), a saccharide structure expressed on the cell 
surface of all mammals except humans, apes, and Old World monkeys. With the 
generation of pigs lacking αGAL, HAR has largely been overcome, as evidenced by 
the transplantation of hearts and kidneys derived from the modified pigs into 
baboons. A second rejection mechanism, the acute vascular rejection (AVR), is 
characterized by the infiltration of natural killer (NK) cells, monocytes/macrophages, 
and neutrophils into the transplant. The role of NK cells in the rejection of xenografts 
has been demonstrated in various studies, both in vitro and in vivo. NK cells are large 
granular lymphocytes with a cytotoxic potential that is tightly regulated by both 
inhibitory as well as activating receptors that NK cells express on their surface. 
Inhibitory receptors, such as the members of the CD94 and NKG2 family, recognize 
major histocompatibility complex (MHC) class I molecules, in this case human 
leukocyte antigen E (HLA-E), on the surface of potential target cells and therefore 
deliver a negative signal preventing an NK cell from killing the target cell. On the 
other hand, activating NK cell receptors, such as natural cytotoxicity receptors (NCR) 
and NKG2D, promote the ability of NK cells to kill a potential target cell after having 
encountered their corresponding, as yet unidentified, ligands on the surface of a 
target cell. Consequently, NK cytotoxicity occurs if stimulatory signals outweigh 
inhibitory signals derived from a potential target cell. Porcine endothelial cells (pEC) 
are susceptible to human NK cell-mediated lysis, possibly due to the inability of 
porcine MHC class I molecules to signal through human NK cell inhibitory receptors. 
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Furthermore, pEC are also known to express ligands for activating human NK cell 
receptors. 
 
The aims of this study were: (1) to identify those activating receptors on human NK 
cells that are involved in xenogeneic NK cell-mediated cytotoxicity against pEC; (2) to 
identify the porcine ligand(s) for two activating receptors of the human NK cells, 
namely NKG2D and NKp44; and (3) to study whether transgenic expression of HLA-
E can protect pEC from human NK cell-mediated xenogeneic cytotoxicity.  
 
It is demonstrated in this study that human NK cells mediate xenogeneic cytotoxicity 
against porcine cells through activating receptors NKG2D and NKp44, but not 
through NKp30 and NKp46. Furthermore, cytotoxicity of human NK cell clones 
against the immortalized pEC line PEDSV.15 strongly correlates with the NKp44 
expression levels. Xenogeneic antibody-dependent cell-mediated cytotoxicity using 
freshly isolated NK cells and autologous human serum is not prevented by blocking 
NKG2D. It was further determined that the homologue of human UL16-binding 
proteins (ULBP), pULBP1, but not the homologue of the human MHC class I chain-
related (MIC) protein, pMIC2, serves as the predominant, if not the only, functional 
ligand for the human NKG2D on porcine cells. It was also shown that the level of 
protection of pEC against human NK cell-mediated cytotoxicity depends both on the 
expression levels of HLA-E and on the respective NK cell receptor CD94/NKG2A. 
Furthermore, the observed effect was specifically mediated by HLA-E expression and 
can be reversed by blocking of its receptor CD94/NKG2A. In addition, pEC derived 
from HLA-E/β2-microglobulin-transgenic pigs are efficiently protected against human 
NK cell-mediated cytotoxicity. 
 
These studies suggest that elimination of pULBP1 and an as yet unidentified NKp44 
ligand on porcine tissues represent attractive possibilities to protect porcine 
xenografts from human NK cell responses, including direct xenogeneic cytotoxicity. 
In addition, transgenic expression of HLA-E on the surface of porcine cells might 
contribute to the successful prevention of NK cell-mediated damage in clinical 
xenotransplantation. Future studies should focus on other detrimental ways, with 
which NK cells target pEC, such as IFN-γ release, activation of pEC, and recruitment 
of other cells of the immune system. 
2. Zusammenfassung 
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2. Zusammenfassung 
Xenotransplantation – die Transplantation von Zellen, Organen oder Geweben über 
die Speziesgrenze hinweg – könnte das Potential besitzen den gravierenden Mangel 
an Organen für die Transplantation zu überwinden. Aus verschiedenen Gründen wird 
das Miniaturschwein als eine passende Quelle für tierische Organe für die 
Transplantation in humane Patienten gesehen. Trotzdem sind die Probleme, welche 
mit der Xenotransplantation assoziiert sind komplex und beinhalten sowohl 
immunologische als auch physiologische Hürden. Präformierte xenoreaktive 
natürliche Antikörper (NAb) im humanen Serum und eine sofortige und heftige 
Abstossungsreaktion, die so genannte hyperakute Abstossung (HAR), kann zu 
einem Verlust des porzinen Organs innerhalb von Stunden führen. Die meisten 
dieser NAb sind gegen die Galaktose-α-1,3-Galaktose (αGAL) gerichtet, eine 
Zuckerstruktur auf der Zelloberfläche aller Säugetiere, mit der Ausnahme von 
Menschen, Menschenaffen und Meerkatzen. Durch die Herstellung von Schweinen 
denen αGAL fehlt, konnte die HAR mehrheitlich überwunden werden. Dies wurde 
mittels der Transplantation von Herzen und Nieren solcher modifizierter Schweine in 
Paviane gezeigt. Ein zweiter Abstossungsmechanismus, die akute vaskuläre 
Abstossung (AVR), ist charakterisiert durch die Infiltration von natürlichen Killerzellen 
(NK Zellen), Monozyten/Makrophagen und Neutrophilen ins Transplantat. Die Rolle 
der NK Zellen in der Abstossung von Xenotransplantaten wurde in verschiedenen 
Studien, sowohl in vitro als auch in vivo, gezeigt. NK Zellen sind grosse granuläre 
Lymphozyten mit einem zytotoxischen Potential, das straff reguliert wird durch 
inhibierende und aktivierende Rezeptoren, welche auf der Oberfläche der NK Zellen 
exprimiert werden. Inhibitorische Rezeptoren, wie zum Beispiel die Mitglieder der 
CD94 und NKG2 Familie, erkennen MHC Klasse I Moleküle, in diesem Fall HLA-E 
auf der Oberfläche potentieller Zielzellen, und senden ein negatives Signal, welches 
die NK Zelle daran hindert diese Zielzelle zu töten. Andererseits fördern aktivierende 
Rezeptoren, wie zum Beispiel natürliche Zytotoxizitäts-Rezeptoren (NCR) und 
NKG2D, die Fähigkeit von NK Zellen potentielle Zielzellen zu töten nachdem sie den 
passenden Liganden (in diesem Fall noch unbekannt) auf der Zelloberfläche der 
Zielzelle gebunden haben. Folglich tritt NK Zell Zytotoxizität dann auf, wenn die 
stimulierenden Signale die inhibierenden Signale einer potenziellen Zielzelle 
2. Zusammenfassung 
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überwiegen. Porzine Endothelzellen (pEC) sind wahrscheinlich empfindlich 
gegenüber humaner NK Zell-vermittelter Lyse, weil die porzinen MHC Klasse I 
Moleküle nicht über die humanen inhibierenden NK Zell Rezeptoren senden können. 
Des Weiteren exprimieren pEC Liganden für die aktivierenden humanen NK Zell 
Rezeptoren. 
 
Die Ziele dieser Studie waren: (1) die Identifizierung der aktivierenden Rezeptoren 
auf den humanen NK Zellen, welche in der xenogenen NK Zell-vermittelten 
Zytotoxizität gegen pEC involviert sind; (2) die Identifizierung der porzinen Liganden 
zweier aktivierender Rezeptoren auf humanen NK Zellen, NKG2D und NKp44; und 
(3) zu untersuchen, ob die transgene Expression von HLA-E pEC vor der humanen 
NK Zell-vermittelten xenogenen Zytotoxizität schützt. 
 
Diese Studie hat gezeigt, dass humane NK Zellen die xenogene Zytotoxizität gegen 
porzine Zellen durch die aktivierenden Rezeptoren NKG2D und NKp44, jedoch nicht 
durch NKp30 und NKp46, vermitteln. Des Weiteren hat die Zytotoxizität humaner NK 
Zell Klone gegen die immortalisierte pEC Linie PEDSV.15 stark mit dem NKp44 
Expressionslevel korreliert. Xenogene Antikörper-abhängige Zell-vermittelte 
Zytotoxizität beim Gebrauch von frisch isolierten NK Zellen in Kombination mit 
autologem humanem Serum wurde nicht verhindert durch die Blockade von NKG2D. 
Ferner wurde ermittelt, dass das Homolog des humanen UL-16-bindenden Proteins 
(ULBP), pULBP1, jedoch nicht das Homolog des humanen MIC Proteins, pMIC2, als 
vorherrschender, wenn nicht einziger, funktioneller Ligand für humanes NKG2D auf 
porzinen Zellen fungiert. Es wurde auch gezeigt, dass die Höhe des Schutzes der 
pEC gegenüber humaner NK Zell-vermittelter Zytotoxizität sowohl abhängig von der 
Expressionshöhe von HLA-E als auch des dazugehörenden NK Zell Rezeptor 
CD94/NKG2A ist. Des Weiteren war der beobachtete Effekt spezifisch vermittelt 
durch die HLA-E Expression und konnte aufgehoben werden durch das Blockieren 
des Rezeptors CD94/NKG2A. Ausserdem waren pEC, die von HLA-E/β2-
mikroglobulin-transgenen Schweinen isoliert wurden effektiv geschützt gegenüber 
humaner NK Zell-vermittelter Zytotoxizität.  
 
Diese Studien weisen darauf hin, dass die Elimination von pULBP1 und bis jetzt 
unidentifizierter NKp44 Liganden auf porzinem Gewebe eine attraktive Möglichkeit 
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zum Schutz des porzinen Xenotransplantates vor der humanen NK Zell Antwort, 
inklusive der direkten Zytotoxizität, darstellt. Ausserdem könnte auch die transgene 
Expression von HLA-E auf der Oberfläche porziner Zellen zur erfolgreichen 
Verhinderung der NK Zell-vermittelten Schädigung in der klinischen 
Xenotransplantation beitragen. Zukünftige Studien sollten sich auf weitere schädliche 
Wege konzentrieren mittels derer NK Zellen pEC angreifen, wie zum Beispiel die 
Sekretion von IFN-γ, die Aktivierung der pEC und die Rekrutierung anderer Zellen 
des Immunsystems. 
 
3. Introduction 
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3. Introduction 
3.1. Xenotransplantation 
The transplantation of cells, tissues, and organs from animals into humans, so-called 
xenotransplantation, has been sought of for over 100 years. In fact, the first 
transplantation experiments in humans used animal organs (1). Interestingly, the 
reason behind this was that the transplant surgeons did not think human organs 
could be obtained in sufficient numbers. For similar reasons, today 
xenotransplantation is considered to be a possible solution for the lack of sufficient 
human organs for clinical transplantation. In the 16th century, the pioneers of 
xenotransplantation performed xenotransfusions, i.e. the transfusion of sheep blood 
into patients. First cell and tissue xenotransplantations were reported in the early 20th 
century. During the 1960s, kidneys, hearts, and livers of primates were transplanted 
by different groups, most notably by Reemtsma (2) and Starzl (3), with moderate 
success. One of the most successful clinical xenotransplantations took place in 1964 
and was performed by the group of Reemtsma. In one patient a chimpanzee kidney 
survived with adequate function for nine months (2). These early clinical efforts on 
xenotransplantation were driven both by the mortality of end-stage organ failure 
unless organ transplantation was performed, and by a relative lack of human organs 
for that purpose. In the later part of the 1960s, these factors changed with the greater 
availability of hemodialysis and the acceptance of the concept of brain death. Thus, 
interest in xenogeneic transplantation diminished over the next 15 years, while 
allogeneic transplantation of heart, lung, liver, kidney, and pancreas became fully 
established. Great progress has also been achieved in terms of surgical techniques, 
immunosuppressive regimens, and pre-transplant diagnostic tools, all of which have 
contributed to increased patient and graft survival after allotransplantation. 
Nevertheless, the increasing success of allogeneic transplantation led to renewed 
interest in xenotransplantation, due to the insufficient supply of human organs for the 
increasing number of patients that would benefit from transplantation. 
For several reasons the miniature pig may be a potential organ source, despite a 
relatively high phylogenetic distance to humans (4, 5). Pigs breed rapidly and in large 
numbers, which guarantees an almost unlimited availability of suitable and cost-
effective organs. Furthermore, they can be housed in pathogen-free environments, 
3. Introduction 
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which limits the risk of infections of the recipient. In addition, their organs share 
anatomic and physiologic similarities with human organs. Lastly, the public 
acceptance of the use of pig organs in medicine is expected to be wide, since pigs 
are also bred for the nutrition industry. In contrast, primates that were considered to 
be the best potential donors for xenotransplantation because of their close genetic 
relation to humans, would hardly be accepted as organ source in the public. 
Furthermore, they are difficult to breed in large numbers and they are of small size. 
Beside the advantages of xenotransplantation, huge immunological barriers still have 
to be overcome, since xenotransplantation excites nearly every inflammatory, 
immune and coagulation pathway (6). 
 
In principle, there are two distinct types of xenotransplants: primary and secondary 
vascularized transplants. Primary vascularized organs, such as the heart, kidney, 
liver, or lung, have to get connected directly to the blood vessels of the recipient in 
order to function properly. Therefore, in these cases, the immediate exposure of 
donor vascular endothelium to the recipient’s circulation determines the character of 
the initial immune response (7). In contrast, secondary vascularized xenotransplants, 
such as islets and skin, or cell transplants including bone marrow cells, neural cells, 
or hepatocytes (8), get vascularized at a later time point and therefore will cause 
distinct biological reactions. Because donor endothelium is not involved in the latter 
cases, several of the immunologic responses that arise against primary vascularized 
xenografts will not occur. 
Furthermore, the degree of relationship between donor and recipient can be 
discriminated. Transplantations between phylogenetically closely related species, for 
example human and baboon, are concordant. Usually there are no preformed 
xenoreactive antibodies (Ab) in this species combination and therefore no hyperacute 
rejection (HAR) will occur. On the other hand, transplantations between species of 
distant relation, including pig–to-human, are called discordant because the recipient 
possess circulating preformed donor-reactive Ab (natural Ab; NAb) which induce 
HAR of the xenograft. 
 
3.1.1. Rejection Mechanisms 
The rejection of a xenograft can be divided into different phases, where one or more 
of these may be involved. Firstly, HAR, a vigorous and irreversible process, may 
3. Introduction 
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arise. In the case of pig-to-human xenotransplantation, this process starts within 
minutes and leads to rejection within hours, caused by binding of preformed 
xenoreactive NAb to the porcine endothelium followed by complement activation and 
coagulation (9). If HAR is prevented, acute vascular rejection (AVR) may be induced 
within hours and lead to rejection within days. This step is represented by a 
sequence of events, including activation and recruitment of several leukocyte 
populations, and activation of the graft endothelium (10). The next hurdle, which may 
be induced after several days, is mediated by T cells. Despite previous reports that 
cellular immunity might be less of a barrier to xenografts than it is to allografts, in the 
most relevant species combination for potential clinical xenografting (i.e. pig to 
primate) the cellular responses in vitro are as great or greater than the corresponding 
allogeneic responses (11). 
 
3.1.1.1. Hyperacute Rejection 
A primary vascularized, discordant xenotransplant will immediately be rejected after 
transplantation (Figure 1). The histology of this type of rejection is marked by 
extensive intravascular thrombosis and extravascular hemorrhage, which is similar to 
the rejection in ABO-incompatible allografts. This observation led to the idea that it 
was primarily an Ab-mediated lesion (12). The binding of Ab to the graft leads to 
complement activation, which is a critical mediator of graft injury (13). Therefore, 
complement regulatory proteins, including DAF (CD55), MCP (CD46), and CD59, 
also play a critical role in determining the intensity of HAR. However, these proteins 
often do not regulate the function of complement proteins from other species (14). 
An important finding was that pig endothelium expresses a single dominant epitope, 
the galactose-α-1,3-galactose (αGAL), which is responsible for the binding of a large 
portion (approximately 85%) of the human NAb (15). This determinant is formed by 
the action of the α-1,3-galactosyltransferase (α1,3GT), which glycosylates N-
acetyllactosamine. On the other hand, humans and all higher order primates after the 
New World monkeys do not have a functional gene for this transferase and instead 
use α-1,2-fucosyltransferase to form the H substance from the substrate. It is 
believed that these species produce anti-αGAL Nab as a result of the colonization of 
the gut by bacteria and of the exposure to viruses, protozoa, or components in food 
carrying αGAL antigens (16). Although the αGAL determinant appears to bind the 
3. Introduction 
majority of preformed human NAb, it is not the only pig determinant that binds human 
Nab (17). 
Binding of xenoreactive NAb to porcine endothelial cells (pEC) leads to so-called 
type I endothelial cell (EC) activation, i.e. non-transcriptional activation (18). This is a 
very rapid step and leads to EC retraction, expression of P-selectin and von 
Willebrand factor, secretion of platelet activating factor and loss of heparan sulfate 
(19). The observed EC retraction might be caused by rapid redistribution of 
platelet/EC adhesion molecule (PECAM-1/CD31) and VE-cadherin away from cell 
junctions as a result of αGAL cross-linking. 
 
extravascular hemorrhage
Xenoreactive Ab
Complement factors
Alpha Gal epitope
Unidentified antigen
Platelets
Erythrocytes
complement activation
deposition of 
xenoreactive Ab
pEC
intravascular thrombosis
 
Figure 1: Hyperacute rejection of a porcine xenograft. The binding of Ab (mainly directed against 
αGAL) to the graft leads to complement activation, which is a critical mediator of the lesion of the graft. 
The histology of this type of rejection is marked by extensive intravascular thrombosis and 
extravascular hemorrhage. 
 
3.1.1.2. Acute Vascular Rejection 
Leventhal et al. were the first to describe AVR in a guinea pig-to-rat transplantation 
model (20). The histology of this type of rejection is characterized by EC swelling, 
ischemia, a diffuse microvascular thrombosis with fibrin deposition, and cellular 
infiltrates consisting of Natural killer (NK) cells, monocytes/macrophages, and 
neutrophils (18, 20-23) (Figure 2). A key factor in the pathogenesis of AVR is the so-
called type II EC activation (24), i.e. transcriptional activation mediated by NF-κB 
(25). This is characterized by increased transcription of genes encoding 
prothrombotic molecules such as tissue factor (26), major histocompatibility complex 
(MHC) class I and II molecules (27, 28), cell adhesion molecules (E-selectin/CD62E, 
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vascular cell adhesion molecule-I/VCAM-1/CD106, intercellular adhesion molecule-
1/ICAM-1/CD54) (29), cytokines and chemokines (interleukin (IL) -1, IL-6, IL-8, 
monocyte chemoattractant protein/MCP-1) (30), as well as costimulatory molecules 
of the B7 family (CD80/CD86) (31, 32). On the other hand, thrombomodulin 
expression is decreased (33). Altogether, these EC changes promote leukocyte 
recruitment, platelet aggregation, and loss of thromboregulation. Thus, EC are not 
merely targets of the immune attack, but are central to the pathogenesis of the 
rejection process by interacting with Ab and regulating leukocyte-EC cross-talk. 
 
Xenoreactive Ab
Alpha Gal epitope
Unidentified antigen
Platelets
thrombus formation
NK
ADCC
NK
direct cytotoxicity
FcγRIII Receptor
NKG2D
NKp44
pULBP1
NKp44 ligand
PMNMono
NK
proinflammatory
cytokines, 
chemokines
cellular infiltrates
Mono
NK
PMN
pEC
 
Figure 2: Acute vascular rejection of a porcine xenograft. A key factor in the pathogenesis of AVR 
is the so-called type II EC activation. The histology of this type of rejection is characterized by EC 
swelling, ischemia, a diffuse microvascular thrombosis with fibrin deposition, and cellular infiltrates 
consisting of NK cells, monocytes/macrophages (Mono), and neutrophils (PMN). 
 
3.1.1.3. Role of Cellular Infiltration during Acute Vascular Rejection 
Since cellular infiltrates are observed in xenografts during AVR, an important role for 
the cellular innate immune system is suggested. Some innate cells, such as NK cells 
(34, 35), monocytes (25, 36), and neutrophils (22), directly recognize and activate 
pEC. Leukocyte extravasation has been shown to be governed by adhesion 
molecules belonging to the selectin, integrin, and immunoglobulin protein families in 
close collaboration with chemokines (37, 38). The current model for leukocyte 
extravasation is common to different leukocyte subpopulations even though they 
employ different members of the adhesion protein families. It is divided into four 
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phases: recruitment of leukocytes by chemotaxis, rolling adhesion, firm adhesion, 
and transendothelial migration (37) (Figure 3). 
 
 
Figure 3: Interaction of human NK cells and pEC (39). Shown is a simplified view of the 
receptor/ligand interactions involved in chemotaxis, rolling adhesion, firm adhesion, and 
transmigration. 
 
Following recruitment of leukocytes from the circulation, E- and P-selectin on pEC 
and L-selectin on leukocytes initiate the rolling phase by binding to carbohydrate 
counter-receptors on leukocytes and pEC, respectively. Rolling is required for the 
subsequent firm adhesion, a phase which is carried out by leukocyte integrins (β1-
integrins such as CD49d/CD29, and β2-integrins such as CD11a/CD18, 
CD11b/CD18, and CD11c/CD18) binding to pEC immunoglobulin (Ig) superfamily 
members (VCAM-1, ICAM-1,-2, and -3) (37). The actual transendothelial migration 
step involves another Ig superfamily member, CD31 (PECAM-1), which facilitates 
migration through the pEC layer and basal lamina by its homophilic and heterophilic 
interactions (40, 41). 
The most significant phenotypic difference between porcine and human EC is the 
expression of αGAL. Whereas this molecule is important in the phase of hyperacute 
graft rejection, its importance in the adhesion step during the AVR remains 
controversial. An αGAL-dependent adhesion of human NK cells to pEC was 
suggested by Miyagawa et al. (42, 43), whereas others claim the interaction of 
 15
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human peripheral blood mononuclear cells (PBMC), polymorphonuclear neutrophils 
(PMN), and NK cells to be independent of αGAL (35, 44). 
Most of the adhesion receptor pairs examined so far seem to be compatible between 
pig and men (29, 39, 45). This has been shown by cloning of porcine E- and P-
selectin as well as by blocking studies using Ab against porcine adhesion molecules 
to successfully block adhesion of human leukocytes. 
 
3.1.1.4. Role of NK Cells during Acute Vascular Rejection 
The role of NK cells in the rejection of both concordant and discordant xenografts has 
been demonstrated in various studies (46, 47). In several species combination, 
including pig-to-human, evidence from in vitro studies suggests NK cells to lyse 
xenogeneic cells (43, 46-52). Furthermore, they activate porcine endothelium upon 
direct contact and act as a potent source for pro-inflammatory cytokines such as 
interferon-γ (48, 53). Human NK cells have further been demonstrated to adhere to 
and lyse porcine target cells both directly and, in the presence of human serum 
containing xenoreactive Ab, by Ab-dependent cell-mediated cytotoxicity (ADCC) (54-
56). In addition, pig organs perfused with human blood ex vivo are predominantly 
infiltrated by NK cells (57-59), and NK cells are present in histological samples of 
graft rejection in concordant and discordant rodent and preclinical pig-to-baboon 
models (60-62). In particular, studies by Waer et al suggest an important role for NK 
cells in the rejection of hamster-to-nude rat xenografts (61-63). Also a slight 
additional prolongation of xenograft survival has been achieved in a small number of 
studies by the additional depletion of NK cells along with other forms of 
immunosuppression (64). In other small animal studies, however, CD4+ T cell 
depletion without NK depletion has led to prolonged xenograft survival, and no effect 
was seen by the additional depletion of NK cells (65, 66). A possible explanation of 
this fact is that T-cell derived IL-2 may be necessary to activate NK cells in order to 
participate in xenograft rejection. There is good evidence that NK cells play an 
especially important role in resistance to xenogeneic bone marrow engraftment, 
since allogeneic engraftment can be achieved with T cell-depleting nonmyeloablative 
conditioning, whereas xenogeneic bone marrow engraftment requires additional anti-
NK cell therapy (67). 
Birmele et al. reported that about 50% of human peripheral blood lymphocytes 
adhering to resting pEC were NK cells (68, 69). In this process, a dominant role for 
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the interactions between CD49d, presumably in combination with CD29, and CD106 
is indicated by several studies (39, 70). Furthermore, masking of human CD62L, 
CD11a/CD18, and CD11b/CD18 by specific Ab also revealed some importance for 
these molecules. In conclusion, xenogeneic NK cell adhesion depends primarily on 
CD49d-CD106 interactions in both rolling and firm adhesion. 
Under normal physiologic conditions, NK cytotoxicity is accurately regulated to lyse 
only transformed or infected cells (71). However, pEC are lysed by human NK cells 
due to the inability of porcine MHC class I molecules, so-called swine leukocyte 
antigen (SLA) class I, to signal through human NK cell inhibitory receptors, (72). In 
addition, functional interactions between NKG2D and NKp44 on human NK cells and 
their corresponding, yet unidentified, ligands on pEC also deliver cytotoxic signals 
(73). The other two activating receptors on human NK cells (NKp30 and NKp46), 
however, do not have any corresponding ligands on pEC. 
Theoretically, xenogeneic NK cytotoxicity could be avoided either by expressing 
human leukocyte antigen (HLA) class I molecules on porcine cells or by blocking the 
function of activating receptors. Indeed, several studies demonstrated that the 
expression of human MHC class I molecules including HLA-B27, -Cw3, -E, and -G on 
porcine cells provided partial protection from lysis mediated by polyclonal human NK 
cells (74-79) (see also results section 5.4. and 5.5). However, complete inhibition of 
NK cytotoxicity has not been achieved by transgenic HLA class I expression since 
the corresponding NK inhibitory receptors for each HLA molecule were expressed 
only on NK subpopulations. Moreover, protection from ADCC by HLA class I 
expression has been demonstrated only for NK clones, but not for polyclonal NK cells 
(76, 80). On the other hand, pEC were almost completely protected against human 
NK cell lysis by the combined blocking of NKG2D and NKp44 receptors by specific 
monoclonal Ab (mAb) (81) (see also results section 5.1.). 
 
3.1.2. Physiologic Function of Xenogeneic Organs 
It is very difficult to estimate, if pig organs are able to function adequately in humans, 
since to date, only few xenotransplants have survived for prolonged periods. 
However, it is already known that chimpanzee kidneys are able to support human life 
and that porcine insulin can regulate blood sugar levels in humans. On the other 
hand, there are reports that primates surviving with pig kidney transplants develop 
marked anemia, raising the possibility that pig erythropoietin may not function 
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properly in primates. And in some species combinations, xenogeneic stem cell 
engraftment is diminished by the lack of appropriate stem cell growth factors (82-84). 
These examples indicate that some physiologic functions of xenogeneic organs will 
remain intact, whereas others might not. On one hand, it could be expected that 
appropriately sized pig hearts might function in humans, on the other hand, 
metabolically more complex organs such as the liver may work insufficiently. 
 
3.1.3. Infectious Risks in Xenotransplantation 
Initial microbiological concern focused on pig-derived bacteria or parasites. However, 
the ability to exclude extracellular organisms and bacteria from herds of swine 
destined for the use as organ donors has focused attention on potential viral 
pathogens. To date, a number of such pathogens have been identified that may 
cause a risk of infection by the transmission from the xenograft to the donor. These 
pathogens include porcine endogenous retrovirus (PERV), porcine cytomegalovirus, 
and porcine lymphotropic herpesvirus (85). Transplantation poses a unique 
epidemiologic hazard due to the efficiency of the transmission of pathogens with the 
graft, facilitated also by the use of immunosuppressive drugs. 
Concern about retroviral transmission in xenotransplantation relates to the potential 
for “silent” transmission, i.e. an unapparent infection which may cause altered gene 
regulation, oncogenesis, or recombination. This may result in an activation of latent 
virus and the development of clinical manifestations, if any, more than a decade later. 
So far, only three closely related C-type PERV (PERV A, B, C) have been identified 
in swine that possess infectious potential (86-89). Two of these, PERV-A and -B, can 
infect human and pig cells in vitro, whereas the third group, PERV-C, infects porcine 
cells only (90). PERV mRNAs are expressed in all pig tissues and in all breeds of 
swine tested so far, but size and amount of it differs, consistent with the in vivo 
recombination and/or processing (91). On the other hand, no evidence of infection of 
human cells has been demonstrated in vivo and no disease resulting from this family 
of viruses has been described in swine or humans to date (92-95). Furthermore, 
PERV appears to be susceptible to currently available antiviral agents (96). 
Activation of latent herpes virus infection during periods of intensive immune 
suppression or immune dysfunction and by immune reactivity to grafts is an 
important problem in human allotransplantation (97). Comparable viruses also exist 
in swine, but tend to be species-specific and therefore would be expected to cause 
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infection only in host species-derived tissues. A variety of other potential human 
pathogens have been described in swine, including porcine circovirus, porcine 
encephalomyocarditis virus, swine influenza viruses, and others. However, none has 
yet been associated with human diseases. 
 
3.1.4. Therapeutical Strategies to Overcome Xenograft Rejection 
Cyclosporine and other immunosuppressive drugs that efficiently inhibit allograft 
rejection, are not able to control the massive induction of immune responses in pig-
to-human xenotransplantation models (98). However, there are strategies shown to 
be efficient in preventing HAR. These include the removal of xenoreactive NAb by 
plasmapheresis or immunoabsorption using columns carrying solid phase αGAL 
oligosaccharides (17), the administration of soluble synthetic α−GAL molecules to 
block anti-αGAL NAb, and the depletion/inactivation of complement using soluble 
complement receptor I (99), cobra venom factor (only for rodents and baboons), and 
mAb directed against complement proteins (100). However, all these therapies 
influence the graft recipient. One great advantage of xenotransplantation is that 
xenogeneic organs may be adapted before transplantation. Since techniques for the 
generation of transgenic and knockout animals have improved a lot in the recent 
years, there are nearly unlimited possibilities for strategies to prevent xenorejection. 
For these reasons, huge efforts to identify potential molecules involved in the process 
of rejection are going on, with the aim of remodelling or eliminating them. On the 
other hand, also molecules with the potential to protect a xenograft need to be 
identified in order to transgenically express them on pig organs. 
To date, a surface molecule on pEC, αGAL, has been identified as a major factor 
leading to HAR (15) (see chapter 3.1.2.1). In the year 2003, αGAL-deficient pigs 
were generated by the elimination of both functional alleles of the α1,3GT gene (101, 
102). Hearts and kidneys of these animals showed a significantly prolonged survival 
in baboon recipients even in the presence of complement and Nab (103-105). These 
studies showed that HAR may be overcome by the use of organs from αGAL-
deficient pigs. Nevertheless, non-α-Gal-specific NAb in human serum may still lead 
to complications. The identification of these Nab and their ligands is currently in 
progress. Another important role in HAR is accredited to the activation of human 
complement (7). Kidneys derived from pigs transgenically expressing human 
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complement regulatory proteins, such as CD46, CD55, or CD59, survived for up to 
three months in baboon recipients (106-108). 
To overcome cell-mediated xenograft rejection, MHC class I molecules to inactivate 
human NK cells, and the human FasL to induce apoptosis in activated human T and 
NK cells, were expressed on pEC (74, 75, 109, 110) (see also results section 5.4.). In 
vitro, such cells were partly protected from cell-mediated xenograft rejection, 
whereas the physiological relevance still needs to be confirmed by in vivo 
experiments. Recently, pEC derived from HLA-E/β2-microglobulin-transgenic pigs 
showed partial protection against human NK cell lysis (see results section 5.5.). 
Another approach, with the aim of immunological tolerance, is the induction of a 
mixed haematopoietic chimerism (111). Here, the organ recipient receives donor 
bone marrow prior to organ transplantation to induce central tolerance via thymic 
presentation of the foreign Ag. Nevertheless, using this method, rejection of the 
haematopoietic stem cells as well as graft-versus-host reactions, need to be 
prevented by immunosuppressive strategies. Finally, the transplantation of thymic 
tissues might also be a possibility to induce tolerance over species barrier (112). An 
overview on possible strategies to prevent xenograft rejection is shown in table 1. 
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Hyperacute Rejection 
 
 
Complement 
 
Application of soluble complement regulatory 
proteins (CRP) 
 
mAb against complement proteins 
 
Overexpression of CRP on pEC 
 
Dextran sulfate 
 
 
Xenoreactive NAb 
 
Immunoabsorption 
 
Plasmapheresis 
 
Blocking of anti-αGAL by the administration of 
soluble αGAL 
 
Removal of αGAL molecules on pig organs 
 
 
Acute Vascular Rejection 
 
 
 
Modulation of thrombogenesis 
 
 
e.g. expression of CD39 
 
Inhibition of Macrophages 
 
 
 
Inhibition of EC activation 
 
 
e.g. with a mutant NF-κB system 
 
Induction of accommodation 
 
 
e.g. by the expression of anti-apoptotic genes 
 
Tolerance induction 
 
e.g. by the induction of a mixed haematopoietic 
chimerism 
 
 
Inhibition of NK-mediated 
rejection 
 
Inhibition of NK recruitment to pEC (blocking of 
chemotaxis, adhesion, and transmigration) 
 
Inhibition of ADCC (same approaches as described 
above for xenoreactive NAb) 
 
Inhibition of NK activation by the transgenic 
expression of MHC class I molecules on pEC 
 
Inhibition of NK activation by the elimination of 
ligands for activating NK receptors 
 
Elimination of activated Fas-positive NK cells by the 
transgenic expression of FasL 
 
 
Table 1: Strategies to prevent xenograft rejection. 
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3.2. Natural Killer Cells 
NK cells are a heterogeneous population of large granular bone marrow-derived 
lymphocytes that are able to lyse target cells and secrete cytokines, such as 
interferon (IFN) -γ , and tumor necrosis factor (TNF) -α. They comprise approximately 
5-15% of PBMC. As a part of the innate immune system, they do not need any prior 
sensitization (113). A primary physiological role of NK cells is to provide early 
defense against pathogenic organisms during the initial response period while the 
adaptive immune system is being activated (114). Although NK cells respond to a 
variety of microorganisms, including bacteria and protozoa, they are particularly 
important in viral infections. NK cells are identified by the surface markers CD16 
(FcγRIII) and CD56 (NCAM), and by the lack of T- and B-cell receptors (71). 90% of 
human peripheral blood NK cells are CD56dimCD16+, whereas the other 10% are 
CD56brightCD16-. While the former exhibit high natural cytotoxicity, the latter produce 
large amounts of cytokines (115). Under physiologic conditions, NK cytotoxicity is 
accurately regulated in order to lyse only transformed or infected cells (71). Two 
major checkpoints control target cell susceptibility to NK cytotoxicity: (i) the 
expression of ligands for various NK activating receptors and (ii) the presence of 
MHC class I molecules interacting with inhibitory NK receptors. As a result of direct 
ligand interaction, the inhibitory receptors that bind HLA class I molecules including 
killer immunoglobulin-like receptors (KIR), Ig-like transcript (ILT) 2 and the 
CD94/NKG2 family (116), prevent NK cell activation and killing, providing the 
molecular basis for Kärre’s “missing-self” hypothesis (117, 118) (Figure 4). On the 
other hand, NK cells also express activation receptors, such as NKp30, NKp44, and 
NKp46 (119), collectively named natural cytotoxicity receptors (NCR), and NKG2D 
(120), that recognize target cell ligands and can trigger perforin-dependent 
cytotoxicity. Consequently, NK cytotoxicity occurs if stimulatory signals outweigh 
inhibitory signals derived from a potential target cell. 
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Figure 4: Missing-self hypothesis (117). Schematic picture of possible outcomes after interaction of 
human NK cells and potential target cells. The amount of activating and inhibitory receptors on NK 
cells and the amount of corresponding ligands on target cells determine the extent of the NK cell 
response. 
 
3.2.1. NK Inhibitory Receptors 
All of the well-defined inhibitory NK receptors possess one or more copies of the 
consensus sequence Ile/Val/Leu/Ser-x-Tyr-xx-Leu/Val, where x denotes any amino 
acid (aa), in their cytoplasmic domains (121). This consensus sequence is called 
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immunoreceptor tyrosine-based inhibitory motif (ITIM) (122). Upon ligand binding, the 
tyrosine residue within the ITIM is phosporylated by a Src family kinase and 
phosphatases are recruited through their SH2-domains. These phosphatases damp 
or prevent NK cell effector functions, i.e. cytotoxicity and cytokine production. 
NK receptors that recognize “classical” and “nonclassical” MHC class I molecules 
have been identified, including the rodent Ly49 receptors, human KIR, Ig-like 
transcripts (ILT or leukocyte Ig-like receptors, LIR), and conserved CD94/NKG2 
receptor family (123) (Table 2). A molecular explanation for the missing-self 
hypothesis was provided first by the demonstration by Yokohama and colleagues 
(124) which demonstrated that the subset of NK cells expressing Ly49A receptor 
were preferentially unable to kill tumor cells expressing H-2Dd. This receptor is the 
prototypic member of a small gene family that encodes type II transmembrane-
anchored glycoproteins expressed on a subset of NK cells and memory T cells. Most 
of these genes encode ITIM-bearing inhibitory receptors, whereas others are 
activating receptors without ITIM (125). Detailed insights into NK cell recognition was 
provided by the analysis of structures of inhibitory Ly49 and H-2 complexes (126). 
The homodimeric Ly49A receptor binds to H-2Dd at two distinct sites, one of which 
involves the α1 and α2 domains of MHC class I, whereas the second interaction site 
spans the α1, α2, α3 domains and β2-microglobulin (β2m). 
Humans do not have Ly49 genes, but an NK receptor system with all of the same 
general features has evolved to provide the same functions in primates: the human 
KIR gene family. These genes are expressed by subsets of NK cells (127, 128), 
γδTCR+ T cells, and memory/effector αβTCR+ T cells (129). KIR evolved from the Ig 
superfamily, whereas Ly49 proteins are C-type lectins in structure. KIR receptors are 
type I transmembrane glycoproteins with two Ig-like domains (designated KIR2D) or 
three Ig-like domains (designated KIR3D) in the extracellular region (130). Their 
cytoplasmic domains are variable in length: some receptors possess long (L) 
cytoplasmic domains with one or two ITIM sequences, and other receptors have 
short (S) cytoplasmic domains without ITIM. They recognize intact HLA class I 
trimers, composed of heavy chain, β2m, and peptide, of different type (HLA-A, -B, 
and -C). Although residues at position seven and eight in the peptide have been 
implicated as the most important, KIR receptors do not distinguish self from nonself 
peptides (131). Binding of inhibitory KIR to their MHC class I ligands on potential 
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target cells results in suppression of cytotoxicity and cytokine secretion by KIR-
bearing NK and T cells. 
The CD94 and NKG2 gene family is present in the genome of humans, rat, and 
mouse (132). Unlike the Ly49 and KIR genes, the CD94 and NKG2 genes have 
limited polymorphism, and the minor allelic variants have not been shown to affect 
the function of these receptors (133). They encode type II transmembrane proteins of 
the C-type lectin family. CD94 is expressed on cell surface either as a disulfide-linked 
homodimer or as a disulfide-linked heterodimer with NKG2A, functioning as an 
inhibitory receptor bearing an ITIM in its cytoplasmic domain, or with NKG2C, serving 
as an activating receptor (134). CD94/NKG2 receptors are expressed on most NK 
cells and on several T cell subsets (135). Unlike the KIR and Ly49 receptors that are 
stably maintained once expressed, CD94/NKG2 receptors are modulated by 
cytokines in the environment, such as IL-15, TGF-β, and IL-12. Human CD94/NKG2A 
and CD94/NKG2C heterodimers bind HLA-E, a monomorphic MHC class I molecule 
expressed at weak levels on most tissues (136-138). The binding of HLA-E to 
CD94/NKG2A, and subsequent negative signaling, is highly dependent on the nature 
of the peptide bound to HLA-E and the HLA class I signal sequence-derived peptides 
are optimal in this regards (136, 139). 
 
Receptor Ligand Superfamily 
KIR2DL1 HLA-C group 2 Ig-like superfamily 
KIR2DL2 HLA-C group 1 Ig-like superfamily 
KIR2DL3 HLA-C group 1 Ig-like superfamily 
KIR3DL1 HLA-Bw4 Ig-like superfamily 
KIR3DL2 HLA-A Ig-like superfamily 
ILT2/LIR1 HLA-G Ig-like superfamily 
CD94-NKG2A/B HLA-E C-type lectin 
 Table 2: NK inhibitory receptors 
 
3.2.1.1. NK Inhibitory Receptors in Xenotransplantation 
The susceptibility of pEC to human NK cytotoxicity may be explained by the failure of 
SLA class I molecules to interact with human NK inhibitory receptors. In line with this, 
several studies demonstrated that transgenic expression of HLA-Cw3 and HLA-G on 
pEC provides partial protection from human NK cytotoxicity (74, 75, 79). However, 
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polymorphic HLA-C expressed on pig cells triggers allorecognition by T cells, which 
can be prevented by genetical modification of HLA-C (76, 79). Conversely, the wide 
expression of HLA-E-specific inhibitory receptors of the CD94/NKG2 family on IL-2-
activated NK cells proposes HLA-E as an attractive candidate to prevent NK cell-
mediated damage in xenotransplants by transgenic expression. Using this concept, 
conflicting results were obtained so far (77, 78, 140). Although not rigorously 
examined, human β2m may also be required for maximal cell-surface expression of 
HLA-E in pig cells. Generating pigs transgenic for HLA-E, the final goal of this 
approach to protect porcine grafts from human NK cytotoxicity, would therefore 
require the addition of three human genes (HLA-E heavy chain, human β2m, and a 
gene encoding for an HLA-E binding peptide) in order to ensure stable HLA-E cell-
surface expression. To circumvent this technically difficult and tedious obstacle, a 
single chain trimer (SCT) of HLA-E has been constructed and expressed in pig cells 
(141), leading to a significant reduction of NK-mediated cytotoxicity (see results 
section 5.4.). Furthermore, pEC derived from HLA-E/β2m-transgenic pigs were 
significantly less susceptible against NK-mediated cytotoxicity in vitro (see results 
section 5.5.). 
 
3.2.2. NK Activating Receptors 
Activating receptors on NK cells include NKp30, NKp44, and NKp46 (119), 
collectively named NCR, and NKG2D (120) (Figure 5, Table 3). NCR play a major 
role in NK-mediated killing of tumor cell lines as revealed by mAb-mediated receptor-
masking experiments. There is a direct correlation between the surface density of 
NCR and the ability of NK cells to kill various tumors (142). However, as shown by 
cytotoxicity assays, human NK cells lyse pEC only through NKG2D and NKp44 
receptors, whereas NKp30 and NKp46 appear not to play a role in NK-mediated 
xenogeneic cytotoxicity (73). Despite considerable efforts, the cellular ligands 
recognized by NCR are still not defined. However, as revealed by cytolytic assays, 
NCR ligands are expressed by cells belonging to different histotypes (119). While 
NKp30 and NKp46 are detected on all NK cells regardless of their activation status, 
NKp44 is selectively expressed by activated NK cells (143). Other triggering surface 
molecules expressed by NK cells appear to function primarily as co-receptors (119) 
because their ability to signal depends on simultaneous co-engagement of a main 
triggering receptor. This group includes NK-specific receptors such as NKp80 (144), 
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2B4 (145), NTB-A (146), and receptors that are not unique to NK cells such as CD59, 
CD2, ICAM, CD69, β1 integrins, and DNAM-1. Apart from the direct cytotoxicity 
described above, NK cells can also be triggered by ADCC. This mechanism is 
mediated by CD16 on NK cells interacting with immunoglobulins bound to target 
cells. 
 
Receptor Ligand Superfamily 
KIR2DS1 HLA-C group 2 Ig-like superfamily 
KIR2DS2 HLA-C group 1 Ig-like superfamily 
KIR3DS1 HLA-Bw4 Ig-like superfamily 
CD94-NKG2C/E HLA-E C-type lectin 
NKG2D MIC-A/-B, ULBP1-4 C-type lectin 
NKp30 unknown Ig-like superfamily 
NKp44 unknown Ig-like superfamily 
NKp46 unknown Ig-like superfamily 
 Table 3: NK activating receptors 
 
 
Figure 5: Surface receptors involved in natural cytotoxicity and their association with distinct 
signal transducing molecules (119). NCR and 2B4 are type I glycoproteins belonging to the Ig-
superfamily. NKG2D and NKp80 are dimeric type II glycoproteins belonging to the C-type lectin 
receptor family. 
 
3.2.2.1. NKG2D and its Ligands 
NKG2D, a C-type lectin surface receptor, is a member of the NKG2 family, but only 
distantly related to the other members of the family and unlike the others, does not 
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form heterodimers with CD94 (147). It is expressed as a disulfide-linked homodimer 
on the surface of all mouse and human NK cells and most γδTCR+ T cells (148). The 
NKG2D expression on NK and T cells can be increased by culture in IL-15 or TNF-α , 
but is significantly downregulated in the presence of TGF-β. In contrast to the other 
triggering receptors, the surface expression of NKG2D requires association with 
DAP10 or KAP10 (149). DAP10 is characterized by the presence of a negatively 
charged residue in the transmembrane portion and by a Tyr-xx-Met motif (where x 
denotes any aa) in the cytoplasmic tail that, upon tyrosine phosphorylation, binds to 
PI3-kinase. 
Several ligands of NKG2D on human cells have been identified, namely the stress-
inducible UL16-binding proteins (ULBP) (150) or MHC class I chain-related proteins 
A and B (MICA/B) (151). The ULBPs were identified based on their ability to bind the 
human cytomegalovirus (CMV) glycoprotein UL16. These are glycosylphosphatidyl-
inositol (GPI) -linked proteins, distantly related to members of the HLA class I family 
possessing α1 and α2 domains, but not an α3 domain (152) and they are unable to 
present peptides (153). MICA and MICB, on the other hand, possess all three α-
domains and are both transmembrane proteins. Like the ULBPs, MICA and MICB do 
not bind β2m or present peptides (154). 
In an attempt to identify the porcine ligands for human NKG2D, molecular cloning 
and characterization of a porcine homologue of the human ULBP proteins, porcine 
ULBP1 (pULBP1) has recently been described (155). PULBP1 exhibits 35-52% aa 
identity to human ULBPs and phylogenetic analyses place pULBP1 evolutionarily 
close to the bovine ULBP-like genes MHCLA1 and MHCLA2. The pULBP1 aa 
sequence exhibits a relatively high level of aa conservation at positions predicted to 
make contact with NKG2D (153). Southern blot analysis suggested that only one 
pULBP exists in the pig genome (155), which is in sharp contrast to the at least six 
expressed in humans. However, considering hybridization conditions in these 
studies, the possibility that other more distantly related porcine ULBP-like genes exist 
cannot be excluded. 
The sequence of porcine MIC2 (pMIC2), a porcine homologue of the human MIC 
proteins, has been previously reported (156). It is comprised of six exons and the 
predicted aa sequence displays characteristics similar to those of the human MIC 
genes, such as four N-glycosylation sites, three of which are apparent counterparts 
of the human glycosylation sites at position 208, 235 and 263. In addition, several 
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cysteine residues within the pMIC2 α2 and α3 domains may participate in the 
formation of disulfide bonds. Similarly to the human MIC genes, a consensus heat 
shock element, but no iron response element, was found upstream of the porcine 
exon one. Both pULBP1 and pMIC2 transcripts could be detected in pEC and pMIC2 
transcripts were increased following heat shock or retinoic acid treatment (155). But 
only pULBP1 represents a functional ligand for the human NKG2D (157) (see results 
section 5.2.). 
 
3.2.2.2. NKp44 
NKp44 displays a molecular size of 44 kDa and induces triggering of NK-mediated 
cytotoxicity upon cross-linking by specific mAb (143). Its expression is restricted to 
IL-2-activated NK cells, whereas it is absent in fresh peripheral blood NK cells. 
Therefore, NKp44 can be used as a specific marker for activated human NK cells. 
Moreover, IL-2-activated NK cells acquire an increased cytolytic activity against NK-
susceptible targets, also of swine origin (158). NKp44 is a glycoprotein with a protein 
backbone that associates with the immunoreceptor tyrosine-based activating motif 
(ITAM)-bearing DAP12 signal-transducing molecules that become tyrosine 
phosphorylated upon NKp44 cross-linking (159). Molecular cloning revealed a 
member of the Ig-superfamily characterized by a single extracellular V-type domain, 
a positively charged transmembrane domain (containing the aa Lys), and a short 
cytoplasmic domain without ITAM. The association of Lys with DAP12 molecules that 
contain a single ITAM in the cytoplasmic portion and are expressed as disulfide-
bonded homodimers, goes over negatively charged residues in the transmembrane 
domain of DAP12. The ligand(s) for NKp44 remain(s) still unidentified, although it 
was described that viral hemagglutinins expressed on the surface of virus-infected 
cells are involved in the recognition by NKp44 and NKp46 (160). 
 
3.2.2.3. NKp30 and NKp46 
NKp30 and NKp46 were both identified as activating NK receptors by redirected 
killing assays. They are expressed on all NK cells, irrespective of their state of 
activation. The molecular size is approximately 30 kDa and 46 kDa, respectively, and 
they are associated with CD3ζ chains that contain several ITAM (119). Molecular 
cloning of the cDNAs encoding for NKp30 (161) and NKp46 (162) revealed members 
of a type I transmembrane glycoprotein belonging to the Ig superfamily. For NKp30, 
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the extracellular portion is characterized by a single domain of the V-type and by a 
region rich in hydrophobic aa. NKp46 has two C2-type Ig-like domains in the 
extracellular portion, followed by a stretch of aa possibly forming a stem connecting 
the ectodomain to the transmembrane region. The transmembrane regions contain 
the positively charged aa Arg, probably involved in the association with CD3ζ chains. 
The cytoplasmic portions do not contain ITAM typically involved in the activation of 
signal cascades, but NKp30 and NKp46 are coupled to the intracytoplasmic 
transduction machinery by their association with CD3ζ chains and, in the case of 
NKp46, also with FcεRIγ, that contains ITAM. Cross-linking of NKp30 and NKp46 by 
mAb resulted in Ca2+ flux, cytotoxicity and cytokine production. Unlike NKG2D, the 
ligands for NKp30 and NKp46 remain elusive. 
 
4. Aims of the Study 
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4. Aims of the Study 
The overall goal of this study was to increase our knowledge of NK cell-mediated 
xenogeneic rejection mechanisms. Here, I focussed on the identification of factors 
regulating the cytotoxic potential of human NK cells against pEC. Because NK cells 
are considered to play a significant role in xenograft rejection, a better understanding 
of the complex interactions between receptors on human NK cells and their 
corresponding ligands on pEC might lead to novel strategies to improve 
xenotransplant survival. 
 
1. NK cells are tightly regulated by inhibitory as well as activating receptors that are 
expressed on their surface. Inhibitory receptors, such as KIR, recognize MHC class I 
molecules and prevent NK cells from killing a potential target cell. On the other hand, 
there are four major activating receptors, namely NKG2D and the NCR NKp30, 
NKp44, and NKp46, which promote NK cell-mediated cytotoxicity. Their surface 
density on NK cells correlates with the magnitude of cytolytic activity against NK cell-
susceptible target cells. Corresponding ligands to these receptors are expressed on 
the surface of a variety of normal human cells, but are upregulated on tumour and 
virus-infected cells. However, this study is the first to investigate the role of activating 
NK cell receptors in a pig-to-human xenotransplant setting. Furthermore, the general 
role of NK cell-mediated cytotoxicity against pEC and the phenotype and cytotoxic 
potential of a panel of NK cell clones were analyzed. 
 
2. Having identified two important activating NK receptors (NKG2D and NKp44) in 
stage 1 of the project, the next step was to identify their corresponding ligands on 
porcine cells. One advantage of xenotransplantation is the possibility to genetically 
manipulate pig organs, with the aim of maximizing transplant survival with an organ-
specific approach, and reducing the amount of drugs and therapies necessary to 
administer to the graft recipient. NKG2D is expressed on all human NK cells 
regardless of their activation status, whereas NKp44 is only expressed on IL-2-
activated human NK cells. Thus, NKG2D may play a more important role in NK cell-
mediated xenograft rejection. Porcine ULBP1 and pMIC2 are homologues of the 
human NKG2D ligands ULBP1-4 and MICA/MICB, respectively. Although pULBP1 
and pMIC2 were known to be expressed in pEC, one aim of this study was to 
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investigate whether these surface molecules also act as functional ligands for human 
NKG2D. After the identification of pULBP1 as the predominant, if not the only, 
porcine ligand for human NKG2D, a mAb was generated and used to characterize 
pULBP1 surface expression levels on pEC after various treatments, such as cytokine 
stimulation, co-incubation with human serum, or CMV infection. 
 
3. Human NK cell-mediated cytotoxicity against porcine cells may be caused by 
incompatible cross-species interactions between porcine MHC class I molecules and 
inhibitory human NK cell receptors. This notion was supported by the finding that 
expression of specific HLA class I molecules on pEC, such as HLA-E, results in 
complete protection from cytotoxicity mediated by NK cell clones expressing the 
respective HLA-specific inhibitory receptor (110). However, only partial protection 
from cytotoxicity mediated by polyclonal human NK cell populations was observed. 
Furthermore, it was shown that this protection depends on extrinsic peptide loading. 
Although not rigorously examined, human β2m may also be required for maximal 
cell-surface expression of HLA-E in pig cells. The generation of transgenic pigs 
providing organ grafts resistant to CD94/NKG2A+ human NK cell-mediated 
cytotoxicity may therefore require transgenic expression of three different human 
genes (HLA-E heavy chain, human β2m, and a gene encoding for an HLA-E-binding 
peptide), in order to ensure stable expression of HLA-E on cell surface. To 
circumvent this technically difficult model, a SCT variant of HLA-E has been 
constructed and expressed in pig cells (141). This construct was composed of a 
canonical HLA-E-binding peptide antigen, VMAPRTLIL, the mature human β2m, and 
the mature HLA-E heavy chain. One aim of this study was to test whether the 
exogenous expression of HLA-E SCT protects pEC against xenogeneic cytotoxicity 
mediated by IL-2-activated human NK cells derived from healthy donors. 
Furthermore, pEC derived from HLA-E/β2m-transgenic pigs were tested for their 
ability to resist NK cell-mediated cytotoxicity in vitro. 
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5.1. Human NK cytotoxicity against porcine cells is triggered by 
NKp44 and NKG2D 
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5.1.1. Abstract 
Pig-to-human xenotransplantation has been proposed as a means to alleviate the 
shortage of human organs for transplantation, but cellular rejection remains a hurdle 
for successful xenograft survival. NK cells have been implicated in xenograft rejection 
and are tightly regulated by activating and inhibitory receptors recognizing ligands on 
potential target cells. The aim of the present study was to analyze the role of 
activating NK receptors including NKp30, NKp44, NKp46, and NKG2D in human 
xenogeneic NK cytotoxicity against porcine endothelial cells (pEC). 51Cr-release and 
antibody blocking assays were performed using freshly isolated, IL-2-activated 
polyclonal NK cell populations as well as a panel of NK clones. Freshly isolated NK 
cells are NKp44 negative and lysed pEC exclusively in an NKG2D-dependent 
fashion. In contrast, the lysis of pEC mediated by activated human NK cells 
depended on both NKp44 and NKG2D, since a complete protection of pEC was 
achieved only by simultaneous blocking of these activating NK receptors. Using a 
panel of NK clones a highly significant correlation between anti-pig NK cytotoxicity 
and NKp44 expression levels was revealed. Other triggering receptors such as 
NKp30 and NKp46 were not involved in xenogeneic NK cytotoxicity. Finally, 
antibody-dependent cell-mediated cytotoxicity (ADCC) of pEC mediated by human 
NK cells in the presence of xenoreactive Ab was not affected by blocking of 
activating NK receptors. In conclusion, strategies aimed to inhibit interactions 
between NKp44 and NKG2D on human NK cells and so far unknown ligands on pEC 
may prevent direct NK responses against xenografts but not xenogeneic ADCC. 
 
5.1.2. Introduction 
The clinical use of porcine organs to alleviate the current shortage of human organs 
in transplantation medicine is impeded by the occurrence of several types of vigorous 
rejection mechanisms that lead to rapid graft failure (4, 6). Recently, advances in the 
prevention of hyperacute rejection in preclinical models using genetically engineered 
pigs suggest the importance of both coagulation disorders and cellular immunity in 
human anti-pig xenogeneic responses (103, 104). Despite the fact that prolonged 
survival of these xenografts has been achieved without specifically inhibiting NK 
cells, they might play an important role in endothelial injury and delayed rejection of 
porcine xenografts. This hypothesis is supported by the finding that in vitro NK cells 
activate porcine endothelium upon direct contact and act as a potent source for pro-
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inflammatory cytokines such as interferon-γ (48, 53). On the other hand, NK cell 
activation depends, amongst others, on T cell-derived IL-2 stimulation, an interaction 
between the innate and adaptive immune system that might be interrupted by 
conventional immunosuppressive protocols used in preclinical models for 
xenotransplantation. Human NK cells have further been demonstrated to adhere to 
and lyse porcine target cells both directly and, in the presence of human serum 
containing xenoreactive Ab, by Ab-dependent cell-mediated cytotoxicity (ADCC) (46, 
54). In addition, pig organs perfused with human blood ex vivo are predominantly 
infiltrated by NK cells (57, 59) and NK cells are present in histological samples of 
graft rejection in concordant and discordant rodent and preclinical pig-to-baboon 
models (60-62). Thus, although the potential role of NK cells is still controversial, 
strategies to inhibit both direct NK cytotoxicity and ADCC against porcine cells might 
facilitate successful clinical xenotransplantation. 
 
Under physiologic conditions NK cytotoxicity is accurately regulated in order to lyse 
only transformed or infected cells (71). Two major checkpoints control target cell 
susceptibility to NK cytotoxicity: (i) the expression of ligands for various NK activating 
receptors and (ii) the presence of MHC class I molecules interacting with inhibitory 
NK receptors. The killing signals transduced by activation receptors are balanced by 
several groups of inhibitory receptors that bind HLA class I molecules including killer 
immunoglobulin-like receptors (KIR), ILT2 and the CD94/NKG2 family (116). 
Consequently, NK cytotoxicity occurs when NK cells encounter ligands for activating 
receptors on potential target cells that, in addition, have lost or downregulated MHC 
class I expression. Porcine endothelial cells (pEC) are susceptible to human NK-
mediated lysis possibly due to the inability of their MHC class I molecules to signal 
through human NK cell inhibitory receptors (72). 
 
Theoretically, xenogeneic NK cytotoxicity could be avoided either by expressing HLA 
class I molecules on porcine cells or by blocking the function of activating receptors. 
Indeed, we and others have previously demonstrated that the expression of human 
MHC class I molecules including HLA-B27, -Cw3, -E, and -G on porcine cells 
provided partial protection from lysis mediated by polyclonal human NK cells (74-79). 
However, complete inhibition of NK cytotoxicity has not been achieved by transgenic 
HLA class I expression since the corresponding NK inhibitory receptors for each HLA 
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molecule were expressed only on NK subpopulations. Moreover, protection from 
ADCC by HLA class I expression has been demonstrated only for NK clones, but not 
for polyclonal NK cells (76, 80). 
 
Activating receptors on NK cells include NKp30, NKp44, and NKp46 (119), 
collectively named natural cytotoxicity receptors (NCR), and NKG2D (120). NCR play 
a major role in NK-mediated killing of tumor cell lines as revealed by mAb-mediated 
receptor-masking experiments. Their surface density on NK cells correlates with the 
magnitude of cytolytic activity against NK-susceptible target cells. Despite 
considerable efforts, the cellular ligands recognized by NCR are still not defined. 
However, as revealed by cytolytic assays, NCR ligands are expressed by cells 
belonging to different histotypes (119). While NKp30 and NKp46 are detected on all 
NK cells regardless of their activation status, NKp44 is selectively expressed by 
activated NK cells (143). In contrast to NCR, several ligands of NKG2D have been 
identified, including the stress-inducible MHC class I chain-related proteins A (MICA) 
and B (MICB) or UL16-binding proteins (ULBP) (150). Other triggering surface 
molecules expressed by NK cells appear to function primarily as co-receptors (119), 
because their ability to signal depends on simultaneous co-engagement of a main 
triggering receptor. This group includes NK-specific receptors such as NKp80, 2B4, 
NTB-A, and receptors that are not unique to NK cells such as CD59, CD2, ICAM, 
CD69, β1 integrins, and DNAM-1. Apart from the direct cytotoxicity described above, 
NK cells can also be triggered by ADCC. This mechanism is mediated by FcRIII 
receptors (CD16) on NK cells interacting with immunoglobulins bound to target cells.  
 
The aim of the present study was to explore the hypothesis that human NK 
cytotoxicity against porcine cells might be overcome by blocking activating NK 
receptors. We demonstrate that human NK cytotoxicity against pEC depends 
exclusively on NKp44 and NKG2D signals. 
 
5.1.3. Material and Methods 
Cells 
Two SV40-immortalized pEC lines, the aortic PEDSV.15 and the bone-marrow-
derived microvascular 2A2 cell lines, were established and characterized in our 
laboratory (163). A primary aortic pEC (PAEC) was isolated using a protocol 
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previously described (163) and cultivated in S199 (Gibco, Basel, Switzerland) 
supplemented with 15% FCS (PAA Laboratories, Lucerne, Switzerland), non-
essential amino acids (100x) (Invitrogen, Basel, Switzerland), 
1% penicillin/streptomycin (Gibco), 20mM HEPES (Invitrogen), 50 µg/ml ECGS (BD 
Biosciences, Allschwil, Switzerland), and 100 µg/ml heparin (Sigma, Buchs, 
Switzerland). The human melanoma cell line Mel-15 (a kind gift of M. Urosevic, 
University Hospital Zürich), the immortalized porcine lymphoblastoid cell line 
13271.10 (a kind gift of G. Waneck (Massachusetts General Hospital, Boston, MA) 
(76, 164) and the human lymphoblastoid cell line 721.221 (ATCC, Molsheim Cedex, 
France) (165) were cultured in RPMI (Invitrogen) supplemented with 12.5% FCS. 
Isolation of PBMCs from healthy blood donors, purification of NK cells, and 
generation of monoclonal and polyclonal human NK cell populations have been 
described previously (74). After isolation, the purity of NK cells was routinely > 95%, 
the cells were either used directly or activated by culture in AIM-V medium 
(Invitrogen) supplemented with 10% human plasma obtained from healthy donors, 1 
mM sodium pyruvate, 2 mM L-glutamine, essential amino acids (50x), non-essential 
amino acids (100x), 1% penicillin/streptomycin, 20 mM HEPES (all Invitrogen), and 
300 U/ml of human IL-2 (Chiron, Emeryville, CA). 
 
Flow cytometry 
Surface expression of NKp30, NKp44, NKp46, and NKG2D on human NK cells was 
analyzed on a FACScan (Becton Dickinson, Basel, Switzerland) by indirect 
immunofluorescence using the following primary mouse mAb: Z25 (anti-NKp30, 
IgG1, Beckman Coulter/Immunotech, Marseille, France), Z231 (anti-NKp44, IgG1, 
Beckman Coulter/Immunotech), BAB281 (anti-NKp46, IgG1, Beckman 
Coulter/Immunotech), 149810 (IgG1, anti-NKG2D, R&D Systems, Abingdom, UK), 
supernatants of AZ20 (IgG1, anti-NKp30), Z231, BAB281 and ON72 (IgG1, anti-
NKG2D) were a kind gift of A. Moretta, University of Genova. FITC-conjugated goat 
anti-mouse IgG Ab (Chemicon International, Dietikon, Switzerland) was used as a 
secondary reagent. Human NK cells were resuspended at 2 to 5x105 cells per tube in 
staining buffer (HANKS, 0.1% BSA) and incubated for 30 min at 4°C with saturating 
Ab concentrations. Phenotypic analysis of NK cells was carried out by direct 
immunofluorescence using FITC-UCHT1 (anti-CD3), PE-B73.1 (anti-CD16), and PE-
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B159 (anti-CD56) mAb (all from Pharmingen, Allschwil, Switzerland). An irrelevant, 
isotype-matched control mAb (MOPC21, mouse IgG1, Sigma) was used as control 
and propidium iodide gating to exclude dead cells in all experiments. To compare the 
levels of surface expression, the geometric mean fluorescence intensity ratios (MFIR) 
were calculated by dividing the mean fluorescence intensity of staining with the mAb 
of interest with the mean fluorescence intensity of the control mAb. 
 
Cytotoxicity assays 
The cytotoxic activity of freshly isolated and IL-2-activated monoclonal and polyclonal 
human NK cells was tested in two or four hours 51Cr-release assays in serum-free 
AIM-V medium as described previously (166). Briefly, labeled target cells were added 
to triplicate samples of serial twofold dilutions of NK cells in round-bottom 96-well 
plates. Four E:T ratios ranging from 40:1 to 2.5:1 were determined in each 
experiment. For blocking studies, NK cells were preincubated for 30 min at 4°C with 
10 µg/ml mAb (for all figures except figure 4A) or 10l hybridoma supernatant (for 
figure 4A) either independently or in combinations. Monoclonal Ab were also present 
during the coincubation of target and effector cells at a concentration of 5 µg/ml. To 
determine ADCC, 51Cr-release assays were performed in the presence of 10% 
decomplemented (heat-inactivated) human serum. Human sera were obtained from 
healthy adult volunteers. Decomplementation by heat-inactivation was carried out at 
56°C for 30 min. Samples were stored at 4°C for short periods or aliquoted and 
stored at -20°C. After incubation for 2 or 4 h at 37°C, the assays were stopped, 51Cr-
release was analyzed on a gamma counter and the percentage of specific lysis was 
calculated. 
 
5.1.4. Results 
Expression of natural cytotoxicity receptors and NKG2D on human NK cells 
To comprehensively evaluate the role of activating receptors involved in human NK 
cell-mediated lysis of pEC, it was necessary to carefully determine the cell surface 
expression of NCR and NKG2D on the NK cells used for functional studies under our 
conditions. Freshly isolated NK cells were NKp30, NKp46, and NKG2D positive, but 
NKp44 negative (Fig. 1A), whereas IL-2-activated NK cells were also positive for 
NKp44 (Fig. 1B). The MFIR of NKG2D and NKp30 were higher on activated NK cells, 
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whereas the MFIR of NKp46 was higher on freshly isolated NK cells. We also 
analyzed the surface expression of activating NK receptors 2 to 3 weeks following 
limiting dilution cloning on NK clones cultured in the presence of IL-2. MFIR values 
equal or greater than 1.5 were considered to be positive. In close agreement to the 
analyses of polyclonal NK populations, all NK clones analyzed (n=77) were NKG2D 
positive (mean MFIR of 13 ± 6), 97% were also NKp44 positive (mean MFIR of 9 ± 
6), 91% were NKp30 positive (mean MFIR of 3 ± 1) and 71% were NKp46 positive 
(mean MFIR of 2 ± 0.6). In a repeated flow cytometry analysis after additional four 
weeks of culture no significant changes in the expression level of NKp30, NKp44, 
and NKG2D were observed, whereas all NK clones were now NKp46 positive. 
However, these results were obtained from a limited number of NK clones (n=7), due 
to their restricted life-time in culture. The NKp44 and NKG2D expression pattern of 
the polyclonal NK populations from which the clones were generated was similar: 
97% of the cells were NKG2D positive (MFIR of 19) and 50% NKp44 positive (MFIR 
of 3.5). In contrast, only a minor fraction of polyclonal NK populations was NKp30 
(8%, MFIR of 1.6) or NKp46 (2%, MFIR of 2.5) positive. Flow cytometry analysis of 
the activating NK receptors was always repeated at the day of the cytotoxicity assay. 
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Figure 1: Cell surface expression of NCR and NKG2D. Freshly isolated (A) and IL-2-activated (B) 
NK cells were analyzed by flow cytometry using either anti-NKp30 , -NKp44, -NKp46, and -NKG2D 
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mAb (filled histograms) or an isotype-matched control mAb (empty histograms, dashed lines). 
Numbers indicate MFIR. 
 
Cytotoxicity of freshly isolated and IL-2-activated NK cells against immortalized 
porcine endothelial cells 
Freshly isolated NK cells and polyclonal NK populations generated in the presence of 
IL-2 were tested for their ability to lyse the immortalized pEC lines PEDSV.15 and 
2A2. A substantial difference in NK cytotoxicity against PEDSV.15 mediated by 
freshly isolated versus IL-2-activated NK cells at an E:T ratio of 20:1 was evident (21 
± 9% versus 48 ± 22% median specific lysis, n=10 and 37, respectively, Fig. 2A). The 
lysis of 2A2 cells by activated NK cells was comparable (43 ± 21% median specific 
lysis, n=38), whereas lysis of 2A2 cells by freshly isolated NK cells was clearly lower 
(8 ± 5%, n=9), as shown in Figure 2B. 
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Figure 2: Cytotoxicity mediated by freshly isolated or IL-2-activated human NK cells against 
PEDSV.15 and 2A2 target cells. A summary of the cytotoxic activity of freshly isolated (triangles) and 
IL-2-activated (diamonds) NK cells against PEDSV.15 (A) and 2A2 (B) cells is shown. Cytotoxicity was 
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measured in 4 h 51Cr-release assays at an E:T ratio of 20:1 and is expressed as percentage of specific 
lysis. Each triangle/diamond represents one independent experiment, the horizontal lines represent 
the median value of lysis. 
The variability among different donors in the ability of their freshly isolated NK cells to 
lyse pEC was remarkable. This finding is illustrated in Figure 2. Overall, freshly 
isolated NK cells displayed a cytolytic activity ranging between 3 and 54% at an E:T 
ratio of 40:1. Importantly, freshly isolated NK cells displaying a weak cytotoxicity 
against porcine targets were still able to efficiently lyse the MHC class I-deficient 
human target cell line 721.221 (data not shown). Blocking of NKp30, NKp44 and 
NKp46 independently or in combination did not lead to a reduced cytotoxicity of 
freshly isolated NK cells against PEDSV.15 (Fig. 3). Regardless of the individual 
killing efficiency of different donors, blocking of NKG2D was always able to reduce 
xenogeneic cytotoxicity of freshly isolated NK cells significantly without further 
reduction of cytotoxicity by additional blocking of NKp30 and NKp46 (Fig. 3B). 
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Figure 3: NKG2D triggers cytotoxicity of freshly isolated NK cells against PEDSV.15. Freshly 
isolated NK cells purified from different donors were analyzed for the cytolytic activity against 
PEDSV.15  in the presence of the following mAb: IgG1 isotype-control, anti-NKp30, anti-NKp44, anti-
NKp46, anti-NKG2D, or anti-NKG2D/-NKp30/-NKp46 mAb in combination. All results are expressed 
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as percentage of specific lysis and were obtained at four different E:T ratios. Results are 
representative for one out of four (A) and one out of ten (B) independent experiments performed with 
NK cells purified from five different donors. 
In contrast, the cytolytic activity of IL-2-activated human polyclonal NK cells against 
PEDSV.15 depended on both NKG2D and NKp44, but not on NKp30 or NKp46. A 
partial inhibition of xenogeneic NK cytotoxicity was observed by mAb-mediated 
masking of either NKp44 (44% inhibition) or NKG2D (56% inhibition) while isotype-
matched control mAb as well as blocking of NKp30 or NKp46 had no effect (Fig. 4A). 
Neither did a combination of anti-NKp44 mAb with either anti-NKp30 or anti-NKp46 
mAb enhance the inhibitory effect of anti-NKp44 (data not shown).. As a positive 
control for the activity of the anti-NKp30 and -NKp46 mAb to inhibit NK killing we 
used the human melanoma cell line MEL-15. NK-mediated lysis of MEL-15 was 
clearly reduced in blocking assays using NKp30 and NKp46 mAb alone or in 
combination (data not shown). Nearly complete blocking of activated NK-cell 
cytotoxicity against PEDSV.15 was achieved by simultaneous blocking of NKp44 and 
NKG2D receptors (Fig. 4B and C). No difference with regard to the blocking 
efficiency was observed comparing 2 h to 4 h 51Cr-release assays (Fig. 4B and C), 
we only observed a higher specific lysis when co-incubating target and effector cells 
for longer time periods. The cytotoxic response of freshly isolated and IL-2-activated 
NK cells against pEC did not correlate with NKG2D receptor surface densities that 
were similar between different donors (data not shown). 
 
Altogether, these data indicate that NKG2D plays a pivotal role in xenogeneic NK 
cytotoxicity mediated by both freshly isolated and IL-2-activated human NK cells 
whereas NKp44 triggers lysis mediated by IL-2-activated human NK cells. In 
contrast, NKp30 and NKp46 do not play a role in human NK cytotoxicity against pEC. 
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Figure 4: NKp44 and NKG2D but not NKp30 and NKp46 receptors trigger cytotoxicity of NK 
cells against PEDSV.15 cells. The cytotoxic activity of IL-2-activated NK cells was tested against 
PEDSV.15 cells in two and four h 51Cr-release assays in the presence of different combinations of the 
following mAb: IgG1 isotype-control, anti-NKG2D, anti-NKp30, anti-NKp44, anti-NKp46, and anti-
NKG2D/-NKp44 in combination.(A) shows a summary of four independent experiments where 
cytotoxicity is expressed as percentage of relative lysis of PEDSV.15 cells in the presence of the 
indicated mAb as compared to the respective intra-assay control (lysis with isotype-control mAb, 
index=100). The mean relative cytotoxicity was calculated at four different E:T ratios (40:1 to 5:1), 
error bars indicate SEM. (B and C) show representative experiments for one out of five (B) and one 
out of 15 (C) independent experiments performed with NK cells purified from ten different donors. 
 
Xenogeneic cytotoxicity of NK clones against immortalized porcine aortic endothelial 
cells correlates with NKp44 expression levels 
To further analyze the role of NCR and NKG2D in NK-mediated xenogeneic lysis of 
PEDSV.15 a panel of NK clones was generated. NK clones expressing different 
levels of NKG2D and NCR provide a unique tool to study the role of these activating 
receptors. The potential of NK clones to lyse PEDSV.15 cells was tested in the 
absence or presence of mAb against NCR and NKG2D. Lysis of PEDSV.15 
mediated by an NK clone expressing high levels of NKp30 (MFIR of 9) and NKp46 
(MFIR of 6) was markedly reduced (93% inhibition) only by blocking with NKp44- and 
NKG2D-specific mAb, but not by blocking with NKp30- and NKp46-specific mAb 
(Fig. 5A). The combined use of anti-NKp44, -NKG2D, -NKp30, and -NKp46 mAb did 
not further enhance the inhibitory effect of anti-NKp44/NKG2D mAb, providing 
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additional evidence that NKp30 and NKp46 receptors do not recognize any ligands 
on PEDSV.15. 
 
In addition, ten different NKG2D-positive NK clones with MFIR for NKp44 expression 
ranging from 3 to 26, were analyzed for their capacity to lyse PEDSV.15. In the 
absence of NKG2D-mediated activation, i.e. in the presence of saturating 
concentrations of anti-NKG2D mAb, NK cytotoxicity was proportional to the 
expression level of NKp44. Thus, as shown in Figure 5B, PEDSV.15 cells were 
efficiently killed by NKp44bright NK clones while they were partially resistant to 
cytotoxicity mediated by NKp44dull NK clones. In contrast, clonal NK cytotoxicity did 
not correlate with NKp30 and NKp46 cell surface densities. 
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Figure 5. Cytotoxicity of NK clones against PEDSV.15 cells is proportional to NKp44 
expression and independent from NKp30 and NKp46. (A) The cytotoxic activity of an NK clone 
expressing high levels of NCR and NKG2D molecules was tested against PEDSV.15 in the presence 
of the following mAb: IgG1 isotype-control, anti-NKG2D, anti-NKp30, anti-NKp44, anti-NKp46, anti-
NKG2D/-NKp44 and anti-NKG2D/-NKp44/-NKp30/-NKp46 in combination. This experiment is 
representative for one out of two independent experiments. (B) shows cytotoxicity of different NK 
clones in relation to their NKp44, NKp30 and NKp46 expression. Cytotoxicity is expressed as 
percentage of relative lysis of PEDSV.15 cells in the presence of anti-NKG2D mAb as compared to 
the respective intra-assay control (lysis without mAb, index=100). The correlation coefficient (r2) is 
0.956 for NKp44, 0.286 for NKp30 and 0.082 for NKp46. NKp44, NKp30 and NKp46 expression is 
indicated as MFIR. Each square represents a value from a single NK clone. 
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Lysis of primary aortic and immortalized bone marrow-derived porcine endothelial 
cells as well as porcine lymphoblastoid cells depends on NKp44 and NKG2D 
The finding that NKp44 and NKG2D are responsible for IL-2-activated xenogeneic 
NK lysis of PEDSV.15 cells raised the question about the role of these receptors in 
the lysis of other porcine target cells. Thus, NK cytotoxicity against primary porcine 
aortic derived EC (PAEC) (Fig. 6A) and immortalized bone marrow-derived pEC 
(2A2) (Fig. 6B) was analyzed. Both PAEC and 2A2 were protected from IL-2-
activated human NK cytotoxicity in the presence of anti-NKp44 and -NKG2D mAb, 
whereas isotype-matched and anti-HLA class I mAb had no effect. NK cytotoxicity 
against 2A2 seemed to depend predominantly on NKp44 as compared to NKG2D, 
whereas PEDSV.15 cells were mainly killed through NKG2D (Fig. 4). In line, we 
observed that 2A2 cells were clearly less susceptible than PEDSV.15 to NK 
cytotoxicity mediated by freshly isolated NKp44 negative NK cells (Fig. 2B). Taken 
together, these results show that NKp44 and NKG2D function as unique receptors 
involved in human NK-mediated cytotoxicity against pEC independent of the 
respective NK donor. In order to expand our study to cell types other than endothelial 
cells, xenogeneic human NK cytotoxicity against porcine lymphoblastoid cells was 
tested. In parallel to pEC, blocking of NKG2D and NKp44 inhibited the lysis of 
lymphoblastoid cells (Fig. 6C), whereas NKp30 and NKp46 had no effect (data not 
shown). In contrast to pEC, blocking with NKG2D and NKp44 mAb was not sufficient 
to prevent the lysis of lymphoblastoid cells indicating that other activating receptors 
are involved in the lysis of non-endothelial hematopoietic target cells. 
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Figure 6: NKp44 and NKG2D mediate NK cytotoxicity against primary porcine aortic endothelial 
cells (PAEC), the bone marrow-derived 2A2 cell line and the lymphoblastoid cell line 13271.10. 
The cytotoxic activity of IL-2-activated NK cells was tested against PAEC (A), 2A2 cells (B) and 
13271.10 (C) in a 4 h 51Cr-release assay in the presence of the following mAb: IgG1 isotype-control, 
anti-HLA class I, anti-NKG2D, anti-NKp44, and anti-NKG2D/-NKp44 in combination . (A) shows the 
mean specific lysis of three independent cytotoxicity assays using PAEC as targets, error bars indicate 
SEM. The experiments shown in (B) and (C) are representative for one out of three (B) and one out of 
six (C) independent experiments. 
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Xenogeneic ADCC is not prevented by interfering with NKG2D activation 
ADCC of human NK cells against pEC represents a very efficient mechanism of lysis. 
While the involvement of CD16 in ADCC is well documented the role of other 
activating receptors has currently not been investigated. Therefore, the contribution 
of NCR and NKG2D in xenogeneic NK-mediated ADCC against pEC was analyzed. 
NK cytotoxicity mediated by freshly isolated NK cells against PEDSV.15 cells was 
evaluated in the presence of heat-inactivated human serum containing saturating 
amounts of xenoreactive natural Ab. The addition of human serum clearly increased 
the lysis of PEDSV.15 by freshly isolated NK cells, demonstrating a strong NK cell-
mediated ADCC. Blocking with NCR- and NKG2D-specific mAb in 51Cr-release 
assays revealed no inhibitory effect on NK cell-mediated ADCC against PEDSV.15 
cells (Fig. 7). These findings indicate that activation signals transmitted by CD16 are 
sufficient to induce efficient lysis of pEC and do not require additional activation 
signals through NKG2D, NKp30 or NKp46. 
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Figure 7: ADCC is independent of NKG2D and NCR signalling. The cytotoxicity of freshly isolated 
NK cells was tested against PEDSV.15 in the presence (triangles) or absence (squares) of 10% 
decomplemented human serum in 4 h 51Cr-release assays. The following blocking mAb were used as 
indicated: IgG1 isotype-control, anti-NKG2D, anti-NKp30, anti-NKp44, and anti-NKp46. The data 
shown are representative for one out of three independent experiments performed with NK cells 
purified from totally eight different donors. 
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5.1.5. Discussion 
The generation of galactose-alpha-1,3-galactose (alphaGal) knockout pigs has 
overcome the barrier of anti-Gal mediated rejection in pig-to-nonhuman primate 
xenotransplantation. Therefore, strategies to reduce other rejection mechanisms 
need to be explored. These may include natural or elicited non-Gal-specific 
xenoreactive Ab and cellular immunity mediated by direct NK cell responses, all of 
which lead to porcine endothelial activation, injury and eventually to graft dysfunction. 
Human NK cytotoxicity against pEC is readily observed in vitro, whether or not it 
contributes to xenograft rejection in vivo remains unknown. Nevertheless, recognition 
of xenogeneic pEC by human NK cells in vitro leads to activation and injury of pEC 
by several mechanisms. Taking the limitations of in vitro studies into careful 
consideration, NK cytotoxicity studies may represent relevant NK cell responses in 
vivo. Similarly, the level and specificity of allogeneic cytotoxic T cell responses in 
vitro reproduce in vivo graft rejection which also does not necessarily involve 
cytotoxic functions. Here, we further analyzed the molecular mechanisms leading to 
NK cell activation and cytotoxicity in response to porcine endothelium, the first 
immunological target following vascularized pig-to-human xenotransplantation. 
Human NK cytotoxicity against porcine target cells requires cross-species 
compatibility between human NK activating receptors and their respective porcine 
ligands. At the same time it reflects the absence of sufficient interactions between NK 
inhibitory receptors and MHC class I molecules across the species barrier. Whereas 
human NK cells are inhibited only weakly, if at all, by swine MHC class I molecules 
(167), human activating NK receptor interactions with porcine ligands have not been 
investigated so far.  
 
The data presented here provides clear evidence that NKG2D and NKp44 function 
as triggering receptors involved in direct human NK cytotoxicity against pEC, while 
NKp30 and NKp46 do not play a role. NKG2D was the only activating receptor 
involved in pEC lysis mediated by freshly isolated NK cells. Intriguingly, the 
significant variability among donors in the response of freshly isolated NK cells 
against pEC did not correlate with NKG2D receptor surface densities that were 
similar between different donors. Therefore, the reason for this variability might 
depend on the different efficiency of the respective cytotoxic effector pathways such 
as the perforin-granzyme release that is important in xenogeneic NK cytotoxicity 
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(168). Indeed, it has been shown that NK cell culture conditions, in particular IL-2 and 
IL-15 supplements, up-regulate the expression levels of molecules involved in the 
perforin-granzyme cytolytic pathway (169). Moreover, the cytolytic potential of 
individual freshly isolated NK populations might depend on the immunologic condition 
of the donor since NK cells collected at different time points from the same donor 
differed in their ability to kill pEC without apparent differences in NKG2D expression 
(data not shown). The importance of NKp44 for NK cytotoxicity mediated by activated 
human NK cells against pEC was clearly supported by (i) antibody blocking studies, 
(ii) the correlation of lysis with NKp44 expression levels on NK clones, and (iii) the 
association of poor xenogeneic NK cytotoxicity against 2A2 cells with the absence of 
NKp44 on freshly isolated NK cells. Since it was not addressed in the present study, 
we can only speculate on the role of the numerous additional co-receptors involved in 
human NK cytotoxicity. Their triggering function appears to depend on the 
simultaneous engagement of the main activating receptors (119).  
 
The involvement of NKp44 and NKG2D in NK-mediated lysis of pEC indicates the 
presence and recognition of porcine homologues of human NKp44 and NKG2D 
ligands on pEC or of "unique" ligands in pigs without apparent human homologues. 
Compatibility of NK activating receptors and their respective ligands has also been 
described in other species combinations. In fact, the putative ligand for the human 
NKp46 receptor is responsible for xenogeneic NK-mediated lysis of murine cells 
(170). The notion that NCR and NKG2D receptors are, at least partially, conserved 
between humans and other species is clearly different from the divergent evolution 
that has been documented for the MHC class I-specific inhibitory receptors (171-
173). Allelic specificity of human KIR for HLA class I molecules suggests a co-
evolution of inhibitory KIR with the respective MHC genes. This might explain why 
human KIR have a low affinity for MHC class I molecules of unrelated species (174). 
In contrast, it is conceivable that NCR and NKG2D as well as their ligands have not 
been subjected to the pressure that caused the evolution of MHC genes and their 
receptors. The porcine NCR and NKG2D ligands are unknown, however, comparison 
of porcine and human genomic sequences suggests the presence of one ULBP gene 
and one MIC-A/-B-like gene (MIC2) in the pig genome (175, 176). NKG2D ligands 
are generally poorly expressed by normal cells but are up-regulated in transformed, 
infected, and stressed cells in both mice and humans (120). These findings are 
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compatible with the supposed expression of porcine NKG2D ligands on transformed 
pEC lines like PEDSV.15 and 2A2 but are in contrast with the involvement of NKG2D 
in NK-mediated lysis of primary pEC. However, stress generated by isolation and cell 
culture conditions could be responsible for NKG2D ligand expression on primary pEC 
and subsequent susceptibility to xenogeneic NK lysis. Similarly, it is easy to predict 
that triggers of inflammation, ischemia reperfusion injury, and rejection mechanisms 
following xenotransplantation might also allow the expression of porcine ligands of 
human NKG2D. This hypothesis is supported by the finding that human kidney 
allografts undergoing both acute and chronic rejection episodes have been shown to 
express polymorphic MIC molecules which may even induce allospecific Ab (177, 
178). Future studies are needed to identify the porcine ligands for NKG2D and 
NKp44, thereby it will be of interest whether only two or more ligands are involved in 
this interspecies NK recognition.  Beside cytokine secretion, endothelial cell 
activation and direct NK cytotoxicity, human NK cells are also able to kill porcine cells 
via ADCC. As reported previously, the lack of alphaGal on porcine cells strongly 
reduced NK-mediated ADCC, whereas binding and direct cytotoxicity of human NK 
cells were not inhibited (44, 179). The fact that ADCC was not influenced by blocking 
NCR and NKG2D indicated that the two mechanisms of human NK cytotoxicity 
against porcine target cells are independent.  
 
Emerging evidence over the past few years indicated that the expression of HLA 
class I molecules in porcine tissues did not provide complete protection from direct 
xenogeneic human anti-pig NK cytotoxicity through inhibitory receptors. In the 
present paper we demonstrate that the abrogation of human NKp44 and NKG2D 
interactions with their porcine ligands was able to completely prevent direct human 
NK cytotoxicity against pEC. Thus, the identification and elimination of porcine 
ligands of NKp44 and NKG2D might have important implications by representing a 
complementary approach to protect porcine xenografts from human NK cell 
responses including direct xenogeneic NK cytotoxicity. 
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5.2.1. Abstract 
Cellular rejection mechanisms including NK cells remain a hurdle for successful pig-
to-human xenotransplantation. Human anti-pig NK cytotoxicity depends on the 
activating receptor NKG2D. Porcine UL-16 binding protein 1 (pULBP1) and porcine 
MHC class I chain-related protein 2 (pMIC2) are homologues of the human NKG2D 
ligands ULBP 1-4 and MICA and B, respectively. Although transcribed in porcine 
endothelial cells (pEC) it is not known whether pULBP1 and pMIC2 act as functional 
ligands for human NKG2D. Here, surface protein expression of pULBP1 was 
demonstrated by flow cytometry using a novel pULBP1-specific polyclonal Ab and by 
cellular ELISA using NKG2D-Fc fusion protein. Reciprocally, pULBP1-Fc bound to 
primary human NK cells, whereas pMIC2-Fc did not. Transient and stable 
downregulation of pULBP1 mRNA in pEC using short interfering RNA (siRNA) 
oligonucleotide duplexes and short hairpin RNA (shRNA), respectively, resulted in a 
partial inhibition of xenogeneic NK cytotoxicity through NKG2D in 51Cr-release 
assays. In contrast, downregulation of pMIC2 mRNA did not inhibit NK cytotoxicity. 
Human NK cytotoxicity against pEC mediated by freshly isolated or IL-2-activated NK 
cells through NKG2D was completely blocked using anti-pULBP1 polyclonal Ab. In 
conclusion, this study suggests that pULBP1 is the predominant, if not only, 
functional porcine ligand for human NKG2D. Thus, the elimination of pULBP1 on 
porcine tissues represents an attractive target to protect porcine xenografts from 
human NK cytotoxicity. 
 
5.2.2. Introduction 
Organ shortage is a severe problem in transplantation medicine, therefore pig-to-
human xenotransplantation has become an important field of research to overcome 
this hurdle (4). Currently, insufficient long-term graft function prevents the successful 
clinical application of xenotransplantation (6). Nevertheless, advances in preventing 
hyperacute rejection in preclinical non-human primate models using genetically 
engineered pigs as organ source indicate that all coagulation disorders, antibodies to 
non-Gal antigens, and cellular immunity play a role in xenogeneic responses (103, 
104, 180). There are also several lines of evidence that NK cells may be a factor in 
delayed rejection of porcine xenografts (46). Pig organs perfused with human blood 
ex vivo are infiltrated by NK cells (57, 59) and NK cells are present in histological 
samples of graft rejection in concordant and discordant rodent and pig-to-baboon 
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models (60-62). In addition, in vitro NK cells lyse porcine target cells both directly 
and, in the presence of human serum containing xenoreactive Ab, by Ab-dependent 
cell-mediated cytotoxicity (ADCC) (54). In contrast to hematopoietic stem cell 
transplantation, the involvement of NK cells in rejecting organ grafts was thought to 
be of minor importance until recently. However, several new findings support the 
notion that NK cells also participate in the immune response against solid organ allo- 
and xenografts (47, 181). Thus, implementation of strategies to inhibit NK cytotoxicity 
and other yet to be defined NK cell responses such as cytokine release and 
enhancement of adoptive immune responses may promote both successful clinical 
xenotransplantation and allotransplantation. 
 
NK cells are tightly regulated through signals mediated by inhibiting and activating 
receptors expressed on their cell-surface (71). Many of the inhibitory NK receptors 
recognize MHC class I molecules and therefore allow NK cells to discriminate 
between normal self, non-self and altered cells (116). Porcine endothelial cells (pEC) 
are susceptible to human NK cell-mediated lysis possibly due to the inability of swine 
leukocyte antigen (SLA) class I molecules to signal through human NK inhibitory 
receptors (72, 74). On the other hand, the activation of human NK cells by potential 
ligands expressed on pEC may be equally, or more, important. Activating receptors 
on NK cells include NKp30, NKp44, and NKp46 (119), collectively named natural 
cytotoxicity receptors (NCR), and the C-type lectin receptor NKG2D (120). While 
NKp30 and NKp46 are detected on all NK cells regardless of their activation status, 
NKp44 is selectively expressed by activated NK cells (143). There is a direct 
correlation between the surface density of NCR and the ability of NK cells to lyse 
various tumor cells (142), but the cellular ligands recognized by NCR remain 
unidentified. As recently reported, human NK cytotoxicity against pEC is mediated 
primarily through NKG2D and NKp44, whereas NKp30 and NKp46 are not involved 
(81). 
 
NKG2D is constitutively expressed on NK, NKT, and CD8-positive T cells  as a 
homodimeric receptor associated with the transmembrane adaptor molecule DAP10 
(148). Over the past few years several regulation mechanism of surface expression 
have been reported (120, 182). Cellular ligands of NKG2D include the stress-
inducible MHC class I chain-related proteins A/B (MICA/B) (151) and UL16-binding 
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proteins (ULBP) (150). The latter were identified based on their ability to bind the 
human CMV glycoprotein UL16. Although these GPI-linked proteins are distantly 
related to members of the HLA class I family possessing α1 and α2, but not α3 
domains (152), they are unable to present peptides (153). On the other hand, both 
MICA and MICB are transmembrane proteins and possess all three α-domains. 
Similar to ULBP, MICA and MICB do not bind β2-microglobulin or present peptides 
(154).  
 
Blocking of human NK cytotoxicity against porcine cells with anti-NKG2D mAb 
provided indirect evidence for cross-species interactions between human NKG2D 
and one or several different porcine ligands (81). However, little is known about the 
nature and function of these putative ligands. The porcine NKG2D gene has been 
cloned and revealed a 66% sequence identity with human NKG2D, transcripts are 
expressed in PBL, NK cells, macrophages, and monocytes (183). The sequence of 
porcine MIC2 (pMIC2), a homologue of human MIC proteins, has also been reported 
previously (156). It is comprised of six exons and the predicted amino acid sequence 
displays characteristics similar to those of the human MIC genes, such as four N-
glycosylation sites, three of which are apparent counterparts of the human 
glycosylation sites at position 208, 235 and 263. In addition, several cysteine 
residues within the pMIC2 α2 and α3 domains may participate in the formation of 
disulfide bonds. Similarly to the human MIC genes, a consensus heat shock element, 
but no iron response element, was found upstream of the porcine exon one. Only 
recently, porcine ULBP1 (pULBP1) was cloned and characterized as a homologue of 
human ULBP (155). Phylogenetic analyses place pULBP1 evolutionarily close to the 
bovine ULBP-like genes MHCLA1 and MHCLA2. It exhibits 35-52% amino acid 
identity to human ULBP including a relatively high level of conservation at positions 
predicted to make contact with human NKG2D (153). Southern blot analysis 
suggested that only one pULBP exists in the pig genome, which is in sharp contrast 
to the much higher number of ULBP genes, at least six, that were described in 
humans. However, considering hybridization conditions in these studies (155), the 
possibility that other more distantly related porcine ULBP-like genes exist can not be 
fully excluded. 
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Since both pULBP1 and pMIC2 transcripts were detected in a pEC (155) they 
represent potential ligands for human NKG2D. Therefore, the aim of the present 
study was to test whether pULBP1 and pMIC2 can act as functional ligands for 
human NKG2D resulting in xenogeneic human anti-pig endothelial cell NK 
cytotoxicity. Several lines of evidence are presented which suggest that pMIC2 is 
ineffective in binding to NKG2D, and that pULBP1 is the predominant, if not only, 
porcine ligand for human NKG2D. 
 
5.2.3. Material and Methods 
Cells 
The SV40-immortalized aortic pEC line PEDSV.15 was established and 
characterized in our laboratory (163). PAEC were isolated from a normal pig 
following standard procedures (166) and cultured in DMEM (Invitrogen AG, Basel, 
Switzerland) supplemented with 10% FCS (PAA Laboratories, Luzern, Switzerland), 
1 mM sodium pyruvate, 2 mM L-glutamine, non-essential amino acids (100x), 
essential amino acids (50x), and 20 mM HEPES (all Invitrogen). Isolation of PBMCs 
from healthy blood donors, purification of NK cells, and generation of polyclonal 
human NK cell populations have been described previously (74). Isolated NK cells 
with a purity of routinely >95% were either used directly or activated by culture in 
AIM-V medium (Invitrogen) supplemented with 10% human plasma obtained from 
healthy donors, 1 mM sodium pyruvate, 2 mM L-glutamine, essential amino acids 
(50x), non-essential amino acids (100x), 1% penicillin/streptomycin (Invitrogen), 20 
mM HEPES, and 300 U/ml of human IL-2 (Chiron, Emeryville, CA). The immortalized 
human NK line NK92 (a kind gift of C. Falk, University of Munich, Germany) was 
cultured in RPMI 1640 (Invitrogen) supplemented with 15% FCS (PAA Laboratories), 
5% human plasma obtained from healthy donors, 1 mM sodium pyruvate, 2 mM L-
glutamine and 1% penicillin/streptomycin. The human embryonic kidney cell line 
HEK293 (a kind gift of J. Wittwer, University Hospital Zürich, Switzerland) was 
cultured in the same medium as PAEC. 
 
Fusion protein production 
The vector encoding a pULBP1-Fc fusion protein (amino acids 1–219, seven amino 
acid linker, Fc of human IgG1) under control of the CMV immediate-early promoter 
was constructed by standard techniques and was stably expressed in HEK293 cells 
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selected with 1 mg/ml G418 (Invitrogen). After limiting dilution cloning, a clone 
secreting high amounts of fusion protein was selected and expanded. The pULBP1-
Fc fusion protein was purified using a protein A column (Amersham Biosciences, 
Freiburg, Germany) and dialysed against PBS. Protein concentration was determined 
photospectrometrically. The purity and specificity of the fusion protein pULBP1-Fc 
was confirmed by western blot and coomassie staining showing one specific band. A 
gene encoding a pMIC2-Fc fusion protein was similarly constructed and was 
transiently expressed in HEK293 cells and pMIC2-Fc was purified from culture 
medium using a protein A column. 
 
Polyclonal Ab production 
Two rabbits were immunized with pULBP1-Fc by i.v. injection of 150g protein in 
CFA, followed by three booster immunizations with 100 µg protein in IFA (every four 
weeks). Four weeks after the last boost, sera were collected, purified using a protein 
A column and dialysed against PBS. One of the rabbits elicited a specific immune 
response. Preimmune sera of the immunized rabbits were collected for control 
experiments. 
 
Flow cytometry 
Surface expression of NKG2D on human NK cells, and expression of pULBP1 on 
pEC was analyzed on a FACScan (Becton Dickinson, Basel, Switzerland) by indirect 
immunofluorescence. After resuspension of 1x105 cells per tube in staining buffer 
(HANKS, 0.1% BSA) cells were incubated for 30 min at 4°C with saturating amounts 
of Ab. As primary Ab the mouse mAb 149810 (IgG1, anti-NKG2D, R&D Systems, 
Abingdom, UK) and a polyclonal rabbit anti-pULBP1 (obtained in our laboratory, see 
Results), respectively, were used. As secondary reagents FITC-conjugated goat anti-
mouse IgG Ab (Chemicon International, Dietikon, Switzerland) and FITC- or PE-
conjugated goat anti-rabbit IgG Ab (Sigma, Buchs, Switzerland) were used. 
Phenotypic analysis of NK cells was carried out by direct immunofluorescence using 
FITC-UCHT1 (anti-CD3), PE-B73.1 (anti-CD16), and PE-B159 (anti-CD56) mAb (all 
from Pharmingen, Allschwil, Switzerland). An irrelevant, isotype-matched control 
mAb (MOPC21, mouse IgG1, Sigma) was used as control for mAb stainings, and 
normal rabbit IgG (R&D Systems) or preimmune sera were used as control for the 
polyclonal rabbit Ab. To exclude dead cells, propidium iodide gating was performed 
5. Results 
 58
in all experiments. To compare the levels of surface expression, the geometric mean 
fluorescence intensity ratios (MFIR) were calculated by dividing the mean 
fluorescence intensity of each sample with the mean fluorescence intensity of the 
control Ab. 
 
Cytotoxicity assays 
The cytotoxic activity of freshly isolated and IL-2 activated human NK cells was 
tested in 4 h 51Cr-release assays in serum-free AIM-V medium as described 
previously (166). Briefly, labeled target cells were added to triplicate samples of serial 
twofold dilutions of NK cells in round-bottom 96-well plates. Four E:T ratios ranging 
from 40:1 to 5:1 were used in each experiment. For blocking studies, NK cells were 
preincubated for 30 min at 4°C with 10 µg/ml of the following mAb: MOPC21, 3G8 
(mouse IgG1, anti-CD16, Immunotech, Nyon, Switzerland), and 149810. MAb were 
also present during the coincubation of target and effector cells at a concentration of 
5 g/ml. A saturating amount of 10 µl of the polyclonal anti-pULBP1 Ab as well as 
normal rabbit IgG were used for blocking studies. After incubation for 4 h at 37°C, the 
assays were stopped, 51Cr-release was analyzed on a gamma counter and the 
percentage of specific lysis was calculated. 
 
Short interfering RNA oligonucleotides and short hairpin RNA vectors 
The following targeting siRNA oligonucleotide duplexes were purchased from Proligo 
(Paris, France): pMIC2 (5’-ACAGCUUCACAGAGAGAACA-3’), pULBP1 (5’- 
CCACAUCGAUUCAGACAAUAU-3’). Transfection of PEDSV.15 cells was performed 
using X-tremeGene siRNA transfection reagent (Roche Applied Science, 
Switzerland). A transfection efficiency of >95% was determined by FACS analysis 8 
hours post transfection using a 3’-fluorescein-labelled control siRNA (5’-
CUACCAAUACUUCATT(Fluo)-3’). The shRNA expression vector pRNAT-H1.1 
(Genscript, NJ, USA) was used to construct the following vectors: pULBP1-targeting 
vector pRNAT-H1.1-U2 (encoding the shRNA ACUUU-
GUACCUUUCACCUUCUCUUGAUAUCCGGAGAAGGUGAAAGGUACAAAG) and 
pMIC2-targeting vector pRNAT-H1.1-M3 (encoding the shRNA AUUGGUCUCUUU-
ACGCCAUGUCUUGAUAUCCGGACAUGGCGUAAAGAGACCAAU). PEDSV.15 
cells were Ca2PO4 co-transfected with each of these vectors and pCDNA3.1-
hygromycin (Invitrogen) and selected with 200 µg/ml hygromycin (Invitrogen). 
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RT-PCR and quantitative RT-PCR 
RNA was isolated using Trizol (Invitrogen), and the concentration was determined 
photospectrometrically. The RNA quality was verified by agarose gel electrophoresis. 
Reverse transcription was achieved using AMV Reverse Transcriptase (Promega, 
Wallisellen, Switzerland) following the manufacturers protocol. The following primers 
were used in PCR: β2-microglobulin-specific (5’-
ATGATATCCCACTTTTCACACCGCTCCAGTAGC-3’ and 5’-
ATAGATCTGGATTCATCCAACCCAGATGCAGC-3’), pMIC2-specific (5’-GGTACA-
ACTTCACGGTGATGGCCC-3’ and 5’-CACGGCGTGGACACTGTGATTCCC-3’), and 
pULBP1-specific (5’-GCGGCCTGCGATACTCACTCTCTTTGC-3’ and 5’-
GGAAGCTGGTCACAATCCGGTCACTCTCCC-3’). PCR products were run on a 1% 
agarose gel. Quantitative PCR was performed using Absolute QPCR SYBR Green 
Mix (ABgene, Hamburg, Germany) on a ABI Prism 7700 (Applied Biosystems, 
Rotkreuz, Switzerland) following the manufacturers protocol. Results were analyzed 
after the comparative threshold cycle method. 
 
Western Blot 
PEDSV.15 and PAEC cells were lysed using Cell Lytic M (Sigma). Cell lysates were 
analyzed by Western blot using standard protocols, and normal rabbit IgG and affinity 
purified anti-pULBP1 Ab were employed as primary polyclonal Ab. An HRP-
conjugated secondary goat anti-rabbit Ab (Biorad, Reinach, Switzerland) was added 
and specific bands were visualized using Opti-4CN (Biorad). 
 
ELISA and cellular ELISA 
Maxisorp ELISA plates (Becton Dickinson) were coated 16 h before the assay using 
1 µg of pULBP1-Fc or NKG2D protein in a volume of 100µl. Rabbit anti-pULBP1 
polyclonal Ab was used as primary Ab with AP-conjugated goat anti rabbit IgG Ab 
(Sigma) as secondary Ab. For cellular ELISA, 5x103 PEDSV.15 or 1x105 NK cells 
were seeded 16 h before the assay in 96-well plates. NKG2D-Fc (R&D Systems), 
pULBP1-Fc, or pMIC2-Fc proteins were added (0.5µg per well) and incubated at 
37°C for two h. An AP-conjugated goat anti-human IgG Ab (Sigma) was used as 
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secondary Ab. Then, 4-nitrophenyl phosphate (Merck, Dietikon, Switzerland) was 
added and the absorbance was measured at 405 nm. 
 
5.2.4. Results 
Human NKG2D binds to porcine endothelial cells and pULBP1 
In order to test the ability of the activating human NK receptor NKG2D to directly 
interact with a ligand on pEC, the pEC line PEDSV.15 was incubated with the 
chimeric fusion protein NKG2D-Fc. NKG2D-Fc bound to PEDSV.15 cells in a dose-
dependent manner as shown by cellular ELISA (Fig. 1A). Binding of NKG2D-Fc was 
also observed using primary porcine aortic endothelial cells (PAEC) (data not 
shown). Accordingly, FACS analysis revealed staining of PEDSV.15 cells with 
NKG2D-Fc, but not with an irrelevant Fc fusion protein (Fig. 1B). Preincubation of 
NKG2D-Fc with anti-NKG2D mAb abolished its binding to PEDSV.15 underscoring 
the specificity of the staining. 
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Figure 1: Human NKG2D-Fc binds to the surface of porcine endothelial cells. (A) Dose-
dependent binding of human NKG2D-Fc to PEDSV.15 cells in cellular ELISA. Results are 
representative for one out of three independent experiments. Error bars represent standard deviations. 
(B) Binding of human NKG2D-Fc to PEDSV.15 cells as shown by flow cytometry (filled histogram), an 
irrelevant Fc fusion protein was used as negative control (empty histogram), binding of human 
NKG2D-Fc to PEDSV.15 cells was completely abrogated by preincubation with anti-NKG2D mAb 
(empty histogram, dashed line). MFIR were calculated by dividing the mean fluorescence intensity of 
NKG2D-Fc binding with the irrelevant Fc fusion protein binding. 
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Figure 2: PULBP1-Fc but not pMIC2-Fc binds to recombinant human NKG2D and to the surface 
of human NK cells. (A) Binding of an irrelevant Fc fusion protein (black bar), pMIC2-Fc (grey bar), 
and pULBP1-Fc (white bar) to recombinant NKG2D protein measured by ELISA. Results are 
representative for one out of two independent experiments. Error bars represent standard deviations. 
(B) Binding of an irrelevant Fc fusion protein (black bar), pMIC2-Fc (grey bar), and pULBP1-Fc (white 
bar) to primary human NK cells measured by cellular ELISA. Results are representative for one out of 
two independent experiments. Error bars represent standard deviations. 
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To test whether pULBP1 and/or pMIC2 interact functionally with NKG2D on human 
NK cells, cytotoxicity assays were performed following transient down-regulation of 
the respective mRNAs using short interfering RNA (siRNA). PEDSV.15 cells were 
transfected with siRNA oligonucleotide duplexes specifically targeting pULBP1 and 
pMIC2 and a non-targeting control siRNA. Compared to PEDSV.15 cells transfected 
with control siRNA, a reduction of 39±23% (mean ± SD) for pULBP1 and of 58±20% 
for pMIC2 mRNA was observed 48 h post transfection by quantitative RT-PCR (data 
not shown). A reduced susceptibility of PEDSV.15 cells to NK92-mediated 
cytotoxicity was observed in 51Cr-release cytotoxicity assays using pULBP1 siRNA, 
whereas pMIC2 siRNA transfection slightly increased the susceptibility (data not 
shown). Since mRNA levels were only transiently downregulated by siRNA, 
experiments were performed within 48 to 72 h post transfection. There were many 
variable parameters in these siRNA assays such as the unknown half-life of NKG2D 
ligands on the surface of pEC and the exact duration and extent of mRNA down-
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regulation. Consequently, the optimal time point for functional assays was difficult to 
estimate. 
 
Therefore, PEDSV.15 lines with stable down-regulation of mRNA were generated 
using short hairpin RNA (shRNA) expressing vectors. The reduction of pULBP1 
mRNA was 46±11% (mean ± SD) in the PEDshU2 line, and 87±17% for pMIC2 
mRNA in the PEDshM3 line, respectively, as demonstrated by quantitative RT-PCR 
(Fig. 3 A and B). NK cytotoxicity mediated by IL-2 activated human NK cells against 
PEDshU2 was reduced to a relative level of 70±3% (mean ± SEM; n=8) as compared 
to PEDsh control targets (Fig. 3C). Blocking with NKG2D mAb reduced NK 
cytotoxicity to a level of 40±3% regardless of whether PEDsh control or PEDshU2 
were used as target cells (Fig. 3C). In contrast, PEDshM3 target cells were more 
susceptible to NK cytotoxicity (119±3%; n=9), and blocking with NKG2D mAb 
reduced the lysis by 48±3% and 52±2%, respectively, in comparison to the respective 
isotype control (Fig. 3D). These observations were consistent with the results 
obtained by transient siRNA transfection. The reduced NK susceptibility of PEDshU2 
was pULBP1-specific and corresponded to the level of remaining pULBP1 
expression. The increased NK susceptibility of PEDshM3 was independent of 
NKG2D. Taken together, these results show that pULBP1, but not pMIC2, appears to 
act as a functional ligand for human NKG2D. 
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Figure 3: Decreased susceptibility of PEDSV.15 to human NK cytotoxicity following down-
regulation of pULBP1 but not pMIC2 mRNA. (A) Agarose gel of RT-PCR products using RNA 
isolated from PEDsh control (lane 1), PEDshU2 (lane 2), or PEDshM3 (lane 3) as templates and either 
pULBP1- or pMIC2-specific primers (indicated above the lanes). Specific PCR products of 469 bp and 
798 bp for pULBP1 and pMIC2 are depicted. β2-microglobulin-specific RT-PCR was used as positive 
and loading control. (B) Quantitative PCR analyzed with the comparative threshold analysis. Results 
reflect percentage of indicated mRNA level in comparison to PEDsh control. Error bars represent 
standard deviations. (C and D) Xenogeneic human NK cytotoxicity against PEDsh control (black bars), 
PEDshU2 (white bars), and PEDshM3 (grey bars) targets analyzed by 4 h 51Cr-release cytotoxicity 
assays. The mouse IgG1 anti-NKG2D mAb 149810 was used for blocking. The percentage of relative 
lysis of PEDshU2 and PEDshM3 target cells in the presence of the indicated mAb was obtained by 
comparison to the lysis of PEDsh control targets in the presence of isotype control mAb (index=100). 
A summary of three independent experiments with eight different donors is shown. The mean relative 
cytotoxicity was calculated at four different E:T ratios (40:1 to 5:1), error bars represent SEM. 
Asterisks mark statistical significance in a student’s t-test (*p<0.05, **p<0.01). 
 
Generation of a polyclonal anti-pULBP1 antibody 
In an effort to confirm pULBP1 surface expression on pEC by flow cytometry and to 
completely block activating signals elicited by pULBP1 in cytotoxicity assays, a 
polyclonal Ab against pULBP1 was generated. Following immunization of rabbits with 
 63
5. Results 
 64
pULBP1-Fc a polyclonal pULBP1 Ab was purified from the serum of one rabbit. This 
Ab bound to pULBP1-Fc protein in ELISA whereas purified rabbit Ig obtained from 
preimmune serum did not (Fig. 4A). To further characterize the polyclonal Ab and to 
show pULBP1 specificity, PEDSV.15 and PAEC cell lysates were analyzed by 
Western blotting. As shown in Figure 4B a band of 55-60 kDa was detected by the 
affinity-purified polyclonal anti-pULBP1 Ab corresponding to the predicted size of 
pULBP1 dimers. In contrast, no band was seen with the control rabbit Ig obtained 
from preimmune serum (data not shown). Cell surface expression of pULBP1 on 
PEDSV.15 and PAEC cells was demonstrated by flow cytometry using the anti-
pULBP1 polyclonal Ab (Fig. 4C). Providing additional support for the specificity of the 
Ab, HEK293 cells stably transfected with full-length pULBP1 were positively stained 
by anti-pULBP1 polyclonal Ab whereas untransfected HEK293 were negative (Fig. 
4D). Finally, pULBP1 cell surface expression on the PEDshU2 obtained by shRNA 
transfection (described above) was reduced by 50% as compared to PEDsh control 
cells (data not shown), supporting the results obtained by quantitative RT-PCR (Fig. 
2B). These data show that rabbit anti-pULBP1 polyclonal Ab specifically binds to 
pULBP1 expressed on the surface of porcine cells. 
 
5. Results 
B
116 kDa
66 kDa
45 kDa
1 2
negative
control
anti-
pULBP1
A
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
N
et
 O
D
 v
al
ue
C D
MFIR =13
101 102 103
MFIR =4.5
Ev
en
ts
101 102
MFIR =2
101 102 103
E
 
Figure 4: Characterization of polyclonal rabbit anti-pULBP1 Ab. (A) Binding of anti-pULBP1 Ab 
(black bar) to pULBP1-Fc measured by ELISA, normal rabbit IgG (white bar) was used as negative 
control. Net OD values are given and error bars represent standard deviations. (B) Western blotting of 
both PEDSV.15 (lane 1) and PAEC (lane 2) lysates using affinity-purified anti-pULBP1 Ab revealed a 
single band of 55-60 kDa. Results are representative for one out of two independent experiments. 
Binding of anti-pULBP1 polyclonal Ab (filled histograms) to (C) PEDSV.15 and (D) PAEC 
demonstrated by indirect flow cytometry. Staining with normal rabbit IgG was used as negative control 
(empty histograms, dashed line). (E) Binding of anti-pULBP1 polyclonal Ab to HEK 293 cells 
transfected with pULBP1 (filled histogram) and mock-transfected HEK293 cells (empty histogram, 
dashed line) shown by indirect flow cytometry. 
 
Anti-pULBP1 polyclonal Ab completely blocks human NK cytotoxicity against porcine 
endothelial cells mediated through NKG2D 
 
The ability of rabbit anti-pULBP1 polyclonal Ab to block functional pULBP1/NKG2D 
interactions was examined in cytotoxicity assays. Incubation of PEDSV.15 cells with 
anti-pULBP1 polyclonal Ab reduced NK cytotoxicity mediated by freshly isolated and 
IL-2 activated human NK cells by 67±13% (specific lysis±SEM) and 41±4%, 
respectively Fig. 5A,B). This level of inhibition correlated well with the blocking of NK 
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cytotoxicity observed with anti-NKG2D mAb preincubation of freshly isolated and IL-2 
activated NK cells; 67±14% and 39±5% inhibition, respectively. Finally, as compared 
to single Ab blocking, combined Ab blocking of pULBP1 and NKG2D on porcine 
PEDSV.15 and human NK cells did not further enhance the inhibition of NK 
cytotoxicity. Similar results were obtained in cytotoxicity assays using primary porcine 
target cells (Fig.5C,D). Together, these findings not only demonstrate specific 
functional interactions between pULBP1 and human NKG2D, but also strongly 
suggest that pULBP1 is the predominant, if not the only, functional ligand for human 
NKG2D on porcine cells. 
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Figure 5: Anti-pULBP1 polyclonal Ab completely blocks human NK cytotoxicity against porcine 
endothelial cells mediated through NKG2D. NK cytotoxicity mediated either by freshly isolated (A 
and C) or IL-2 activated (B and D) human NK cells against PEDSV.15 (A and B) and PAEC (C and D) 
was tested in 4 h 51Cr-release cytotoxicity assays. For blocking, anti-NKG2D (open squares), anti-
pULBP1 (filled triangles), a combination of both (open triangles), and control Abs (filled squares) were 
used. To prevent ADCC the Fc receptor CD16 was blocked by incubation of NK cells with anti-CD16 
mAb in all assays. Data shown represent one out of two independent experiments using four different 
NK cell donors (A and C), one out of six independent experiments using five different donors (B), and 
one out of three independent experiments with six different donors (D). 
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5.2.5. Discussion 
NK cell-mediated rejection mechanisms may represent one of the remaining 
obstacles preventing the clinical application of pig-to-human xenotransplantation. As 
shown in a series of previous studies by several investigators, human NK cells are 
able to adhere to and activate pEC (35, 39, 48, 51). These interactions lead to 
morphological changes, the release of pro-inflammatory cytokines and endothelial 
damage. Whether these in vitro phenomena correspond to tissue damage and 
consequently to the loss of xenografts in vivo is still a matter of debate (54). Human 
NK cytotoxicity against pEC might depend on incompatible cross-species interactions 
between porcine MHC class I molecules and inhibitory human NK receptors (72). 
This notion was supported by the expression of HLA class I molecules on pEC and 
their complete protection from NK clones expressing the respective HLA-specific 
inhibitory NK receptor. However, only partial protection from human NK cytotoxicity 
mediated by polyclonal NK populations was observed (77, 110, 184, 185). Beside the 
lack of MHC class I inhibition, the recognition of putative porcine ligands by human 
activating NK receptors plays an important role in xenogeneic NK cytotoxicity. 
Recently, we demonstrated that lysis of pEC mediated by freshly isolated human NK 
cells is mainly triggered by NKG2D (81). In contrast, lysis mediated by IL-2 activated 
human NK cells depends on both NKG2D and NKp44. These results predicted the 
presence of one or several porcine ligand(s) for human NKG2D expressed on pEC. 
 
Here we analyzed two recently identified porcine homologues of human NKG2D 
ligands and demonstrate that pULBP1, but not pMIC2, functionally interacts with 
human NKG2D. Using an algorithm to score potential ligands (153) pULBP1 was 
predicted to bind human NKG2D using both the crystal structure of human 
NKG2D/human ULBP3 and human NKG2D/mouse Rae-1β interactions as template, 
whereas pMIC2 was predicted to bind NKG2D only using the structure of human 
NKG2D/human ULBP3 as template (data not shown). Intriguingly, a previous study 
showed no binding of pULBP1-Fc to the human NK cell line NKL by flow cytometry 
whereas binding to porcine PBMC was revealed (155). It was concluded then that 
pULBP1 does not interact with human NKG2D. The discrepant data regarding 
pULBP1 binding to human NKG2D might be explained by different experimental 
conditions. First, the relatively low affinity of Fc fusion proteins used in the previous 
report may prevent positive staining in flow cytometry assays. In the present paper 
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pULBP1 binding to human NK cells was demonstrated by cellular ELISA. Second, 
primary human NK cells as well as the NK92 cell line were used, which may exhibit 
different surface molecule expression patterns as compared to the NKL cell line. 
Finally, the inability of the soluble Fc fusion proteins to bind to human NK cells may 
be due to aberrant folding as compared to the membrane-bound form on the cell 
surface. 
 
However, these binding results did not shed light on the functionality of human 
NKG2D/pULBP1 interactions which we further explored by downregulation of mRNA 
by stable transfection of shRNA expressing vectors (186). These experiments added 
further evidence that pULBP1 acts as a ligand for human NKG2D. The fact that not a 
complete abrogation of the NKG2D-mediated cytotoxicity was observed was 
probably due to the remaining pULBP1 mRNA (Fig. 3B) and surface protein (data not 
shown). On the other hand, the reason why downregulation of pMIC2 rendered 
PEDSV.15 cells more susceptible to NK-mediated killing remains unclear. Since 
pMIC2 is closely related to MHC class I, we tested whether a protecting signal was 
delivered by pMIC2 through one of the MHC-specific inhibitory NK receptors on 
human NK cells. In such a situation, downregulation of pMIC2 would interfere with 
these inhibiting signals leading to an enhanced NK cytotoxicity. However, blocking 
receptor-ligand interaction using specific mAb against several MHC-specific inhibitory 
NK receptors (KIR2DL2, KIR2DL3, KIR3DL1, ILT2) did not provide proof for this 
hypothesis (data not shown). Another possible explanation for the observed increase 
in lysis of pEC following pMIC2 downregulation are potential RNAi off-target effects 
that were reported by Jackson et al (187). Further studies are necessary to 
understand how pMIC2 down-regulation, independent of NKG2D signaling, increases 
susceptibility to lysis by human NK cells. 
 
Complete inhibition of xenogeneic NK cytotoxicity triggered by pULBP1 was achieved 
by polyclonal anti-pULBP1 Ab blocking. The relative inhibition was stronger when 
freshly isolated NK cells were used as compared to IL-2 activated NK cells. This 
finding was expected, since only the latter express NKp44 which is also involved in 
xenogeneic NK cytotoxicity (81, 143). However, the incomplete blocking of 
xenogeneic NK cytotoxicity observed using freshly isolated NK effectors indicated the 
presence of yet unidentified interactions between porcine ligands with human 
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activating NK receptors. The identification of these ligand/receptor pairs as well as 
the porcine ligands for NKp44 is currently being addressed in order to completely 
overcome NK-mediated xenograft rejection. 
 
This study suggests that pULBP1 is the predominant, if not the only, functional ligand 
for human NKG2D on porcine cells. Porcine EC express at least one other ULBP-like 
transcript (pULBP2) although at the mRNA level its expression is about 20-fold less 
then pULBP1. Also, preliminary analysis of a porcine bacteria artificial chromosome 
clone suggests several additional loci encoding ULBP-like proteins (own unpublished 
observations). In this regard pigs appear similar to humans where several ULBP and 
MIC proteins serve as ligands for NKG2D (150, 151), and also mice, cattle and 
primates which express several NKG2D ligands (188, 189). The redundancy of the 
NKG2D system within a species might be driven by immune evasion mechanisms of 
pathogens such as CMV. However, considering that no evolutionary pressure acted 
on interactions between human and porcine molecules, the lack of redundancy 
across the species barrier (i.e. pULBP1 being the only ligand for human NKG2D) is 
not very surprising and sheds more light on the molecular incompatibilities between 
man and pig already identified. On the other hand, the molecular compatibility 
between human NKG2D and pULBP1 might help to prevent zoonoses and infections 
of porcine xenografts by human pathogens. Therefore, future studies need to 
address the important question of whether the elimination of pULBP1 might pose a 
risk by interfering with anti-infectious NK cell responses. 
 
In conclusion, similar to hyperacute xenograft rejection which has been largely 
overcome using organs derived from alphaGal knockout pigs, the elimination of 
pULBP1 on porcine tissues might have important implications as a complementary 
approach to protect porcine xenografts from human NK cell responses. Here we 
focused on direct human NK cytotoxicity against pEC, but there are other potentially 
harmful interactions between human NK cells and pEC. These include direct cellular 
activation of pEC, the release of chemokines and cytokines such as porcine TNF-α 
and IL-8 leading to further EC activation and the recruitment of additional human 
leukocytes to the graft. Moreover, the proposed protection of pEC from human NK 
cytotoxicity by interfering with pULBP1/human NKG2D interactions indicates a 
possible use to facilitate hematopoietic stem cell xenotransplantation, which has 
5. Results 
 70
been proposed as a method to induce xenogeneic tolerance (190, 191). Finally, the 
potential of pULBP1 to induce additional xenogeneic human NK cell responses such 
as IFN-γ secretion by triggering NKG2D remains to be considered. 
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5.3.1. Abstract 
NK cells are tightly regulated through signals mediated by inhibiting and activating 
receptors expressed on their cell surface. In vitro, freshly isolated human NK cells kill 
porcine endothelial cells (pEC) through the interaction of the activating receptor 
NKG2D and its corresponding ligand on pEC, porcine UL-16 binding protein 1 
(pULBP1). The aims of the study were (I) to generate a mAb against pULBP1, and 
(II) to characterize pULBP1 cell-surface expression on primary porcine aortic 
endothelial cells (PAEC) after treatment with various stimuli. In order to obtain mAb 
against pEC surface molecules, C57BL/6 mice were immunized with the pEC line 
PEDSV.15. Porcine ULBP1 cell surface expression on primary PAEC was measured 
with cellular ELISA. Primary PAEC were either left untreated or stimulated with 
human or porcine cytokines (IFN-γ, TNF-α), co-cultured with human serum, cultured 
under hypoxic conditions, or infected with human or porcine cytomegalovirus (CMV). 
The mouse anti-pULBP1 mAb clone aE5-63 specifically stained pULBP1 on the pEC 
surface. IFN-γstimulation did not change pULBP1 cell surface expression, whereas 
human and porcine TNF-αstimulation as well as human and porcine CMV infection 
significantly decreased pULBP1 cell surface expression on primary PAEC. Coculture 
of primary PAEC for 24h with human serum strongly increased the pULBP1 cell 
surface expression in a dose-dependent manner. Also, culture under hypoxic 
conditions led to a slight but significant increase of pULBP1 cell surface expression. 
In conclusion, (I) the novel anti-pULBP1 mAb aE5-63 is specific and may represent a 
useful tool for the study of NKG2D-mediated responses in xenotransplantation, and 
(II) pULBP1 cell surface expression on primary PAEC is tightly regulated in response 
to various stimuli. 
 
5.3.2. Introduction 
NK cells participate in the immune response against solid organ allo- and xenografts 
(47, 181) and are tightly regulated through signals mediated by inhibiting and 
activating receptors expressed on their cell-surface (192). Many of the inhibitory NK 
receptors recognize MHC class I molecules and therefore allow NK cells to 
discriminate between normal self, non-self and altered cells (116). Porcine 
endothelial cells (pEC) are susceptible to human NK cell-mediated lysis possibly due 
to the inability of swine leukocyte antigen (SLA) class I molecules to signal through 
human NK inhibitory receptors (72, 74). On the other hand, the activation of human 
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NK cells by potential ligands expressed on pEC could be even more important. 
Activating receptors on NK cells include NKp30, NKp44, and NKp46 (119), 
collectively named natural cytotoxicity receptors (NCR), and the C-type lectin 
receptor NKG2D (120). While NKp30 and NKp46 are detected on all NK cells 
regardless of their activation status, NKp44 is selectively expressed by activated NK 
cells (143). As recently reported, human NK cytotoxicity against pEC is mediated 
primarily through NKG2D and NKp44, whereas NKp30 and NKp46 are not involved 
(81). 
 
NKG2D is constitutively expressed on NK, NKT, and CD8+ T cells as a homodimeric 
receptor associated with the transmembrane adaptor molecule DAP10 (148). Over 
the past few years several regulatory mechanisms of NKG2D surface expression 
have been reported (120, 182). Cellular ligands of NKG2D include the stress-
inducible MHC class I chain-related proteins A/B (MICA/B) (151) and UL16-binding 
proteins (ULBP) (150). The latter were identified based on their ability to bind the 
human CMV (hCMV) glycoprotein UL16. Although these GPI-linked proteins are 
distantly related to members of the HLA class I family possessing α1 and α2, but not 
α3 domains (152), they are unable to present peptides (153). ULBP1 and -2 cell 
surface expression is decreased following hCMV infection due to the association with 
the CMV protein UL16 in the endoplasmic reticulum or cis-Golgi compartments (193, 
194). Therefore, maturation and transport of the proteins to the cell surface is 
prevented. Both MICA and MICB are transmembrane proteins and possess all three 
α-domains. Similar to ULBP, MICA and MICB do not bind β2-microglobulin or present 
peptides (154). 
 
Only recently, porcine ULBP1 (pULBP1) was cloned and characterized as a 
homologue of human ULBP (155). Furthermore, pULBP1 was shown to be the 
predominant, if not only, ligand for the human NK activating receptor NKG2D (157). 
Phylogenetic analysis places pULBP1 evolutionarily close to the bovine ULBP-like 
genes MHCLA1 and MHCLA2. It exhibits 35-52% amino acid identity to human ULBP 
including a relatively high level of conservation at positions predicted to make contact 
with human NKG2D (153). Southern blot analysis suggested that only one pULBP 
exists in the pig genome, which is in sharp contrast to the much higher number of 
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ULBP genes, at least six, that were described in humans. Transient and stable 
downregulation of pULBP1 mRNA in pEC using short interfering RNA resulted in a 
partial inhibition of xenogeneic NK cytotoxicity through NKG2D in cytotoxicity assays. 
Furthermore, human NK cytotoxicity against pEC mediated by freshly isolated or IL-
2-activated NK cells through NKG2D was completely blocked using anti-pULBP1 
polyclonal Ab (157). 
 
The aim of this study was to generate a specific anti-pULBP1 mAb. Furthermore, the 
influence of various stimuli, including cytokines and human serum, and 
transplantation related phenomenons, such as hypoxia/reoxygenation and CMV 
infection, on pULBP1 cell surface expression was analyzed. 
 
5.3.3. Materials and Methods 
Cells 
Primary PAEC and primary PAEC α-1,3-galactosyltransferase (αGAL) knockout (KO) 
were isolated from a normal and an αGAL KO pig, respectively, following standard 
procedures (166) and cultured as described earlier (44). The SV40-immortalized 
aortic pEC line PEDSV.15 was established and characterized in our laboratory (163). 
HEK293/pULBP1 cells were generated as described earlier (157). Hybridomas were 
cultured in IMDM (Invitrogen AG, Basel, Switzerland) supplemented with 10% FCS 
(PAA Laboratories, Luzern, Switzerland), 1% penicillin/streptomycin (Invitrogen), and 
50mM β-mercaptoethanol (Sigma, Buchs, Switzerland). 
 
Flow cytometry 
Surface expression of pULBP1 on PAEC, PEDSV.15 and HEK293/pULBP1 cells was 
analyzed on a FACScanto (Becton Dickinson, Basel, Switzerland) by indirect 
immunofluorescence using the primary mouse mAb aE5-63 (generated as described 
in the Results section) or the polyclonal rabbit anti-pULBP1 Ab (157). PE-conjugated 
mouse anti-mouse IgMb Ab (Becton Dickinson, Basel, Switzerland) and FITC-
conjugated goat anti-rabbit IgG Ab (Sigma) were used as secondary Ab. An 
irrelevant, isotype-matched control mAb (G155-228, mouse IgG1, BD Pharmingen) 
was used as control for aE5-63 mAb stainings, and normal rabbit IgG (R&D Systems) 
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was used as control for the polyclonal rabbit Ab. Cells were fixed with 2% PFA 
(Sigma) prior to mAb incubation. To compare the levels of surface expression, the 
geometric mean fluorescence intensity (MFI) ratios (MFIR) were calculated by 
dividing the MFI of staining with the mAb of interest with the MFI of the control mAb. 
 
Monoclonal Ab production 
After initial immunization of C57BL/6 mice (H-2b, obtained from the Institute of 
Laboratory Animal Science, University of Zürich, Zürich, Switzerland) with 5x106 
PEDSV.15 cells i.v. and 107 PEDSV.15 cells i.p. in PBS, mice received two booster 
immunizations (107 PEDSV.15 cells i.p.) at 2-week intervals. Final immunization was 
performed 1 month after the last booster immunization on day minus 4 (four days 
prior to removal of the spleen) by another 107 PEDSV.15 i.p. Peritoneal 
macrophages from three Balb/c mice (H-2d, obtained from Charles River Breeding 
Laboratories, Hannover, Germany) were harvested on day minus 1 and plated on six 
96-well flat bottom tissue culture plates to support the efficiency of the fusion by 
removing cell debris and stimulating cell proliferation by cytokine production. On day 
zero, fusion of splenocytes of immunized mice to the mouse myeloma cell line 
X63Ag8.653 was performed according to standard procedures (195). Hybridoma 
supernatants were screened for their ability to bind PEDSV.15 cells in a cellular 
ELISA and positive hybridomas were subcloned by limiting dilution cloning. 
Monoclonal hybridoma supernatants were screened for their ability to bind pULBP1-
Fc fusion protein and inability to bind human IgG in ELISA. The hybridoma 
supernatant was purified using a Mannan Binding Protein column (Pierce, Lausanne, 
Switzerland) following the manufacturer’s protocol. 
 
ELISA and cellular ELISA 
Maxisorp ELISA plates (Becton Dickinson) were coated 16 h before starting of the 
assay using 1 µg of pULBP1-Fc or human IgG in a volume of 100µl. The mouse anti-
pULBP1 mAb aE5-63 was used as primary Ab with AP-conjugated goat anti-mouse 
polyvalent Ig, or HRP-conjugated mouse anti-mouse IgMa, mouse anti-mouse IgMb 
(Sigma), rat anti-mouse IgD (The binding site, Birmingham, UK), rat anti-mouse IgE 
(Southern Biotech, Reinach, Switzerland), goat anti-mouse IgA (Sigma), rabbit anti-
mouse IgG1 (Zymed, Basel, Switzerland), goat anti-mouse IgG2a (Southern 
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Biotech), rabbit anti-mouse IgG2b (Zymed), goat anti-mouse IgG2c (Bethyl, Lausen, 
Switzerland) and rat anti-mouse IgG3 (The binding site) as secondary Abs. For 
cellular ELISA, 2.5x103 primary PAEC cells were seeded 24 h before starting of the 
assay in 96-well plates. Cells forming intact monolayers were fixed with 2% PFA and 
incubated at 37°C for 2 h with isotype control or aE5-63 mAb. Goat anti-mouse 
polyvalent Ig Ab was used as secondary Ab. Finally, 4-nitrophenyl phosphate (Merck, 
Dietikon, Switzerland) was added and the absorbance was measured at 405 nm. 
Cells were either left untreated or were treated as follows: 48h with 1000U/ml human 
IFN-γ (Peprotech, London, UK), or 10ng/ml porcine IFN-γ (Innogenetics, Zwijndrecht, 
Belgium); 6 h with 1000U/ml human TNF-α or 100 ng/ml porcine TNF-α (both 
Peprotech); 6 h or 24 h co-culture with heat-inactivated human serum (56°C, 30 min) 
observed from healthy donors or with αGAL absorbed heat-inactivated human serum 
(179); 10 h incubation at hypoxic conditions (1% O2, 5% CO2, 94% N2) and either no 
or subsequent re-oxygenation for 1 h, 2 h, 4 h; 8 h, or 48 h; or infection with human 
and porcine CMV for 4 hours. 
 
Human and porcine CMV infection 
For infection with human CMV, a laboratory-type strain Ad 169, (American Type 
Culture Collection, Rockville, MD, USA) was cultured in human embryonic 
fibroblasts. Porcine CMV was cultivated from a respiratory isolate from an 
immunosuppressed Massachusetts General Hospital miniature swine. The virus was 
grown on confluent porcine Fallopian tube (PFT) endothelial cells (a kind gift of J. 
Fishman, Massachusetts General Hospital, Harvard Medical School) at 37°C,, as 
described (196) Viral inocula were prepared by removing medium from infected cell 
cultures. The medium was centrifuged at 12,000 g for 2 min, the resulting 
supernatant was filtered through a 0.45 µm syringe filter (Fisher Scientific SA, 
Wohlen, Switzerland), and aliquots were stored at -70°C. Mock infections were made 
using medium from uninfected human embryonic fibroblasts and PFT cells, 
respectively, processed identically to the infected medium. Human CMV infection 
(MOI=1) was documented by the immunocytological staining of the pp65 protein, a 
matrix structural phosphoprotein of 65 kDa, which appears in the nuclei of infected 
cells within one hour post infection, and represents uptake from the viral innoculum. 
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Porcine CMV infection (MOI=170) was shown by increasing titers of porcine CMV by 
quantitative PCR,as described previously (197). 
 
5.3.4. Results 
Generation of a mouse monoclonal anti-pULBP1 Ab 
Mice were immunized after the protocol described in materials and methods. 
Supernatants of growing hybridomas were tested for their ability to bind to PEDSV.15 
cells in a cellular ELISA. Of the hybridoma supernatants, 21 bound to PEDSV.15 
cells and were subcloned resulting in 328 monoclonal hybridomas, 104 of which 
bound to PEDSV.15 cells. Supernatant from one clone, designated as aE5-63, bound 
to pULBP1-Fc fusion protein in ELISA but showed no binding to human IgG (Fig 1A). 
The mAb aE5-63 was of the IgMb isotype as revealed in an ELISA using secondary 
Ab against all different mouse immunoglobulin isotypes (Fig. 1B). Therefore, a 
mannan binding protein column was used to specifically purify this mAb. The purified 
mAb aE5-63 bound PEDSV.15 cells in a cellular ELISA (Fig. 1C). Providing 
additional support for the specificity of the mAb, PFA-fixed HEK293 cells stably 
transfected with full-length pULBP1 were positively stained by this mAb whereas 
mock-transfected HEK293 were negative (Fig. 1D). Furthermore, the mAb aE5-63 
stained PFA-fixed primary PAEC (Fig. 1E), PEDSV.15 cells (Fig. 1F), the porcine 
bone marrow-derived aortic endothelial cell line 2A2, and the porcine lymphoblastoid 
cell line 13271.10 cells in FACS (data not shown). FACS stainings were only 
achieved with PFA-fixed but not unfixed cells. Western blots of pULBP1-Fc fusion 
protein revealed the same bands using either anti-human IgG Ab or the anti-pULBP1 
mAb aE5-63 (data not shown). Altogether, these data prove that the mouse anti-
pULBP1 mAb clone aE5-63 specifically stains pULBP1. 
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Figure 1: Characterization of the monoclonal anti-pULBP1 Ab aE5-63. (A) Binding of aE5-63 
hybridoma supernatant to pULBP1-Fc but not to human IgG as measured by ELISA. ELISA plates 
were coated either with pULBP1-Fc (black bars) or human IgG (white bars). Hybridoma supernatant 
not binding PEDSV.15 cells was used as a negative control. (B) Designation of the isotype of aE5-63 
hybridoma supernatant by ELISA. Error bars represent SEM. (C) Binding of purified anti-pULBP1 mAb 
aE5-63 (black bar) to PEDSV.15 cells in cellular ELISA. Isotype-matched Ab (white bar) and 
polyclonal anti-pULBP1 Ab (grey bar) were used as negative and positive controls, respectively. Error 
bars represent standard deviations. .(D-F) Binding of anti-pULBP1 mAb to HEK 293 cells transfected 
with pULBP1 (D), primary PAEC (E), and PEDSV.15 cells (F) shown by indirect flow cytometry (filled 
histograms). Empty dashed histograms depict binding of anti-pULBP1 mAb on mock-transfected 
HEK293 cells (D) or of isotype-matched control mAb on primary PAEC (E) and PEDSV.15 cells (F). 
 
TNF-α stimulation decreases pULBP1 cell surface expression on primary PAEC 
Porcine IFN-γ and human TNF-α  induce the expression of SLA and adhesion 
molecules on pEC (198). To examine whether cytokine stimulation also influences 
pULBP1 cell surface expression, primary PAEC were stimulated with human or 
porcine IFN-γ, or human or porcine  TNF-α. Surface expression of pULBP1 on 
primary PAEC was measured by cellular ELISA using the anti-pULBP1 mAb aE5-63. 
As expected, human IFN-γ stimulation did not show any effect, since porcine cells 
lack a receptor for human IFN-γ (198). However, porcine IFN-γ also did not influence 
pULBP1 cell surface expression. On the other hand, human as well as porcine TNF-
α significantly decreased pULBP1 cell surface expression on primary PAEC (31±5% 
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and 33±3%, respectively; mean percentage decrease of pULBP1 cell surface 
expression as compared to untreated cells ±SEM, n=18) (Figure 2). Thus, TNF-α but 
not IFN-γ stimulation has an influence on pULBP1 cell surface expression on primary 
PAEC. 
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Figure 2: TNF-αstimulation decreases pULBP1 cell surface expression on primary PAEC. 
Shown is the relative percentage of pULBP1 cell surface expression after cytokine stimulation as 
compared to untreated cells (index=100). Error bars represent SEM. Asterisks depict statistical 
significance in a student’s t-test (*p<0.0005, n=18). 
 
Human serum increases pULBP1 cell surface expression on primary PAEC 
In solid organ xenotransplantation, pEC represent the first line of contact between the 
graft and the immune system of the recipient. Therefore, we analyzed, whether the 
binding of human anti-pig xenoreactive Ab in the serum of a healthy donor has an 
influence on pULBP1 cell surface expression. Whereas the co-culture of primary 
PAEC with human serum for 6 h did not significantly change pULBP1 cell surface 
expression (data not shown), co-culture for 24 h led to a strong increase dependent 
on the amount of human serum added to the cells (Figure 3A). The mean increase of 
pULBP1 cell surface expression as compared to untreated cells was 49±7%, 
75±19%, and 91±17% (±SEM, n=12) after coculture with 12.5%, 25%, and 50% 
human serum, respectively. No significant increase of pULBP1 cell surface 
expression was observed after coculture of primary PAEC with αGAL-absorbed 
human serum (Fig. 3B). Furthermore, co-culture of primary PAEC αGAL KO cells 
with normal as well as αGAL-absorbed human serum did not significantly change 
pULBP1 cell surface expression (data not shown). Therefore, the binding of 
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xenoreactive Ab in human serum to cell surface molecules on primary PAEC, the 
majority directed against αGAL, strongly increased pULBP1 cell surface expression. 
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Figure 3: Human serum increases pULBP1 cell surface expression on primary PAEC. Shown is 
the relative percentage of pULBP1 cell surface expression after co-culture with human serum (A) and 
αGAL absorbed human serum (B) as compared to untreated cells (index=100). Error bars represent 
SEM. Asterisks and rhomb depict statistical significance in a student’s t-test for human serum 
stimulation versus control, *p<0.01, n=12, and for 50% versus 12.5% human serum stimulation, 
#p<0.05, n=12, respectively. 
 
Hypoxia/re-oxygenation increases pULBP1 cell surface expression on primary PAEC 
Susceptibility of human microvascular EC to NK cytotoxicity was shown to be slighty 
reduced by hypoxia/reoxygenation in a model analyzing ischemia/reperfusion injury 
(199). Therefore, we tested whether pULBP1 cell surface expression on primary 
PAEC was influenced by hypoxia/reoxygenation. A slight but significant increase of 
approximately 20% of pULBP1 cell surface expression was observed after 8 h of 
hypoxia as well as after reoxygenation for 2 h, 4 h (Fig.4), and 8 h (data not shown). 
After 24 h of reoxygenation, pULBP1 cell surface expression returned to the basal 
level (Fig. 4). Thus, pULBP1 cell surface expression is slightly but significantly 
increased after of hypoxia/reoxygenation. 
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Figure 4: Hypoxia/reoxygenation increases pULBP1 cell surface expression on primary PAEC. 
Shown is the relative percentage of pULBP1 cell surface expression after hypoxia/re-oxygenation as 
compared to untreated cells (index=100). Error bars represent SEM. Asterisks depict statistical 
significance in a student’s t-test (*p<0.005, n=12). 
 
Human and porcine CMV infection decreases pULBP1 cell surface expression on 
primary PAEC 
Human CMV infection is known to decrease the expression of the human NKG2D 
ligands ULBP1, -2, and MICB (194). Therefore, we tested whether pULBP1 on 
porcine cells is also decreased upon human or porcine CMV infection. Indeed, at 48 
h and 72 h post infection with either human or porcine CMV, a slight but significant 
decrease of surface pULBP1 was observed (Fig. 5). No significant difference in cell 
surface expression between the two timepoints was recorded. These data suggest, 
that the human and porcine CMV-derived glycoprotein UL-16 partially retains 
pULBP1 intracellularly. 
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Figure 5: Human and porcine CMV infection decreases pULBP1 cell surface expression on 
primary PAEC. Shown is the relative percentage of pULBP1 cell surface expression after human 
CMV (A) and porcine CMV (B) infection as compared to mock-infected cells (index=100). Error bars 
represent SEM. Asterisks depict statistical significance in a student’s t-test (*p<0.0005, 
n=12;**p<0.0001, n=12). 
 
5.3.5. Discussion 
NK cell-mediated rejection mechanisms may represent one of the remaining 
obstacles preventing the clinical application of pig-to-human xenotransplantation. 
Human NK cytotoxicity against pEC might depend on incompatible cross-species 
interactions between porcine MHC class I molecules and inhibitory human NK 
receptors (72) and simultaneously on recognition of putative porcine ligands by 
activating human NK receptors. Recently, we demonstrated that lysis of pEC 
mediated by freshly isolated human NK cells is mainly triggered by NKG2D (81) and 
that pULBP1 is the predominant, if not only, functional ligand for human NKG2D on 
porcine cells (157). Therefore, we generated a mAb against pULBP1 in order to 
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systematically test the influence of various stimuli on cell surface expression of 
pULBP1 on primary PAEC. 
 
In this study we show that the mouse anti-pULBP1 mAb clone aE5-63 specifically 
binds pULBP1 on porcine cells. Unexpectedly, the anti-pULBP1 mAb only stained 
PFA-fixed but not unfixed cells. Since the mice were immunized with the pEC line 
PEDSV.15 it was expected to obtain a mAb that recognizes the native form of the 
protein. However, it is known that fixation and therefore denaturation might 
ameliorate the accessibility of certain epitopes by eliminating possible steric 
hindrance. 
 
Both human and porcine TNF-α stimulation significantly downregulated pULBP1 cell 
surface expression on primary PAEC. It was previously published that human TNF-α 
is crossreactive with the porcine TNF-α receptor, inducing upregulation of SLA class I 
and class II, and of B7, vascular cell adhesion molecule (VCAM), and E-selectin 
(198). Therefore, TNF-α acts as a proinflammatory cytokine on PAEC and is likely to 
enhance the cellular response to xenogeneic organs in vivo. Since a reduced cell 
surface expression of pULBP1 leads to decreased NK cell susceptibility (157), TNF-
α downregulation of pULBP1 may render pEC less susceptible to NK cytotoxicity. 
This might prevent pEC from being lysed after NK cell adherence and therefore 
contribute to increased infiltration of NK cells into the tissue. 
 
The strong increase in pULBP1 cell surface expression on αGAL-positive PAEC 
upon coculture of primary with human serum was dependent on the presence of anti-
αGAL Ab. In agreement, no significant increase in pULBP1 cell surface expression 
was observed on primary PAEC αGAL KO when cocultured with human serum 
containing anti-αGAL Ab. Thus, the binding of αGAL-specific xenoreactive Ab may, in 
addition to the induction of hyperacute rejection, also stimulate innate immunity via 
pULBP1 cell surface upregulation. In this view, αGAL KO pigs may not only avoid 
hyperacute rejection, but also be less sensitive to human NK cell responses in vivo. 
 
An earlier study showed a slight reduction of susceptibility of human microvascular 
EC to NK cytotoxicity after hypoxia/reoxygenation (199). In theory, this reduction may 
have been observed because of a slight reduction of one of the ligands for NK 
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activating receptors. However, our finding that pULBP1 expression was upregulated 
after hypoxia/reoxygenation does not support such an hypothesis. Nevertheless, 
Maurus et al. used human EC that express many different ligands for activating NK 
receptors, whereas pEC only express ligand(s) for NKp44 and pULBP1. 
 
Herpesviruses, such as CMV, are associated with significant morbidity after solid-
organ transplantation (97). In pig-to-baboon xenotransplantation, activation of porcine 
CMV has been associated with xenograft injury and an increased incidence of 
consumptive coagulopathy and graft loss (196). In vitro, infection of pEC with human 
CMV and porcine CMV led to a decreased pULBP1 cell surface expression. This 
finding is in line with results observed after the human CMV infection of human 
fibroblasts (194) and is possibly due to a, at least partial, intracellular retention of 
pULBP1 by the human CMV-derived glycoptotein UL-16. The exact mechanism 
underlying the data observed in this study is a topic of ongoing research. If the slight 
reduction of pULBP1 cell surface expression after porcine CMV infection is also due 
to a UL-16-like pCMV-derived protein remains unclear. 
 
In conclusion, the monoclonal anti-pULBP1 Ab described in this study might 
represent a useful tool for NK-related research in the field of xenotransplantation. 
Furthermore, insights in the regulation of pULBP1 cell-surface expression might help 
to better understand the rejection mechanisms mediated by human NK cells in pig-to-
human xenotransplantation. 
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5.4.1. Abstract: 
Background: The susceptibility of porcine endothelial cells (pEC) to human natural 
killer (NK) cells is related to the failure of human MHC-specific killer inhibitory 
receptors to recognize porcine MHC class I molecules. The aims of this study were 
(1) to assess the protection of pEC against xenogeneic NK-mediated cytotoxicity 
afforded by the stable expression of HLA-E single chain trimers (SCT) composed of a 
canonical HLA-E binding peptide antigen, VMAPRTLIL, the mature human β2-
microglobulin, and the mature HLA-E heavy chain, and (2) to test whether HLA-E 
expression on pEC and porcine lymphoblastoid cells affects the adhesion of human 
NK cells. 
Methods: Porcine EC lines expressing different levels of HLA-E SCT were generated 
by Ca2PO4-transfection followed by limiting dilution cloning. Surface expression of 
HLA-E was measured by flow cytometry. Susceptibility of transfected pEC lines 
against human NK cells was tested in 51Cr-release cytotoxicity assays. Interactions 
between human NK cells and HLA-E positive pEC or porcine lymphoblastoid cells 
were further addressed in adhesion and conjugation assays. 
Results: The level of protection of pEC from human NK-mediated cytotoxicity 
correlated with the intensity of surface HLA-E expression. Furthermore, the HLA-E 
SCT-mediated protection was specifically reversed by blocking the HLA-E specific 
NK inhibitory receptor CD94/NKG2A. HLA-E expression does neither affect the 
adhesion of human NK cells to pEC nor the heteroconjugate formation between 
human NK and porcine 13271.10 cells. 
Conclusions: Stable surface expression of HLA-E on pEC was achieved in the 
absence of extrinsic peptide pulsing and provided partial protection from human NK 
cytotoxicity. Though insufficient to inhibit xenogeneic NK cell reactivity completely, 
transgenic HLA-E expression on pig organs might contribute to a successful 
application of clinical xenotransplantation in combination with other protective 
strategies. 
 
5.4.2. Introduction 
 
In addition to overcoming hyperacute humoral rejection, cellular rejection 
mechanisms seem to play a crucial role to achieve prolonged graft survival in pig-to-
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human xenotransplantation models (6). Among other cell types human NK cells may 
play an important role in the cellular rejection of porcine xenografts (46, 47). This 
hypothesis is supported by the finding that in vitro NK cells activate porcine 
endothelium upon direct contact and act as a potent source for pro-inflammatory 
cytokines such as interferon-γ (48). Human NK cells have further been demonstrated 
to adhere to and lyse porcine target cells both directly and, in the presence of human 
serum containing xenoreactive antibodies (Ab), by Ab-dependent cell-mediated 
cytotoxicity (ADCC) (54). In addition, pig organs perfused with human blood ex vivo 
were predominantly infiltrated by NK cells (57, 59), and NK cells were present in 
histological samples of graft rejection in concordant and discordant rodent and 
preclinical pig-to-baboon models (53, 60-62). 
 
A variety of molecules that deliver either activating or inhibitory signals tightly 
regulate NK cell activity (200). There are four main activating NK receptors, including 
NKp30, NKp44, and NKp46, collectively named natural cytotoxicity receptors (NCR) 
(119), and NKG2D (120). As previously reported, human NK cells kill porcine 
endothelial cells (pEC) only through NKG2D and NKp44 receptors, whereas NKp30 
and NKp46 do not play a role in NK-mediated xenogeneic cytotoxicity (81, 157). The 
positive signals transduced by activating NK receptors are balanced by several 
groups of inhibitory NK receptors that bind HLA class I molecules including killer 
immunoglobulin-like receptors (KIR), Ig-like transcript 2 (ILT2), and the CD94/NKG2 
family (116). Consequently, NK cytotoxicity occurs if stimulatory signals outweigh 
inhibitory signals derived from a potential target cell. Porcine EC are susceptible to 
human NK-mediated lysis possibly due to the inability of their MHC class I molecules 
to signal through human NK cell inhibitory receptors (72). 
 
One of the inhibitory human NK receptors, the CD94/NKG2A heterodimer, is widely 
expressed on human NK cells and binds HLA-E, a monomorphic MHC class I 
molecule expressed at weak levels on most tissues (136-138). We and others have 
previously demonstrated that the expression of human MHC class I molecules, 
including HLA-B27, -Cw3, -Cw4, -G, and –E, provides only partial protection against 
xenogeneic human NK cytotoxicity (74-79, 110). However, in these studies stable 
expression of HLA-E molecules was only achieved by the extrinsic pulsing with 
stabilizing HLA-E binding peptides and interferon-γ treatment (110). Although not 
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rigorously examined in the latter study, human β2-microglobulin (β2m) may also be 
required for optimal cell-surface expression of HLA-E in pig cells. Generating pigs 
transgenic for HLA-E, the final goal of this approach to protect porcine grafts from 
human NK cytotoxicity, would therefore require the addition of three human genes 
(HLA-E heavy chain, human β2m, and a gene encoding for an HLA-E binding 
peptide) in order to ensure stable HLA-E cell-surface expression. To circumvent this 
technically difficult and tedious obstacle, a single chain trimer (SCT) of HLA-E has 
been constructed and expressed in pig cells (201). This HLA-E SCT construct is 
composed of linked sequences encoding for a HLA-Cw*03-derived canonical HLA-E 
binding peptide antigen, VMAPRTLIL, the mature human β2m, and the mature HLA-
E heavy chain. The first aim of this study was to test whether HLA-E SCT expression 
protects pEC against xenogeneic human NK cytotoxicity mediated by primary IL-2 
activated human NK cells derived from healthy donors as opposed to the 
immortalized NK clonal cell lines previously employed (201). The second question 
addressed in this report was whether HLA-E surface expression on pEC and porcine 
lymphoblastoid cells interferes with the adhesion of human NK cells. This issue arose 
based on previous reports that NK receptors, including KIR2DL1 and ILT-2, not only 
inhibit NK cytotoxicity but also regulate cell adhesion through their interaction with 
HLA-Cw4 and HLA-G, respectively (75, 202). 
 
5.4.3. Material and Methods 
Cells 
The SV40-immortalized aortic pEC line PEDSV.15 was established and 
characterized in our laboratory (163), and the porcine AOC endothelial cell line was 
reported previously (203). The immortalized porcine lymphoblastoid cell line 
13271.10 was a gift of G. Waneck (Massachusetts General Hospital, Boston, MA) 
(76, 164). The 13271.10-E/A2 cell line (110), the isolation of PBMC from healthy 
blood donors, purification of NK cells, and generation of polyclonal human NK cell 
populations have been described previously (74). After isolation, NK cells were 
activated by culture in AIM-V medium (Invitrogen, Basel, Switzerland) supplemented 
with 10% human plasma obtained from healthy donors, 300 U/ml of human IL-2 
(Chiron, Emeryville, CA), 1 mM sodium pyruvate, 2 mM L-glutamine, essential amino 
acids (50x), non-essential amino acids (100x) (all Invitrogen), 1% 
penicillin/streptomycin (Gibco, Basel, Switzerland), and 20 mM HEPES (Invitrogen). 
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Transfection 
PEDSV.15 and AOC cells were transfected with the HLA-E SCT construct (201) 
using Ca2PO4-transfection and selected using G418 at a concentration of 0.5 mg/ml 
(Life Technologies, Gaithersburg, MD). After antibiotic selection stably transfected 
cells expressing HLA-E were further purified by limiting dilution cloning. 
 
Flow cytometry 
Surface expression of CD94 and NKG2A on human NK cells was analyzed on a 
FACScan (Becton Dickinson, Basel, Switzerland) by indirect immunofluorescence 
using the primary mouse mAb DX22 (anti-CD94, IgG1, L. Lanier, University of 
California, San Francisco, CA) or Z199 (anti-NKG2A, IgG2b, Beckman Coulter, Nyon, 
Switzerland). HLA-E SCT expression on PEDV.15 and AOC cells was analyzed 
using the 3D12 mAb (anti-HLA-E, IgG1, D. Geraghty, Fred Hutchinson Cancer 
Research Center, Seattle, WA), which recognizes both HLA-E free chain and HLA-E 
noncovalently associated with peptide antigen and β2m (204) in addition to HLA-E 
SCT (204). FITC-conjugated goat anti-mouse IgG Ab (Chemicon International, 
Dietikon, Switzerland) was used as a secondary reagent. Phenotypic analysis of NK 
cells was carried out by direct immunofluorescence as described previously (74). To 
compare the levels of surface expression, the geometric mean fluorescence intensity 
ratios (MFIR) were calculated by dividing the mean fluorescence intensity (MFI) of 
staining with the mAb of interest with the MFI of the control mAb. 
 
Cytotoxicity assays 
The cytotoxic activity of IL-2-activated polyclonal human NK cells was tested in 4 h 
51Cr-release assays in serum-free AIM-V medium as described previously (166). For 
blocking studies, NK cells were preincubated for 30 min at 4°C with 10 µg/ml of anti-
CD94 (DX22), anti-NKG2A (Z199) or isotype-control mAb MOPC21 (IgG1, Sigma, 
Buchs, Switzerland) or MOPC141 (IgG2b, Sigma). Monoclonal Ab were also present 
during the coincubation of target and effector cells at a concentration of 5 µg/ml. After 
incubation for 4 h at 37°C the assays were stopped, 51Cr-release was analyzed on a 
gamma counter and the percentage of specific lysis was calculated. 
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Conjugation assays 
NK and 13271.10 cells were labeled at room temperature for 5 min with 10 µM of the 
fluorescent cell linkers PKH67-GL and PKH26-GL, respectively (Sigma). The staining 
reaction was stopped by adding two volumes of FCS. Cells were washed three times, 
incubated at 37°C for 2 h to allow excess of fluorochrome to diffuse off the cells, and 
resuspended in cold AIM-V medium supplemented with 5% FCS. 1x105 labeled NK 
cells were mixed with 2x105 labeled target cells in a final volume of 0.2 ml in 6-ml 
polystyrene FACS tubes (Becton Dickinson), centrifuged at 1000 rpm for 3 min, and 
immediately incubated at 37°C for 1, 5, 10, or 15 min. Following incubation, tubes 
were placed on ice and cell pellets were carefully disrupted by gentle mixing, fixed by 
adding 1 ml of cold paraformaldehyde, and immediately analyzed on a FACScan. 
Double positive PKH26+PKH67+ events were defined as conjugates. Results are 
expressed as percentage of NK cells that formed conjugates with target cells. To 
perform antibody blocking experiments NK cells were preincubated for 30 min at 4°C 
with 10 µg/ml of the following mouse IgG1 mAbs: HP-2/1 (anti-CD49d), 7E4 (anti-
CD18) (both Beckman Coulter, Nyon, Switzerland), or an isotype control mAb 
(MOPC21). 
 
Adhesion assay 
Adhesion of human NK cells on PEDSV.15 and AOC cells was analyzed using a 
modified Stamper-Woodruff assay as previously described (39). Briefly, pEC were 
grown to confluency in a 30 mm culture dish within the limits of a circle of 20 mm in 
diameter administered with a non-toxic silicon oil coat (dimethylpolysiloxane; Sigma). 
The resulting monolayers were washed and overlayed with 100 µl of Weissmann-
buffer containing IL-2-activated NK cells (107 cells/ml), glucose (5.55 mM, Sigma) 
and human albumin (5 mg/ml, Fluka, Deisenhofen, Germany). The dishes were 
either incubated statically or were rotated at 64 rpm in a prewarmed (37°C) horizontal 
shaker-incubator (Infors AG, Bottmingen, Switzerland). This rotation speed induces a 
continuous flow of NK cells on pEC monolayers, thus simulating the shear stress and 
contact times present in the postcapillary vascular system. After 10 min the assay 
was stopped by rapidly placing the dishes on ice and by prefixing the cells for 2 min 
with 1% paraformaldehyde (Sigma) in PBS. The monolayers were then gently 
washed, fixed for additional 15 minutes, and finally protected with a glass coverslip. 
For quantification, four fields of 0.16 mm2 were defined at a distance of 0.6 cm from 
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the center of rotation and the number of adhering cells was counted by light 
microscopy. 
 
5.4.4. Results 
Analysis of HLA-E SCT expression on transfected porcine cells 
The expression level of HLA-E SCT on both PEDSV.15 (Fig. 1A) and AOC cells (Fig. 
1B) varied widely between different clones obtained by limiting dilution cloning. In 
order to test the effect of different levels of HLA-E SCT cell surface expression in the 
experiments described below we selected three clones with either no, low or high 
HLA-E cell surface expression (Fig. 1). The cells were stained by the HLA-E-specific 
mAb 3D12, but not by the HLA class I-specific mAb DX17 presumably due to 
conformational changes (data not shown) Neither untransfected nor mock-
transfected PEDSV.15 cells were stained by the anti-HLA-E mAb 3D12. The 
expression levels of HLA-E SCT remained stable over time as tested at different time 
points of cell culture (data not shown). 
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Figure 1: Cell surface expression of HLA-E SCT on transfected PEDSV.15 (A) and AOC (B) 
cells. Three selected clones for each cell line are depicted with either no (left panel), low (middle 
panel) or high (right panel) HLA-E cell surface expression. Cells were analyzed by indirect 
immunofluorescence staining using the HLA-E-specific 3D12 mAb (filled histograms). Histograms for 
an isotype-matched control mAb are also depicted (empty histograms). Numbers indicate the MFIR of 
HLA-E expression and are representative of at least two independent experiments. 
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HLA-E SCT expression protects porcine endothelial cells from xenogeneic human 
NK cytotoxicity 
In order to test whether the HLA-E SCT-transfected pEC lines PEDSV.15 and AOC 
were protected from xenogeneic human NK cytotoxicity by HLA-E surface 
expression, we performed 51Cr-release cytotoxicity assays using the different pEC 
clones described above as targets and IL-2-activated polyclonal human NK cell 
populations as effector cells. Since the protective potential of HLA-E depends on its 
recognition by the corresponding inhibitory NK receptor CD94/NKG2A, we also 
determined the CD94 as well as the NKG2A expression levels on the human NK 
cells used for xenogeneic killing assays by flow cytometry. HLA-E SCT protected 
pEC from human NK cytotoxicity to an extent dependant on both the level of surface 
HLA-E SCT expression on pEC and the level of CD94/NKG2A expression on human 
NK effector cells (Fig. 2). Pooled cytotoxicity results using human NK cells 
expressing different levels of CD94/NKG2A as effectors against PEDSV.15 and AOC 
target cells expressing low amounts of HLA-E SCT showed a mean reduction of 
cytotoxicity of 40±8% and 33±5% (±SEM; n=11), respectively. PEDSV.15 and AOC 
cells expressing high amounts of HLA-E SCT showed a reduced susceptibility 
against human NK cells of 48±5% and 45±8%. Taken together, the level of protection 
of pEC against human NK-mediated cytotoxicity depends on both the expression 
levels of HLA-E SCT and the respective NK receptor CD94/NKG2A. 
 
Inhibition of NK-mediated cytotoxicity against HLA-E SCT-positive porcine 
endothelial cells is reversed by blocking of CD94/NKG2A 
In order to confirm that the inhibitory effect observed in the previous experiments was 
indeed specifically mediated through the interaction of HLA-E SCT with 
CD94/NKG2A, we performed cytotoxicity assays in the presence of an anti-CD94 as 
well as an anti-NKG2A blocking mAb. NK-mediated cytotoxicity against pEC was 
completely restored by blocking CD94/NKG2A whereas isotypic control mAb had no 
effect (Fig. 3A). A general non-specific inhibitory effect of the anti-CD94/NKG2A mAb 
was excluded by their addition to HLA-E SCT-negative target cells (data not shown). 
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Figure 2: HLA-E SCT protects porcine endothelial cells from xenogeneic human NK 
cytotoxicity. Shown is the specific lysis obtained in 4 h 51Cr-release cytotoxicity assays using 
PEDSV.15 (A) and AOC (B) cells expressing different levels of HLA-E SCT as targets and either 
CD94/NKG2Abright (MFIR=34 and 9, respectively) or CD94/NKG2Adim (MFIR=7 and 2, respectively) 
polyclonal IL-2-activated human NK populations as effectors at four different E:T ratios. Results are 
representative for six independent experiments performed with NK cells purified from five different 
donors. 
 
Pooled data of all cytotoxicity assays using either PEDSV.15 or AOC cells 
expressing low or high amounts of HLA-E SCT revealed an average reduction in NK-
mediated cytotoxicity of 51±1% and 48±9%, respectively (Fig. 3B), with complete 
reversion by CD94-blocking. In conclusion, these data clearly show that the reduction 
of human NK-mediated cytotoxicity against HLA-E SCT positive pEC depends 
specifically on molecular interactions of HLA-E with CD94/NKG2A. 
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Figure 3: Inhibition of NK-mediated cytotoxicity against HLA-E SCT positive porcine 
endothelial cells is reversed by blocking of CD94/NKG2A. (A) Shown is a representative 
experiment where the cytotoxicity of IL-2-activated polyclonal human NK cells against PEDSV.15 cells 
negative for HLA-E SCT (closed symbols) and PEDSV.15 cells expressing high levels of HLA-E SCT 
(open symbols) was tested in 4 h 51Cr-release assays in the presence of anti-CD94 (triangles), anti-
NKG2A (diamonds), or isotype-control (circles) mAb. (B) A summary of four independent experiments 
is shown. Cytotoxicity is expressed as percentage of relative lysis of PEDSV.15 (filled bars) and AOC 
(empty bars) cells expressing high levels of HLA-E SCT, in the presence of the indicated mAb, as 
compared to the respective intra-assay control (lysis of HLA-E SCT negative PEDSV.15 and AOC 
cells, respectively, dashed line, index=100). The mean relative cytotoxicity was calculated at three 
different E:T ratios (20:1 to 5:1), error bars indicate SEM. Asterisks designate statistical significance in 
a Student’s t-test (*p<0.01). Dashed line marks 100% relative lysis. 
 
HLA-E expression does not affect adhesion of NK cells to porcine endothelial cells or 
conjugate formation of NK cells with porcine lymphoblastoid cells 
In order to test whether adhesion of human NK cells to pEC is reduced upon HLA-E 
SCT expression, a modified Stamper-Woodruff adhesion assay was performed either 
under static or under rotating condition. The number of CD94/NKG2Abright NK cells 
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that adhered to pEC after 10 min co-incubation with a pEC monolayer was not 
influenced by the expression of HLA-E SCT (Fig. 4 A). To address the question 
whether HLA-E surface expression on porcine lymphoblastoid cells interferes with 
the adhesion of human NK cells, heteroconjugate formation between human NK and 
porcine 13271.10 cells was studied by flow cytometry. As previously shown, 
13271.10-E/A2 cells stably express HLA-E without extrinsic peptide pulsing and are 
partially protected against human NK cytotoxicity (110). Binding equilibrium in the 
conjugation assay was reached by 10 min at 37°C with 49 ± 9% (n=6) of 
CD94/NKG2Abright NK cells bound to 13271.10 cells. Conjugate formation was 
temperature-dependent, i.e. it was only observed at 37°C, but not at 4°C (data not 
shown), indicating that 13271.10 cells need to be metabolically active for conjugate 
formation or that membrane fluidity facilitating lipid raft migration and clustering are 
required to form the synapse. However, the expression of HLA-E on 13271.10 cells 
did not influence the number of conjugates formed with NK cells (Fig. 4B). To 
demonstrate that the formation of conjugates can be blocked, control experiments 
using mAb against integrins were performed. Conjugation between human NK cells 
and porcine 13271.10 cells was partially inhibited by masking the β2-integrin CD18 
but not the β-integrin CD49d (Fig. 4C), implying that β2-integrin adhesion molecules 
are required for xenogeneic adhesion. In conclusion, these data strongly suggest that 
HLA-E expression does neither affect the adhesion of human NK cells to pEC nor the 
heteroconjugate formation between human NK and porcine 13271.10 cells. 
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Figure 4: HLA-E neither affects the adhesion of human NK cells to pEC nor the conjugate 
formation between human NK and porcine 13271.10 cells. (A) Adhesion of human NK cells to pEC 
in a static and a rotating adhesion assay. Shown is the percentage of relative NK cell adhesion to 
HLA-E SCT positive (white bars) as compared to HLA-E SCT negative (black bars) PEDSV.15 and 
AOC cells, respectively. Error bars represent SEM. (B) The percentage of conjugates that NK cells 
form with 13271.10 (filled symbols) and 13271.10-E/A2 (open symbols) cells was measured at 37°C 
after 1, 5, 10, and 15 min incubation time. (C) Conjugate formation partially depends on the -
integrin CD18. The percentage of conjugates between human NK cells and 13271.10 cells was 
measured after 10 min incubation at 37°C in the presence of an isotype control mAb (black bar), anti-
CD49d mAb (gray bar), or anti-CD18 mAb (white bar). Shown is the relative amount of NK conjugates 
in the presence of the indicated mAb as compared to the percentage of conjugates in the presence of 
an isotype control mAb (index=100). The mean relative percentage of conjugates of three independent 
experiments is shown, as calculated from (5, 10, and 15 minutes). Error bars represent SEM. 
Asterisks mark statistical significance in a Student’s t-test (*p<0.01). 
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The non-classical human MHC molecule HLA-E is a potent inhibitory ligand for 
CD94/NKG2A receptor-bearing NK cells and, unlike classical MHC molecules, does 
not induce allogeneic T cell responses (79). Therefore, transgenic expression of 
HLA-E on pig organs has the potential for substantially alleviating human NK cell-
mediated rejection of porcine xenografts without the risk of allogeneic responses. 
However, in order to express correctly folded HLA-E complexes on porcine cell 
surfaces, all three elements, the HLA-E heavy chain, human β2-microglobulin and a 
stabilizing peptide, may be necessary (110). It has been observed previously that 
transfection of a single chain trimeric HLA-E construct, consisting of all three 
elements in a single peptide chain, resulted in stable HLA-E surface expression on a 
porcine epithelial cell line and completely protected from xenogeneic NK cytotoxicity 
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mediated by monoclonal human NK lines (201). In this study, we observed a 
significant decrease of polyclonal human NK-mediated cytotoxicity against pEC by 
the transgenic expression of HLA-E SCT. However, the previous finding of complete 
protection against NK lines was not observed being in line with earlier observations 
using various other HLA constructs and polyclonal human NK cell lines as effectors 
(77, 110). In contrast to monoclonal NK lines such as NKL and NK92, primary human 
NK cells express a much broader and diverse repertoire of cell surface molecules 
potentially interacting with porcine target cells. The consequences might be either the 
lack of an inhibitory signal mediated by HLA-E SCT, or strong activating signals 
delivered to subsets of the polyclonal NK population. Diversity of the NK cell receptor 
repertoire is thought to be evolutionarily adaptive by not allowing a pathogen to 
completely shut off NK-mediated responses by interfering with just one molecular 
pathway. Moreover, it is well known that the polymorphism of MHC molecules in the 
population leads to differential responses of individuals to the same pathogens (205). 
The protective effect of HLA-E SCT expression on pEC against NK-mediated 
cytotoxicity was completely reversed by blocking CD94/NKG2A. This finding directly 
demonstrated the specificity of HLA-E SCT interactions with CD94/NKG2A. 
Moreover, the observation that CD94/NKG2A expression correlated with the 
inhibitory potential of HLA-E SCT is in line with earlier results (110), showing a clear 
correlation between CD94/NKG2A expression on NK clones and their cytotoxic 
potential against HLA-E-positive pEC. This fact supports the theory that the lack of 
complete protection from polyclonal NK populations is most likely explained by the 
presence of CD94/NKG2A-negative or dim effector subpopulations. Moreover, HLA-
E is known to interact not only with the inhibitory receptor CD94/NKG2A but also with 
the activating receptor CD94/NKG2C. Although HLA-E might trigger an activating NK 
response our  CD94- and NKG2A-blocking data indicate that HLA-E on pEC was 
solely interacting with CD94/NKG2A. In line with this observation, Valés-Gómez et al. 
reported that HLA-E loaded with the Cw*03 leader peptide, which was used for the 
HLA-E SCT construct in the present study, strongly binds to CD94/NKG2A but only 
poorly to CD94/NKG2C and therefore is unlikely to induce NK activation (206).  
 
The NK effector cells used in vitro are highly activated by stimulation with IL-2. We 
assume that inhibitory HLA-E-specific signals are not sufficiently strong to override 
triggering signals delivered by activating receptors in the CD94/NKG2A dim NK cell 
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subset. Supporting this notion, a weak allogeneic NK-mediated cytotoxicity (10-20% 
specific lysis) can be observed using primary human target cells which are expected 
to express normal levels of HLA-E molecules (unpublished results). Moreover, using 
ex vivo naïve NK cells without in vitro culture/activation rather than activated NK cells 
revealed an even better relative protective effect of HLA-E expression in previously 
published xenogeneic NK cytotoxicity assays (77) as well as in our experiments (data 
not shown). Another possible explanation for the only partial inhibitory effect of HLA-
E might be the upregulation of porcine ligands of other activating NK receptor such 
as NKG2D (150, 157) during cell culture adding to the overall triggering of NK 
cytotoxicity. 
 
HLA-E expression on 13271.10 cells did not influence the conjugate formation with 
human NK cells indicating that CD94/NKG2A, unlike other NK receptors, is not 
involved in mechanisms that control cell adhesion. On the other hand, this finding 
suggests that the successful inhibitory interaction of HLA-E with CD94/NKG2A with 
respect to cytotoxicity is not explained by an inhibition of  prior adhesion steps 
mediated by HLA-E. 
 
In conclusion, high HLA-E expression on porcine cells achieved using a SCT 
construct prevents human NK cytotoxicity in vitro to a great extent. Unlike other 
approaches to express HLA-E on pig cells that depended on extracellular peptide 
loading, this construct might be used for the production of HLA-E transgenic pigs. 
Such pigs might eventually contribute to the successful future application of 
xenotransplantation in combination with other protective strategies. 
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5.5.1. Introductory Paragraph 
The development of α1,3 galactosyltransferase (α1,3GT) deficient pigs (101) was an 
important step to overcome hyperacute rejection of pig organs transplanted into 
primates (207, 208). However, the lack of galactose-α1,3-galactose (αGal) epitopes 
does not protect against subsequent rejection mechanisms, including xenogeneic 
natural killer (NK) cell responses (209). A majority of activated human NK cells 
express the HLA-E specific inhibitory receptor CD94/NKG2A. Based on in vitro 
results (110), the aim of the present study was to overcome xenogeneic NK cell 
responses by expressing functional HLA-E/humanβ2-microglobulin (huβ2m) in 
transgenic pigs. A transgenic founder animal (designated as #8404) with high copy 
number integration was obtained following microinjection and transfer of 1584 
zygotes to 45 recipients. Presence of HLA-E/huβ2m was demonstrated by Northern, 
Southern, and Western blotting, immunohistochemistry and flow cytometry analyses. 
Finally, lymphoblasts and endothelial cells derived from these HLA-E/huβ2m 
transgenic pigs were effectively protected against human NK cell-mediated 
cytotoxicity. This novel approach against cell-mediated xenogeneic responses has 
major implications for the generation of multitransgenic pigs as organ donors for 
clinical xenotransplantation. 
 
5.5.2. Results/Discussion 
NK cells represent a potential hurdle to successful pig-to-human xenotransplantation 
since they infiltrate pig organs perfused with human blood ex vivo (57, 210) and lyse 
porcine cells in vitro both directly, and in the presence of human serum, by antibody-
dependent cell-mediated cytotoxicity (ADCC) (211). NK cell autoreactivity is 
prevented by the expression of MHC class I ligands of inhibitory NK receptors such 
as HLA-E on normal autologous cells (212) including the HLA-E specific inhibitory 
receptor CD94/NKG2A that is expressed on a majority of activated human NK cells. 
It is generally believed that HLA-E, unlike classical MHC molecules, is not 
polymorphic and induces allogeneic T cell responses to a much lower degree (213). 
To overcome xenogeneic NK cell responses in vivo transgenic pigs expressing HLA-
E/huβ2m were generated. HLA-E is assembled in the ER and transported to the cell 
surface as a stable trimeric complex consisting of the HLA-E heavy chain, β2m and a 
peptide derived from the leader sequence of some MHC class I molecules (214). 
Since the HLA-B7 signal sequence-derived peptide (VMAPRTVLL) has the strongest 
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effect on HLA-E cell surface expression (215), exon 1 coding for the signal peptide of 
a genomic 7.7-kb fragment of HLA-E (E*01033) (216) was replaced by exon 1 of 
HLA-B7 in the construct HLA-EsigB7 used for microinjection (Fig 1a). Functionality of 
the HLA-EsigB7 construct was tested in vitro by cytotoxicity assays using mock-
transfected and HLA-EsigB7-transfected K562 cells as targets for the human NK cell 
line NKL. HLA-E expression protected K562 cells against NK cell-mediated lysis by 
50% (Fig 3a). To achieve appropriate cell surface expression of HLA-E in transgenic 
pigs, HLA-EsigB7 and a 15-kb genomic huβ2m fragment, were co-injected into 
pronuclei of zygotes. In total, 1584 microinjected zygotes were transferred to 45 
recipient sows, six (13.3%) of which became pregnant. Two sows gave birth to a total 
number of nine piglets. 
 
The presence of the transgenes was analyzed by PCR and Southern blot analysis of 
genomic DNA isolated from ear tissue or blood samples of the piglets identifying 
three male transgenic founder animals carrying both the HLA-EsigB7 and the huβ2m 
fragment. Pigs #8403 and #8405 revealed a low copy number integration, whereas a 
high copy number integration was detected in pig #8404 (Fig 1b). Northern blot 
analysis of peripheral blood mononuclear cells (PBMC) from founder #8404 revealed 
both HLA-E transcripts of 1.6 and 2.7 kb as expected due to differential 
polyadenylation (217) and a huβ2m-specific transcript of the expected size of 1.2 kb 
(Fig 1c). Gene expression of both transgenes was markedly lower in PBMC derived 
from founder #8405, and not detectable in founder #8403. As a positive control, the 
human melanoma cell line Mel-Juso was used. Similar results were obtained with 
RNA from human PMBC or different cell lines. Remarkably, both genomic copies and 
numbers of transcripts were higher in the founder animal #8404 as compared to cells 
and cell lines naturally expressing HLA-E and huβ2m. The number of integrated gene 
copies can explain the high expression of the transgenes. In line with the mRNA 
expression, flow cytometry analysis of founder #8404 PBMC and endothelial cells 
revealed high levels of stable HLA-E and huβ2m cell surface co-expression (Fig 1d 
and e). Correct peptide loading of HLA-E heavy chains in founder #8404 was 
indicated by Endopeptidase H-resistance in Western blot analysis of PMBC lysates 
(Fig 1f). Incubation with exogenous B7 peptide ligands did not further increase HLA-
E cell surface expression on PMBC supporting the expression of functional HLA-E 
molecules (218) (data not shown). When founder #8404 was mated with wild-type 
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females hemizygous F1 offspring (e.g. #8568, #9427, #9432) was generated with 
similar transgene expression levels (data not shown). 
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Figure1: a) The exon-intron organization of the microinjected 7.7 kb Hind III/Bgl II fragment of HLA-
EsigB7 and 15 kb BamH I/Sal I fragment for huβ2m with relevant restriction sites are shown. The 
exchanged exon 1 to generate HLA-EsigB7 is underlined. Boxes depict exons and pA depicts the 
alternative polyadenylation sites in the 3´-untranslated region (3´-UT) of HLA-E. b) HLA-E and huβ2m 
genes are present in the genome of HLA-E/huβ2m-transgenic pigs. Shown is the Southern blot 
analysis of DNA derived from HLA-E/huβ2m-transgenic pigs designated as #8503 (low copy number), 
#8505 low copy number), #8406 (negative offspring), and #8404 (high copy number). DNA derived 
from B-LCL LG2 cells was used as positive control. c) HLA-E and huβ2m transcripts are present in 
PBMC derived from HLA-E/huβ2m-transgenic pigs. Shown is a northern blot analysis of RNA isolated 
from PHA-stimulated PMBC derived from HLA-E/huβ2m-transgenic pigs #8403, #8404, and #8405, 
and the human melanoma cell line MJ using the HLA-E 3´-probe (top) or the huβ2m cDNA (bottom). d) 
HLA-E and huβ2m are expressed on the cell surface of PMBC derived from HLA-E/huβ2m-transgenic 
pigs. PBMC derived from a wildtype control animal (left panel) and from the HLA-E/huβ2m-transgenic 
pig #8404 were stimulated for 48 h with PHA and subsequently analyzed for HLA-E heavy chain and 
huβ2m cell surface expression by flow cytometry. e) HLA-E is expressed on the cell surface of 
endothelial cells derived from HLA-E/huβ2m-transgenic pigs. Endothelial cells derived from a wildtype 
control animal (left panel) and from the HLA-E/huβ2m-transgenic pig #8404 were analyzed for HLA-E 
heavy chain cell surface expression by flow cytometry. f) Western blot analysis of cell lysates probed 
with the HLA-E specific mAb MEM E02 revealed correct peptide loading on HLA-E. K-562 HLA-E 
lysate was used as positive control, where due to inefficient ligand supply, HLA-E is not efficiently 
transported to the cell surface. Arrows mark the mature (m=Endo H resistant) and the immature 
(im=Endo H sensitive) HLA-E heavy chains. 
 
Since the protective effect of HLA-E/huβ2m in pig-to-human xenotransplantation 
critically depends on the level and tissue distribution of transgene expression, protein 
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localization studies were performed by immunohistochemistry using different tissues. 
Although several different Ab either recognizing HLA-class I molecules (B9.12.1, 
A1.4) or against HLA-E (MEM E02) were tested, which detected HLA-E by FACS on 
transgenic PMBC or in cell lysates, it was not possible to demonstrate any specific 
HLA-E expression in transgenic pigs due to strong non-specific staining of porcine 
endothelial cells (pEC) in tissues from both wild-type and transgenic pigs. In contrast, 
immunostaining using the species-specific anti-huβ2m mAb BBM1 revealed high 
levels of specific expression in all transgenic pig tissues investigated. In the heart, 
expression of huβ2m was detected on pEC of capillaries and larger blood vessels 
(Fig. 2a). In the kidney, positive staining was observed both in glomerular and 
peritubular capillaries as well as on the endothelium of arteries and venous blood 
vessels of the cortex and medulla. Slight and diffuse positive staining was observed 
in the mesangium of glomeruli. Strong staining of the brush border and the apical 
part of proximal tubular epithelia was seen in a granular pattern (Fig. 2b). In the 
pancreas, capillaries and larger blood vessel pEC as well as epithelial cells of larger 
ducts stained positive for huβ2m (Fig. 2c). No positive staining for huβ2m was found 
in tissues of wild-type animals (data not shown). 
 
The functional effect of HLA-E expression on PBMC derived from HLA-E transgenic 
animals in comparison to wild-type control animals was tested in NK cytotoxicity 
assays. As expected, the killing capacity of NK cells against HLA-E expressing target 
cells was significantly reduced, whereas wild-type target cells were readily lysed by 
IL-2-activated human NK cells (Fig 3b). However, only partial and not complete 
protection was observed, in particular at high, non-physiological E:T ratios. Since the 
protective effect of transgenic HLA-E expression is regarded to result from its 
interaction with the corresponding inhibitory NK receptor CD94/NKG2A, the 
remaining NK lysis is most likely explained by either CD94/NKG2A-independent 
cytotoxic mechanisms such as the Fas/FasL pathway and/or CD94/NKG2A-negative 
NK cell subsets present in the polyclonal effector population used in these killing 
experiments. To test the former hypothesis and to demonstrate that HLA-E 
transgenic lymphocytes are in general still susceptible to cell lysis, human 239 cells 
were transfected with the human CD95(Fas)ligand (293h95L) or mock-transfected 
(293pcDNA) and used as effector cells which induces apoptotic cell death by binding 
to CD95 on target cells (219). 
5. Results 
 
Figure 2: Immunohistochemistry revealed huβ2m expression on tissues derived from HLA-
E/huβ2m-transgenic pigs. (a) Heart endothelia of capillaries and larger blood vessels stained 
positive for huβ2m. (b) In the kidney, positive staining was observed on endothelial cells of glomerular 
and peritubular capillaries as well as on endothelia of larger blood vessels, in the mesangium and, in a 
granular pattern, in the brush border and the apical part of proximal tubular epithelial cells. (c) 
Endothelial cells of pancreatic capillaries and blood vessels stained positive for huβ2m. 
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Whereas HLA-E transgenic porcine lymphocytes were partially protected against NK-
mediated lysis, 293h95L effector cells were able to lyse HLA-E expressing as well as 
HLA-E negative control lymphocytes to the same extent at an E:T ratio of 10:1 (Fig 
3c). These data show that HLA-E expression in transgenic pigs, at least on 
lymphocytes, does not interfere with the susceptibility to apoptosis mediated by the 
Fas/FasL pathway and suggests that the observed protection from NK lysis depends 
on inhibitory interactions between HLA-E and CD94/NKG2A. 
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Figure 3: a) HLA-EsigB7 protects K-562 cells from NKL-mediated cytotoxicity. Shown is the specific 
lysis obtained in 4 h 51Cr-release cytotoxicity assays using mock-transfected and HLA-EsigB7-
transfected K-562 cells as targets and the NK line NKL as effectors at different E:T ratios. b) Pig 
lymphoblasts derived from HLA-E/huβ2m-transgenic pigs are partially protected against human NK-
mediated cytotoxicity. Shown is the specific lysis of either HLA-E negative (wt) or HLA-E positive 
(#8404) lymphoblast target cells by IL-2-activated human NK cells. Results are representative for 
three independent experiments. c) HLA-E expression does not influence CD95L-mediated cytotoxicity. 
1 x 105 IL-2-activated human NK cells, 293pcDNA cells, or 293h95L cells were co-incubated with 104 
51Cr-labeled lymphoblasts derived from the HLA-E/huβ2m-transgenic or a wild-type control pig. Bars 
represent percentage of specific lysis (mean + standard deviation, n=3). Results are representative for 
two independent experiments. 
 
Following pig-to-human xenotransplantation of vascularised solid organs the first 
porcine cell type in contact with human NK cells will be the pEC lining the capillaries 
and larger blood vessels. Therefore, three primary pEC were isolated from HLA-E 
transgenic pigs (#8404, #9427, and #9432, both offsprings of #8404 ) and a HLA-E 
negative litter mate(#9429), expanded ex vivo and tested for protection against 
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human NK cells lysis in vitro. Primary IL-2-activated human NK cells and the human 
NK line NK92 were used as effector cells. Furthermore, to demonstrate interactions 
between HLA-E and CD94/NKG2A, the expression of the latter on NK cells was 
measured by flow cytometry on all NK cells used in these assays. Surface 
expression levels of CD94/NKG2A varied considerably among different NK cell 
subsets, three of which were used for cytotoxicity experiments with either high 
(MFIR=72), medium (MFIR= 31), or low (MFIR=11) expression. As expected, the 
susceptibility of HLA-E positive targets correlated well with the expression of 
CD94/NKG2A on effector cells (Fig. 4a). The relative lysis of HLA-E positive target 
cells as compared to the negative control was 35±6% for CD94/NKG2A high NK 
cells, 62±6% for CD94/NKG2A medium NK cells, and 72±4% for CD94/NKG2A low 
NK cells. Blocking of CD94/NKG2A using a specific mAb rendered HLA-E positive 
target cells NK susceptible (Fig. 4b), further proofing functional specific interactions 
between HLA-E and CD94/NKG2A. Taken together, HLA-E positive pEC were 
partially protected from NK-mediated cytotoxicity by specific triggering of the 
inhibitory receptor CD94/NKG2A on human NK cells (Fig. 4c). Furthermore, ex vivo 
NK cell cytotoxicity using freshly isolated, naive human NK cells was almost 
completely inhibited even by CD94/NKG2A low NK cells (Fig. 4d). In addition, IFN-γ 
secretion of human NK cells after co-incubation with pEC was significantly reduced 
by the expression of HLA-E/huβ2m (Fig. 5). The partial protection of cytotoxicity and 
IFN-γ secretion is consistent with reports from the in vitro generation of pEC 
expressing HLA-E(78, 110, 201) and potential reasons might be miscellaneous. NK 
cells express a broad and diverse repertoire of cell surface molecules potentially 
interacting with porcine target cells. The consequences might be either the lack of an 
inhibitory signal mediated by HLA-E or strong activating signals delivered to subsets 
of the polyclonal NK population. 
 
In conclusion, transgenic expression of HLA-E/huβ2m on porcine cells might 
contribute, in combination with other protective strategies, such as α1,3GT deficiency 
(101), and expression of human complement regulatory proteins CD46 (106), CD55 
(107), or CD59 (108), to the successful prevention of xenograft rejection in clinical 
xenotransplantation. 
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Figure 4: Susceptibility of aortic pEC derived from HLA-E/huβ2m-transgenic pigs against 
human NK cytotoxicity correlates with the expression of CD94/NKG2A on human NK cells and 
is reversed by anti-CD94/NKG2A blocking. (a) Shown is the percentage of specific lysis of either 
HLA-E negative (#9429) or positive (#9427) target cells by human NK cells expressing high, medium, 
or low amounts of CD94/NKG2A. (b) Inhibition of human NK cytotoxicity against HLA-E positive 
(#9432) pEC was blocked by anti-CD94/NKG2A mAb (open circle), while an isotype control mAb 
(closed symbols) had no effect. (c) A summary of two independent cytotoxicity assays with two 
different donors and the NK92 cell line is shown. As targets, pEC derived from three HLA-E positive 
pigs (#9427, #9432, and #8404) and an HLA-E negative litter-mate (#9429) were used. The mean 
relative cytotoxicity was calculated at four different E:T ratios (40:1 to 5:1), error bars represent SEM. 
Asterisks mark statistical significance in a paired student’s t-test (*p<0.0001). (d) Shown is the 
percentage of specific lysis of either HLA-E negative (#9429) or positive (#9432) target cells by human 
NK cells expressing low amounts of CD94/NKG2A. 
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Figure 5: IFN-γ secretion of human NK cells after co-incubation with pEC is reduced by the 
expression of HLA-E/huβ2m. Shown is the amount of IFN-γ secreted by human NK cells after 48h of 
co-incubation with either HLA-E negative (#9429) or positive (#9432) pEC. Error bars represent SD. 
Asterisks mark statistical significance in a paired student’s t-test (*p<0.05). 
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5.5.3. Materials and Methods 
Construction of HLA-EsigB7and huβ2m fragments 
A genomic fragment of 330 bp encoding exon 1 of HLA-B7 was isolated by PCR 
using the primer pair B7-5´UT (5´-GATATCTAGAAGCCAATCAGCG-3) and Eex2as 
(5´-GCGGCCGGGCCGGGACACGGAAGTGTGGAAATACTTCAAGG-3) and was 
subcloned into the vector pCR®2.1-Topo ® (Invitrogen, Netherlands). Afterwards, it 
was inserted in the 7.7 kb genomic HLA-E Hind III/Bgl II fragment (HLA-
E*01033)(220) using the Xba I and Eag I restriction sites. Cloning of huβ2m has been 
previously described(220). The fragments were isolated by restriction enzyme 
digestion and subsequent gel purification. Precipitated DNA was dissolved at 1000 
copies/pL (500 copies of each gene) in 10 mM Tris/HCl, pH 7.5, 0.25 mM EDTA. 
 
Generation of HLA-E/huβ2m transgenic pigs 
Prepubertal gilts (German Landrace × Pietrain) were superovulated by intramuscular 
injections of 1200 IU equine chorionic gonadotropin and, 72 h later, 750 IU human 
chorionic gonadotropin (Intergonan® and Ovogest®; Intervet, Tönisvorst, 
Germany)(220). Twenty-four and 36 h after Ovogest® injection, donors were 
artificially inseminated with 3 × 109 sperms. Thirty-two to 34 h after the first 
insemination, donor gilts were sacrified, the oviducts were recovered and flushed 
with 20 ml of Dulbecco’s phosphate-buffered saline (PBS) containing 5% heat-
inactivated lamb serum (Gibco BRL) and 50 mg/L gentamicin sulfate (Sigma, St. 
Louis, MO). Zygotes were collected under a light microscope (Zeiss Stemi SV 6; 
Zeiss, Oberkochen, Germany) and centrifuged for 3 min at 15,000g to visualize the 
pronuclei. Microinjection was performed using an inverted microscope (Axiovert 135; 
Zeiss). After microinjection, embryos were stored in the incubator (Heraeus Holding 
GmbH, Munich, Germany) at 39°C, 5% CO2, and 90% N2 before the transfer. 
Endoscopic embryo transfer was performed the same day according to the 
procedure of Besenfelder et al.(221). Thirty to 35 injected embryos were inserted into 
one oviduct. Twenty to 25 days after the transfer, recipients were examined 
ultrasonographically for pregnancy. After farrowing, skin samples (ear tips) of the 
born piglets were taken for examination of transgene integration by PCR and 
Southern blot analysis.  
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Analysis of transgene presence by Southern, Northern, and Western blotting 
Southern and Northern blot analyses were performed after a nonradioactive 
hybridization protocol(222) using the following probes. The HLA-E specific probe 
(HLA-E 3´-probe) encompassing exons 5 to 8 of the HLA-E transcript was obtained 
by RT-PCR using the primer pair (5´-CAGCATGAGGGGCTACCCG-3´) and (5´-
GTGTGAGGAAGGGGGTCTG-3´) and was subcloned into pCR®2.1-TOPO ® 
(Invitrogen). This was the only HLA-E probe that did not show cross-hybridization 
with swine sequences. The huβ2m probe used for Northern blots was a full-length 
huβ2m cDNA clone whereas for Southern blots a genomic fragment of 500 bp 
containing exon 2, generated by PCR using the primer pair 2s (5´-
CCCAAGTGAAATACCCTGGCA-3´) and 2as (5´-CGAAGATTCCCTGACAATCCC-3) 
was used.  
Western blot analysis: Lysates equivalent to 100 µg of protein were subjected or not 
to 100 IUB mU of Endo Hf (New England Biolabs, USA) for 3 h at 37°C, separated by 
10% SDS-PAGE, and transferred onto nitrocellulose membranes (Schleicher and 
Schuell, Germany) using standard Western blotting techniques. HLA-E heavy chains 
were detected with the mAb MEM E02 (Acris, Germany) and the Western-Light 
chemiluminescence detection system according to manufacturer’s recommendations 
(Invitrogen).  
 
Immunohistochemistry 
Immunohistochemistry for huβ2m and HLA-E was performed on formalin fixed, 
paraffin embedded heart, kidney and pancreas samples of HLA-E/ huβ2m-transgenic 
(n=2) and wild-type (n=2) pigs, using the streptavidin-biotin-method. The following Ab 
were used: undiluted mouse anti-huβ2m hybridoma supernatant (clone BBM1), 
mouse anti-human HLA-E (clone MEM E02)(223), and biotinylated goat anti-mouse 
Ig (both diluted 1:100 in tris buffered saline, pH 7.4). The indirect peroxidase and the 
streptavidin-biotin-method were applied on frozen tissue sections to stain for HLA-E, 
using the undiluted monomorphic hybridoma supernatant (clone B9.12.1) or A1.4 
(Antigenix America, USA). Biotinylated goat anti-mouse Ig or horseradish peroxidase 
conjugated rabbit anti mouse Ig were diluted 1:100 and 1:300 in TBS, respectively. 
DAB was used as chromogen. Specificity controls included substitution of primary 
antisera with non-immune serum and omission of the secondary antiserum. 
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Cells 
The primary porcine aortic endothelial cells were isolated as described earlier(163) 
and cultivated in RPMI 1640 (Invitrogen) supplemented with 20% FCS (PAA 
Laboratories, Luzern, Switzerland), 1 mM sodium pyruvate, 2 mM L-glutamine, non-
essential amino acids (100x), essential amino acids (50x), and 1% 
penicillin/streptomycin (all Invitrogen). The immortalized human NK line NK92 (a kind 
gift of C. Falk, gsf, Munich, Germany) was cultured in RPMI 1640 supplemented with 
15% FCS, 5% human plasma obtained from healthy donors, 1 mM sodium pyruvate, 
2 mM L-glutamine and 1% penicillin/streptomycin. Isolation of PBMC from healthy 
blood donors, purification of NK cells, and generation of polyclonal human NK cell 
populations have been described previously(74). To obtain lymphoblasts, PMBC 
were stimulated with either 5 µg/ml PHA (Sigma Germany) for 48 hrs or with ConA 
(2 µg/ml, Pharmacia Germany) for 3 days. Isolated NK cells with a purity of routinely 
>95% were activated by culture in AIM-V medium (Invitrogen) supplemented with 
10% human plasma obtained from healthy donors, 1 mM sodium pyruvate, 2 mM L-
glutamine, essential amino acids (50x), non-essential amino acids (100x), 1% 
penicillin/streptomycin (Invitrogen), 20 mM HEPES, and 300 U/ml of human IL-2 
(Chiron, Emeryville, CA). The melanoma cell line Mel-Juso and the lymphoblastoid  B 
cell line LG2 obtained from J. Johnson LMU Munich, were cultured in RPMI medium, 
1 mM sodium pyruvate, 1% penicillin/streptomycin (Invitrogen) supplemented with 
10 % FCS (Biochrom, Germany)(217).  
 
Flow cytometry 
Cell surface expression of HLA-E und huβ2m was measured on a FACScan (Becton 
Dickinson, Mountain View, CA) by indirect immunofluorescence. After resuspension 
of 2x105 cells per tube in staining buffer (HANKS, 0.1% BSA) cells were incubated for 
30 min at 4°C with saturating amounts of Ab. As primary Ab the mouse mAb BBM1 
(anti- huβ2m, ATCC, Wesel, Germany), TP25.99 (anti-HLA-E heavy chain, a kind gift 
of S. Ferrone, Roswell Park Cancer Institute, Buffalo, USA), and 3D12 (D. Geraghty, 
Fred Hutchinson Cancer Research Center, Seattle, WA) were used. As secondary 
reagents PE-conjugated goat F(ab')2 anti-mouse Ig (Dako, Germany) was used. 
Surface expression of CD94/NKG2A on human NK cells was analyzed on a 
FACScanto (Becton Dickinson, Basel, Switzerland) by indirect immunofluorescence. 
As primary Ab the mouse mAb DX22 (anti-CD94, IgG1, L. Lanier, University of 
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California, San Francisco, CA) was used. As secondary reagent FITC-conjugated 
goat anti-mouse IgG Ab (Chemicon International, Dietikon, Switzerland) was used. 
Phenotypic analysis of NK cells was carried out by direct immunofluorescence using 
FITC-UCHT1 (anti-CD3), PE-B73.1 (anti-CD16), and PE-B159 (anti-CD56) mAb (all 
from Pharmingen, Allschwil, Switzerland). An irrelevant, isotype-matched control 
mAb (MOPC21, mouse IgG1, Sigma) was used as control for mAb stainings. To 
exclude dead cells, propidium iodide gating was performed in all experiments. To 
compare the levels of surface expression, the geometric mean fluorescence intensity 
ratios (MFIR) were calculated by dividing the mean fluorescence intensity of each 
sample with the mean fluorescence intensity of the control Ab. 
 
Cytotoxicity assays 
The cytotoxic activity of IL-2 activated human NK cells and the human NK lines NK92 
and NKL was tested in 4 h 51Cr-release assays in serum-free AIM-V medium as 
described previously (74). Briefly, labeled target cells were added to triplicate 
samples of serial twofold dilutions of NK cells in round-bottom 96-well plates. Various 
E:T ratios were used in each experiment. For blocking studies, NK cells were 
preincubated for 30 min at 4°C with 10 µg/ml of the following mAb: MOPC21, DX22. 
MAb were also present during the co-incubation of target and effector cells at a 
concentration of 5 µg/ml. After incubation for 4 h at 37°C, the assays were stopped, 
51Cr-release was analyzed on a gamma counter and the percentage of specific lysis 
was calculated. 
 
IFN-γ ELISA 
Freshly isolated human NK cells (5x105, 2.5x105,1.25x105) and HLA-E/huβ2m 
negative or positive pEC (5x104) were co-cultured in 200 µl AIM-V for 48 hours at 
which time 100 µl supernatant was removed and assayed for IFN-γ using an ELISA 
kit according to the protocol recommended by the supplier (Mabtech AB, Hamburg, 
Germany). 
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6. Discussion 
The role of NK cells in solid organ rejection is controversial. NK cells are thought to 
play a more pronounced role in xenotransplantation as compared to 
allotransplantation. However, recent findings suggest that the role of NK cells in solid 
organ allograft rejection needs to be reassessed (47). This is supported by the facts 
that NK cells (i) are able to reject hematopoietic and tumor cells, (ii) react to 
allogeneic MHC class I molecules, and (iii) possess the necessary effector 
mechanisms to induce cell death both directly and indirectly. In several studies NK 
depletion did not lead to a prolonged graft survival, which was interpreted that NK 
cells do not play a role at all in the process of rejection. But although NK cells might 
not be sufficient to reject a solid allograft alone or directly, they may participate in an 
acute rejection response by facilitating the actions of alloreactive T cells. In 
agreement, Maier et al. observed a significantly prolonged allograft survival in T cell 
costimulation impaired CD28-/- mice, as compared to wild type as well as NK-
depleted wild type mice (224). Other studies have shown the presence of activated 
NK cells following infiltration into solid organ allografts which might at least amplify 
intragraft inflammation (225). NK cells also have the ability to interact with cells of the 
adaptive immune system and therefore serve as a bridge between innate and 
adaptive immunity. One example is the discovery that NK cells can promote 
alloreactive CD4+ T cells to differentiate along a Th1 pathway (226). NK cells also 
support the maturation of immature dendritic cells (227) and produce IFN-γ that may 
contribute to the alloresponse by up-regulating MHC class II expression on graft EC 
(228). Only few studies investigated the role of NK cells in human transplantation and 
conflicting results were observed. NK cells infiltrate human renal allografts during 
acute rejection and express cytolytic proteins such as granzyme A and B (229, 230). 
Furthermore, Vampa et al. noted a high correlation between the presence of 
predicted NK cell alloreactivity and the ability of these NK cells to mount a donor-
specific cytotoxicity (231). However, no such correlation was found by Oertel et al. 
(232). 
 
Focusing on xenotransplantation, NK cells appear to play an important role in the 
rejection of solid organ xenografts (46, 54, 233). This observation was made in vitro 
as well as in vivo in human (57, 58), nonhuman primates (60), and rodent systems 
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(234, 235). Moreover, NK cell rejection is important in hematopoietic stem cell 
xenotransplantation, and has been proposed as a method to induce xenogeneic 
tolerance (190). Importantly, NK cells promote xenograft rejection through several 
separate pathways: Firstly, NK inhibitory receptors fail to recognize pig MHC class I 
(72). Secondly, NK cells lyse porcine cells in an Ab-dependent manner by ADCC, 
induced by xenoreactive Nab bound to pEC (54). Thirdly, the NK activating receptors 
NKG2D and NKp44 recognize corresponding ligands on porcine cells (81, 157). And 
lastly, NK cells activate pig endothelium resulting in an induction of procoagulant 
factors and adhesion molecules that promote immune cell invasion (18, 19). 
 
In summary, a growing number of studies, both in vitro and in vivo, describe the 
involvement and importance of NK cells in allotransplantation and, to an even greater 
extent, in xenotransplantation. Therefore, research aiming at identifying mechanisms 
of detrimental NK effects, might have a significant impact on the outcome of 
xenotransplantation. However, a future advent of clinical xenotransplantation relies 
on a simultaneous interference with several pathways, including such related to NK 
cells as well as to other leukocyte subsets. 
 
In this thesis, mechanisms mediating activation and inhibition of human NK cells 
were studied in a pig-to-human xenogeneic setting. A common criticism of these 
studies was the strict use of in vitro models. Of course it is not possible to mimic all 
the dynamic processes of the immune system in vitro. On the other hand, most in 
vivo models are also highly artificial using inbred animal strains with homologous 
MHC haplotypes, hosted under sterile conditions. In general, in vitro studies allow 
distinct investigations under well-controlled conditions, while in vivo studies permit 
analysis under accurate physiological conditions where, however, all the factors 
involved are much more difficult to control and examine. Still, the studies described 
herein used EC, the first immunological target following vascularized pig-to-human 
xenotransplantation, as target cells in the 51Cr-release assays. Furthermore, both 
immortalized and primary pEC were used as targets. The conclusiveness of the 
current studies is also improved by the use of both freshly isolated and cultivated 
primary human NK cell populations, individually derived from a large donor pool. A 
concern, however, are the E:T ratios of the cytotoxic assays which may be 
unphysiologically high. Nevertheless, the cocultivation time in vitro was limited to 4 h, 
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whereas in vivo every EC may encounter a large number of NK cells sequentially, 
resulting in an accumulation of damages over time. 
 
Intriguingly, the significant variability among donors in the response of freshly 
isolated NK cells against pEC did not correlate with the NKG2D receptor surface 
densities, which were similar between different donors. Therefore, the reason for this 
variability might depend on individual differences in the efficiency of the respective 
cytotoxic effector pathways, such as perforin-granzyme release which is important in 
xenogeneic NK cytotoxicity (168). Indeed, it has been shown that NK cell culture 
conditions, in particular IL-2 and IL-15 supplements, upregulate the expression levels 
of molecules involved in the perforin-granzyme cytolytic pathway (169). Moreover, 
the cytolytic potential of individual freshly isolated NK populations might depend on 
the immunologic condition of the donor. In this respect, NK cells collected at different 
time points from the same donor differed in their ability to kill pEC without apparent 
differences in NKG2D expression (own unpublished observations). Taking the 
limitations of in vitro studies into careful consideration, NK cytotoxicity studies may 
represent relevant NK cell responses in vivo. Nevertheless, complementary in vivo 
experiments would add additional insights into the results and conclusions of the 
current study. 
 
The involvement of NKp44 and NKG2D in NK-mediated lysis of pEC indicates the 
presence and recognition on pEC of porcine homologues of human NKp44 and 
NKG2D ligands or of "unique" ligands in pigs without apparent human homologues. 
Xenogeneic compatibility between NK activating receptors and their respective 
ligands has also been described in other species combinations. In fact, the putative 
ligand for the human NKp46 receptor is responsible for xenogeneic NK-mediated 
lysis of murine cells (170). The notion that NCR and NKG2D receptors are, at least 
partially, conserved between humans and other species is clearly different from the 
divergent evolution of the MHC class I-specific inhibitory receptors (171-173). Allelic 
specificity of human KIR for HLA class I molecules suggests a coevolution of 
inhibitory KIR with the respective MHC genes. This may explain why human KIR 
have a low affinity for MHC class I molecules of unrelated species (174). In contrast, 
it is conceivable that NCR and NKG2D as well as their ligands have not been 
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subjected to the pressure that caused the evolution of MHC genes and their 
receptors. 
 
Beside the fact that pULBP1 is the predominant, if not the only, functional porcine 
ligand for human NKG2D, pEC express at least one alternative ULBP-like transcript, 
the pULBP2. However, the mRNA expression level of pULBP2 is about 20-fold lower 
than pULBP1. Also, preliminary analysis of a porcine bacterial artificial chromosome 
clone suggests several additional loci encoding ULBP-like proteins (M. Crew, 
unpublished observations). Thus, similar to humans, mice, cattle and primates, pigs 
may possess several ULBP and MIC proteins which serve as ligands for NKG2D 
(150, 151, 188, 189). The redundancy of the NKG2D system within a species might 
be driven by immune evasion mechanisms of pathogens such as CMV. However, 
considering that no evolutionary pressure acted on interactions between human and 
porcine molecules, the lack of redundancy across the species barrier (i.e. pULBP1 
being the only ligand for human NKG2D) is not very surprising and in line with other 
known molecular incompatibilities between man and pig. In this regard, the aa 
identity between human ULBPs and pULBP1 is only around 35-52%. Remarkably, 
the level of conservation at the positions predicted to bind human NKG2D is relatively 
high. On the other hand, pig NKG2D has 67% aa identity with human NKG2D (236). 
 
The non-classical human MHC molecule HLA-E is a potent inhibitory ligand for 
CD94/NKG2A receptor-bearing NK cells and It is generally believed that HLA-E, 
unlike classical MHC molecules, is not polymorphic and induces allogeneic T cell 
responses to a much lower degree (213). Therefore, transgeneic expression of HLA-
E on pig organs has the potential for substantially alleviating human NK cell-
mediated rejection of porcine xenografts. However, the stable expression of HLA-E 
on the cell-surface of pEC was previously shown to be problematic but was solvable 
by providing all three elements of the cell-surface HLA-E, i.e. the heavy chain, 
huβ2m, and a peptide, in a single peptide chain. An HLA-E SCT with VMAPRTLIL as 
peptide antigen (identical to the HLA-Cw*03 and UL40 signal sequence-derived 
peptides) folded correctly as evident by (i) its ability to bind several conformation-
dependent mAbs, and (ii) the fact that HLA-E SCT functionally mirrored natural 
trimeric HLA-E in its ability to inhibit NK cell-mediated cytotoxicity and IFN-γ secretion 
(237) (see also results section 5.4.). HLA-E SCT may be further optimized by 
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changing the peptide antigen bound or by altering the HLA-E heavy chain. With 
respect to the peptide antigen, HLA-E bound with the HLA-G signal sequence-
derived peptide, VMAPRTLFL, has an approximately 3-fold higher affinity for 
CD94/NKG2A than HLA-E bound with VMAPRTLIL (206). Furthermore, the use of a 
different HLA-E allele (E*0101), termed HLA-EG, that exhibits higher affinity for most, 
if not all, peptides and has higher thermal stability (238), would further improve the 
HLA-E heavy chain component. This allele was chosen, in combination with the HLA-
B7 signal sequence-derived peptide VMAPRTVLL, for the HLA-EsigB7 construct, used 
to generate HLA-E/huβ2m-transgenic pigs (see results section 5.5.). 
 
There may be several explanations for the only partial protection achieved by the 
transgenic expression of HLA-E on pig cells. Primary human NK cells express a 
diverse repertoire of cell surface molecules potentially interacting with porcine target 
cells. The consequences might be either the lack of an inhibitory signal mediated by 
HLA-E SCT, or strong activating signals delivered to subsets of the polyclonal NK 
population. Diversity of the NK cell receptor repertoire is thought to be evolutionarily 
adaptive by not allowing a pathogen to completely shut off NK-mediated responses 
by interfering with one common molecular pathway. Moreover, it is well known that 
the polymorphism of MHC molecules in the population leads to different individual 
responses to the same pathogens (205). A clear correlation between CD94/NKG2A 
expression on NK clones and their cytotoxic potential against HLA-E-positive pEC 
was also shown earlier (110). Therefore, the lack of complete protection from 
polyclonal NK populations is most likely explained by the presence of subpopulations 
that were low or negative for CD94/NKG2A. The NK effector cells used in vitro were 
highly activated by stimulation with IL-2. It may be assumed that inhibitory HLA-E-
specific signals are not sufficiently strong to override triggering signals delivered by 
activating receptors in the CD94/NKG2A dim NK cell subset. Supporting this notion, 
a weak allogeneic NK-mediated cytotoxicity (10-20% specific lysis) was observed 
using primary human target cells which presumably expressed normal levels of HLA-
E molecules (own unpublished observations). In addition, freshly isolated, naïve 
human NK cells were almost completely inhibited by the expression of HLA-E on 
pEC (see results section 5.5.). Finally, it is well documented that the ligands for the 
activating receptor NKG2D are stress-inducible (150), a state that might be induced 
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during cell culture and does not necessarily need to correlate with the pEC 
phenotype of transplanted HLA-E transgenic pig organs in vivo. 
 
In addition to being expressed on NK cells, the CD94/NKG2A inhibitory receptor is 
present on a subset of CD8+ T cells that have undergone antigen-driven clonal 
expansion. Increased expression of CD94/NKG2A on human CD8+ T cells also 
occurs following xenogeneic coculture with pEC (M. Crew, unpublished 
observations). Thus, HLA-E SCT may also be useful in reducing T cell responses to 
xenografts. 
 
In summary, the clinical application of xenotransplantation on a routine basis may 
become reality one day. Nevertheless, it is important to combine several strategies to 
overcome the divergent xenogeneic immune responses. The generation of αGAL 
knockout pigs as well as pigs transgenic for human complement regulatory proteins, 
such as hDAF, to overcome hyperacute rejection, represented a great advance for 
the xenotransplantation research community. However, the identification and 
subsequent knocking out of the predominant ligands for non-αGAL xenoreactive 
Nab, may be needed to completely surmount HAR. Furthermore, xenograft survival 
would most likely benefit from knocking out the ligands for the human NK activating 
receptors, i.e. pULBP1 and the yet unidentified porcine ligands for human NKp44. In 
conclusion, for successful clinical xenotransplantation a crossbreeding of HLA-
E/huβ2m-transgenic pigs with other transgenic and knockout pigs may be required to 
generate pigs resistant to the majority of rejection mechanisms as an appropriate 
organ source. 
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7.2. List of Abbreviations 
aa amino acid 
Ab antibody 
ADCC antibody-dependent cell-mediated cytotoxicity 
αGAL galactose-α-1,3-galactose 
α1,3GT α-1,3-galactosyltransferase 
AVR acute vascular rejection 
β2m β2-microglobulin 
CMV human cytomegalovirus 
EC endothelial cell 
E:T ratio effector-to-target-ratio 
GPI glycosylphosphatidyl-inositol 
HAR hyperacute rejection 
HLA human leukocyte antigen 
huβ2m human β2m 
ICAM intercellular adhesion molecule 
IFN    interferon 
Ig    immunoglobulin 
IL    interleukin 
ILT    Ig-like transcript 
ITAM    immunoreceptor tyrosine-based activating motif 
ITIM    immunoreceptor tyrosine-based inhibitory motif 
KIR    killer-cell Ig-like receptor 
KO    knockout 
mAb    monoclonal antibody 
MFIR    geometric mean fluorescence intensity ratio 
MHC    major histocompatibility complex 
MIC    MHC class I chain-related protein 
NAb    natural antibody 
NCR    natural cytotoxicity receptor 
NK    natural killer 
PAEC    porcine aortic endothelial cell 
PBMC   peripheral blood mononuclear cell 
PBS    phosphate buffered saline 
pEC    porcine endothelial cell 
PECAM   platelet/endothelial cell adhesion molecule 
PERV    porcine endogenous retrovirus 
pMIC2   porcine MIC2 
PMN    polymorphonuclear neutrophil 
pULBP1   porcine ULBP1 
SCT    single chain trimer 
shRNA   short hairpin RNA 
siRNA    short interfering RNA 
SLA    swine leukocyte antigen 
TNF    tumor necrosis factor 
ULBP    UL16-binding protein 
VCAM   vascular cell adhesion molecule 
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